https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/the-finegfr-study-a-retrospective-observational-study-to-investigate-the-treatment-landscape-and-out.pdf2026-01-20https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-pregnancy-safety-study2026-04-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/amivantamab-plus-lazertinib-in-atypical-egfrmutated-advanced-nonsmall-cell-lung-cancer-nsclc-results.pdf2026-01-20https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-falls-and-fractures2025-11-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/customized-therapy-for-sle-how-disease-severity-influences-the-use-of-corticosteroids-and-biologics.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-how-do-i-start-treatment-with-invega-hafyera2025-11-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-dosage-and-administration-administration-setting2026-03-03https://www.jnjmedicalconnect.com/products/xarelto/medical-content/drug-drug-interaction-profile-of-xarelto2025-06-02https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/effect-of-guselkumab-and-il-17-inhibitors-on-work-productivity-and-activity-impairment-in-psoriatic.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-pride-study2025-09-22https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-sustenna-invega-trinza-invega-hafyera-clinical-data-in-black-andor-african-american-patien2025-07-21https://www.jnjmedicalconnect.com/products/xarelto/medical-content/adverse-event-of-xarelto-hematuria2025-07-14https://www.jnjmedicalconnect.com/products/remicade/isi-english2025-03-05https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-use-in-elderly-patients2026-02-27https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-redirectt-1-study-talvey-and-tecvayli-cohort2026-03-04https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-sites-of-administration2026-03-11https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ean-20252025-08-28https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/aan-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/daratumumab-plus-bortezomib-lenalidomide-and-dexamethasone-in-transplanteligible-patients-with-multi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/phase-1-safety-efficacy-pharmacokinetics-pk-and-presentation.pdf2026-02-26https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/efficacy-and-safety-of-subcutaneous-guselkumab-induction-therapy-in-patients-with-ulcerative-colitis.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/dosage-and-administration-of-darzalex-darzalex-faspro-pre-and-postinfusion-medications2025-07-10https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/treatment-effects-of-paliperidone-palmitate-6month-formulation-on-negative-symptoms-in-patients-with.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ishlt/healthcare-resource-utilization-and-progression-in-patients-with-pulmonary-arterial-hypertension-ini.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/pha/expert-consensus-on-patient-engagement-strategies-and-shared-decisionmaking-to-improve-patient-outco.pdf2026-01-20https://www.jnjmedicalconnect.com/products/topamax2026-01-21https://www.jnjmedicalconnect.com/products/invokamet-xr2025-03-04https://www.jnjmedicalconnect.com/products/xarelto/medical-content/adverse-event-of-xarelto-hypersensitivity-reactions-and-skin-disorders2024-10-16https://www.jnjmedicalconnect.com/products/darzalex/medical-content/storage-and-stability-of-darzalex-vials-at-freezing-temperatures2025-08-26https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/patient-perspectives-on-fixed-dose-combination-therapy-for-pulmonary-hypertension-exploratory-focus.pdf2026-01-20https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/can-simponi-aria-cause-rash2025-09-25https://www.jnjmedicalconnect.com/products/xarelto/medical-content/adverse-event-of-xarelto-gastrointestinal-bleed2025-07-24https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/ascp/lumateperone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-results-from-a-randomi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/dosing-interval-of-invega-trinza-every-12-weeks-versus-every-13-weeks2026-02-27https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-adverse-event-hematologic-events-in-patients-with-relapsed-and-refractor2025-11-10https://www.jnjmedicalconnect.com/products/icotyde/medical-content/overview-of-the-iconic-advance-program2026-03-24https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-occurrence-of-injection-site-reactions2026-01-16https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-rationale-initiation-dosing-regimen2025-05-08https://www.jnjmedicalconnect.com/products/botaretigene-sparoparvovec/medical-content/perioperative-steroid-use2025-10-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/guselkumab-maintenance-therapy-mediates-further-improvements-in-intestinal-immune-homeostasis-and-mu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/use-of-lazcluze-in-patients-with-hepatic-impairment2025-08-21https://www.jnjmedicalconnect.com/products/stelara/medical-content/treatment-of-fistulizing-crohns-disease-with-stelara2026-01-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/tenn-rheum-society/guselkumab-response-and-inhibition-of-structural-damage-progression-in-active-psoriatic-arthritis-ac.pdf2026-02-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-atopic-dermatitis2025-10-29https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-overview-of-clinical-data-from-phoenix-1-and-phoenix-22025-09-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/nei/how-do-patients-with-depression-and-their-providers-talk-about-anhedonia-an-ethnographic-analysis-of.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/efficacy-and-safety-of-nipocalimab-vs-efgartigimod-in-a-randomized-openlabel-phase-3b-interventi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/efficacy-by-baseline-disease-characteristics-of-subcutaneous-guselkumab-induction-therapy-in-patient.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/talquetamab-immunogenicity-and-impact-on-exposure-efficacy-and-safety-analyses-from-patients-with-re.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zavesca/zavesca-niemannpick-type-c-disease-npc.pdf2026-03-12https://www.jnjmedicalconnect.com/products/stelara/medical-content/retreatment-of-crohns-disease-with-stelara-after-a-drug-free-interval2025-11-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/phase-2-study-of-teclistamabbased-induction-regimens-in-patients-with-transplanteligible-te-newly-di.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-outcomes-among-patients-pts-with-relapsed-or-refractory-multiple-myeloma-rrmm-initiating-t.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-use-of-prophylactic-tocilizumab2025-07-18https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/what-are-the-possible-side-effects-of-invega-hafyera2025-06-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ecco-20262026-02-27https://www.jnjmedicalconnect.com/products/sporanox-capsules2026-01-21https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-out-of-specification-oos-product2026-03-19https://www.jnjmedicalconnect.com/products/risperdal/medical-content/adverse-event-of-risperdal-priapism-ejaculatory-dysfunction2025-04-16https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/burden-of-remaining-symptoms-and-fluctuations-of-generalized-myasthenia-gravis-on-patients-daily-liv.pdf2026-01-20https://www.jnjmedicalconnect.com/products/erleada/medical-content/how-should-i-take-erleada2026-03-10https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-sustenna-invega-trinza-invega-hafyera-clinical-data-in-black-andor-african-american-patien2025-07-21https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/population-health-tools/ibd-path2026-02-04https://www.jnjmedicalconnect.com/products/nipocalimab-investigational/medical-content/nipocalimab-clinical-studies-in-hemolytic-disease-of-the-fetus-and-newborn-hdfn2026-03-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/estimation-of-overall-survival-in-immunotherapy-treated-bladder-cancer-using-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/fiveyear-clinical-outcomes-and-disease-course-of-newlydiagnosed-moderatetosevere-ulcerative-colitis.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/maintenance2025-06-16https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-dosage-and-administration-of-zytiga-alternative-prednisone-regimen.pdf2026-01-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/a-deep-learning-approach-using-routine-pathology-images-to-guide-precision-medicine-in-metastatic-cr.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/efficacy-of-guselkumab-in-crohns-disease-based-on-prior-responseexposure-to-biologic-therapy-results.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/mhncs-20262026-02-24https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/acg-20252025-10-14https://www.jnjmedicalconnect.com/products/carvykti/medical-content/what-should-i-mention-to-my-provider-before-starting-carvykti2026-04-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/qcs/elevating-the-patient-voice-understanding-treatment-preferences-in-patients-with-advanced-prostate-c.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/sirturo/sirturo-activity-against-nontuberculous-mycobacterium-species.pdf2025-06-02https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/use-of-lazcluze-in-pediatric-patients2025-08-21https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/use-of-risperdal-consta-in-the-elderly2024-07-02https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/talquetamab-a-gprc5dxcd3-bispecific-video2025-12-06https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/dermatology-education-foundation-np-pa-20252025-08-29https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-nsclc-with-her2-exon-20-insertion-mutations2026-02-18https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-safety-information-effect-on-lipids.pdf2025-07-23https://www.jnjmedicalconnect.com/products/darzalex/medical-content/concomitant-use-of-darzalex-darzalex-faspro-with-vaccines2025-05-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/comparative-efficacy-of-guselkumab-vs-risankizumab-in-induction-phase-for-crohns-disease.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/dermatologic-prophylaxis-and-impact-on-patientreported-outcomes-in-firstline-egfrmutant-advanced-nsc.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-what-are-the-possible-side-effects-of-tremfya.pdf2025-09-26https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ash/health-resource-utilization-among-patients-with-warm-autoimmune-hemolytic-anemia-in-sweden-a-retrosp.pdf2026-01-20https://www.jnjmedicalconnect.com/products/risperdal/medical-content/risperdal-dosing-abrupt-discontinuationwithdrawal2024-10-18https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec2-mmy1004-study-cohort-a2025-11-25https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-patients-with-traumatic-brain-injury2026-03-16https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-needle-specifications-in-clinical-trials2026-02-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/daratumumab-dara-bortezomiblenalidomidedexamethasone-vrd-in-transplanteligible-te-patients-pts-with.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/tenn-rheum-society-20262026-02-20https://www.jnjmedicalconnect.com/products/stelara/medical-content/what-are-the-possible-side-effects-of-stelara2025-11-21https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-combination-with-osimertinib2025-09-23https://www.jnjmedicalconnect.com/products/uptravi/medical-content/does-uptravi-contain-lactose2025-07-30https://www.jnjmedicalconnect.com/media/attestation/products/xarelto/xarelto-safety-data-sheet-sds-for-20-mg-tablets.pdf2025-09-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis-and-comorbid-hepatitis2026-03-31https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/executive-summary2025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/outcomes-of-teclistamab-tec-stepup-dosing-in-outpatienthybrid-settings-among-a-large-sample-of-relap.pdf2026-01-07https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-geriatric-patients2025-10-06https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/dosing-of-invega-trinza-partial-or-divided-dose-administration2026-02-24https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-posterior-reversible-encephalopathy-syndrome-pres2025-04-16https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/injection-instructions2025-06-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-crohns-disease-with-subcutaneous-induction-graviti-study2026-03-11https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/rybrevant-skippirr-study2026-01-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/characteristics-treatment-patterns-and-outcomes-of-patients-with-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-crohns-disease-or-ulcerative-colitis-with-a-history-of-malignanc2026-02-02https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/socu/visible-cohort-a-guselkumab-skin-clearance-results-through-week-100-in-participants-with-moderatetos.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-incidence-of-bleeding-in-vte-prevention2024-09-18https://www.jnjmedicalconnect.com/products/invokana/medical-content/concomitant-use-of-invokana-with-insulin2025-06-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/efficacy-by-baseline-disease-characteristics-of-intravenous-and-subcutaneous-guselkumab-induction-th.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/retrospective-observational-study-to-describe-the-clinical-characteristics-management-and-outcomes-o.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/amivantamab-treatment-and-intratumoral-gene-expression-and-immune-cell-changes-in-refractory-metasta.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-drug-interactions2026-03-20https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/prezcobix-tablet-splitting-crushing-or-chewing.pdf2026-03-03https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ccd-20252025-08-28https://www.jnjmedicalconnect.com/products/caplyta/pivotal-clinical-trial-publications2025-12-23https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-use-of-akeega-in-patients-with-brca-gene-mutations2025-12-25https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-highrisk-smoldering-multiple-myeloma2025-12-24https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-and-darzalex-faspro-use-for-the-treatment-of-autoimmune-hemolytic-anemia2025-06-12https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-hawaii/the-power-of-photos-leveraging-clinical-photos-from-the-visible-study-to-create-an-image-library-for.pdf2026-02-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-patients-with-psoriasis-and-comorbid-multiple-sclerosis2026-01-29https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-superficial-vein-thrombosis2024-12-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/evolution-of-treatment-patterns-and-survival-outcomes-in-european-patients-slides.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/winter-clinical-miami-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/products/tecvayli/operationalization-of-bispecific-therapies-in-multiple-myeloma.pdf2025-01-29https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-hypertension2026-01-27https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-use-in-adult-patients-with-immune-checkpoint-inhibitor-induced-colitis2026-02-24https://www.jnjmedicalconnect.com/products/stelara/medical-content/air-bubble-in-prefilled-syringe-and-prefilled-syringe-based-injectors2025-10-03https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/use-of-invega-hafyera-in-overweight-or-obese-patients2025-09-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/patient-reported-impact-and-satisfaction-with-guselkumab-and-il-17-inhibitors-in-psoriatic-arthritis.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/stability-of-invega-sustenna-invega-trinza-and-invega-hafyera-once-needle-attached2025-07-07https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/psych-elevate-20252025-08-28https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-adverse-event-mortality2026-02-06https://www.jnjmedicalconnect.com/2025-10-30https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-adverse-event-prolactin-effects.pdf2024-05-15https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-origin-of-human-antibody-genes-in-the-development-of-ustekinumab2026-03-25https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-invega-trinza-invega-hafyera-clinical-data-in-black-andor-african-american-patien2025-07-21https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-vte-prevention-for-long-distance-travel2024-12-06https://www.jnjmedicalconnect.com/products/xarelto/medical-content/does-xarelto-have-any-dietary-restrictions2025-06-27https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-comorbid-posttraumatic-stress-disorder-ptsd2025-09-17https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-gastrointestinal-adverse-events2025-06-11https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-mineralocorticoid-excess.pdf2025-05-08https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-atlas-study2025-06-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/patient-reported-impact-and-satisfaction-with-guselkumab-and-il-17-inhibitors-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/effectiveness-of-bridging-therapy-corresponds-to-improved-outcomes-after-receiving-cart-therapy-phas.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-patients-undergoing-ablation2025-12-11https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/isbd/response-and-remission-outcomes-of-lumateperone-for-major-depressive-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-as-monotherapy2026-03-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/talquetamab-a-gprc5dcd3-bispecific-antibody-in-combination-with-pomalidomide-in-patients-with-relaps.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/realworld-clinical-outcomes-of-firstline-ibrutinib-dose-reduction-versus-acalabrutinib-among-patient.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-mechanism-of-action2026-03-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/estimating-the-united-states-cureadjusted-prevalence-of-diffuse-large-bcell-lymphoma-dlbcl-an-epidem.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-coronavirus-disease-2019-covid19.pdf2024-08-29https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/talvey-redirectt-1-study-talvey-and-tecvayli-cohort2026-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/shadows-of-inflammation-exploring-postinflammatory-pigment-changes-in-psoriasis-in-visible-a-phase-3.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/qualityadjusted-survival-analysis-of-ciltacel-vs-standard-of-care-in-lenalidomiderefractory-multiple.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/efficacy-and-safety-of-nipocalimab-in-patients-with-generalized-myasthenia-gravis-top-line-results.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/clinical-practice-guidelines2026-04-01https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-depressive-symptoms-in-patients-with-schizophrenia2026-03-17https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-sustenna-in-patients-with-traumatic-brain-injury2025-12-23https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/minimal-residual-disease-in-multiple-myeloma2025-08-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/smfm-2026/pathophysiology-of-mg-video2026-01-23https://www.jnjmedicalconnect.com/products/invokana/medical-content/adverse-event-of-invokana-fourniers-gangrene-associated-with-sglt2-inhibitors2025-07-09https://www.jnjmedicalconnect.com/products/ventavis2025-11-13https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-occurrence-of-hepatotoxic-events2026-02-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/analysis-of-repeat-step-up-dosing-and-cytokine-release-syndrome-events-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/from-long-acting-injectable-antipsychotics2025-06-16https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/efficacy-and-safety-of-subcutaneous-guselkumab-induction-therapy-in-participants-with-moderately-to.pdf2026-02-17https://www.jnjmedicalconnect.com/products/stelara/medical-content/comparison-to-vedolizumab-in-adult-patients-with-crohns-disease-or-ulcerative-colitis2026-02-05https://www.jnjmedicalconnect.com/products/opsumit/medical-content/can-i-breastfeed-while-taking-opsumit2025-07-22https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-adult-patients-with-psoriasis-receiving-concomitant-dupilumab-for-a-comorbid-c2025-12-05https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-use-in-patients-with-lowdensity-lipoprotein-receptorrelatedprotein-4-antibodypositive-genera2025-07-15https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-psoriatic-arthritis-and-comorbid-nonalcoholic-fatty-liver-diseas2025-12-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/amivantamab-plus-lazertinib-vs-osimertinib-in-first-line-egfr-mutant-advanced-nsclc-pls.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-transition-from-or-to-low-molecular-weight-heparins2025-07-25https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-smm3001-aquila-study-summary2026-03-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rwcs/efficacy-of-guselkumab-in-bionaive-psoriatic-arthritis-patients-with-severe-disease-activity-posthoc.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-drug-interactions.pdf2025-09-02https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/adverse-event-of-invega-trinza-movement-disorders2026-01-27https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-use-of-inlexzo-with-catheterization2026-03-19https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-measuring-ustekinumab-drug-levels-in-patients-with-ulcerative-colitis2025-07-29https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-the-treatment-of-uveitis2026-02-11https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/how-is-simponi-aria-administered2025-09-11https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/characteristics-and-outcomes-of-non-transplanted-video2025-12-06https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccd/icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-the-interleukin23-receptor-for-the-treat.pdf2026-02-17https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-spartan-clinical-study-report2025-05-25https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-should-zytiga-be-taken-in-combination-with-prednisone.pdf2025-08-21https://www.jnjmedicalconnect.com/products/risperdal/medical-content/risperdal-and-risperdal-consta-adverse-events-fecal-incontinence2025-04-16https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-what-should-i-mention-to-my-healthcare-provider-before-taking-caplyta2026-02-25https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/papillon-study2025-10-30https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-short-term-trials-in-treatment-resistant-depression2025-10-28https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-adverse-event-pericardial-effusion2025-10-09https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis-with-comorbid-renal-impa2025-08-13https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-drug-interactions.pdf2024-09-10https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-discontinuation-of-cadd-legacy-pumps-and-issues-notice-for-cadd-infusion-sets.pdf2025-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-east/efficacy-and-safety-of-nipocalimab-an-antifcrn-monoclonal-antibody-in-primary-sjogrens-disease-resul.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/dosing-conversion-from-risperdal-consta-to-oral-risperdal2024-08-20https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/what-is-tecvayli2026-03-09https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-latex-content2025-10-12https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/storage-and-stability-of-darzalex-faspro-prepared-syringe2025-11-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-west/improvements-in-patient-reported-outcomes-through-24-weeks-of-guselkumab-treatment-in-participants-w.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/rwcs/guselkumab-response-and-inhibition-of-structural-damage-progression-in-active-psoriatic-arthritis-ac.pdf2026-02-11https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-pah-associated-with-connective-tissue-disease2025-09-30https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/nsc/through-the-patient-lens-the-diagnostic-journey-from-connective-tissue-disease-to-pulmonary-arterial.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fsr/safety-of-guselkumab-in-inflammatory-bowel-disease-up-to-1-year-integrated-safety-analysis-of-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-chrysalis-2-study2026-02-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-west/guselkumab-response-and-inhibition-of-structural-damage-progression-in-active-psoriatic-arthritis-ac.pdf2026-02-03https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-tablets-200-mg-safety-data-sheet-sds.pdf2025-05-01https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/health-literacy/understanding-and-adherence-checklist2026-02-27https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-serotonin-syndrome2026-03-18https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-alternative-maintenance-dosing-for-tremfya-in-ulcerative-colitis-and-crohns-disease-100-mg2025-12-18https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-of-spravato-with-lamotrigine2025-12-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/subcutaneous-amivantamab-vs-intravenous-amivantamab-both-in-combination-with-lazertinib-in-refractor.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-occurrence-of-infections2026-02-05https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-poster-summary-matchingadjusted-indirect-comparison-study-of-inlexzo-vs-fdaapproved-novel-a2025-09-10https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/wclc-2025/first-line-subcutaneous-amivantamab2026-02-19https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-density2025-12-17https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/safety-information-for-rybrevant-faspro-venous-thromboembolism2026-03-30https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec1-study-cohort-a2026-04-03https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/predictors-of-composite-response-in-mg-based-on-patient-and-clinician-reported-assessments-in-vivaci.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-transition-from-or-to-warfarin2025-07-14https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-use-in-the-treatment-of-uveitis.pdf2025-01-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/early-disease-efficacy-of-guselkumab-therapy-in-biologicnaive-patients-with-moderately-to-severely-a.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/ciltacabtagene-autoleucel-ciltacel-vs-standard-of-care-soc-in-patients-pts-with-relapsedrefractory-m.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-comparison-of-erleada-with-enzalutamide2026-02-23https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-use-of-simponi-in-pediatric-patients-with-ulcerative-colitis-pursuit-2-study.pdf2025-08-30https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/maui-derm-hawaii/comparative-efficacy-of-icotrokinra-and-approved-advanced-treatments-for-achievement-of-completely-c.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/policy-research/2025/amcp-nexus/income-health-and-racial-gaps-between-340b-hospitals-child-sites-and-nearby-neighborhoods.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/risperdal/risperdal-1-mg-tablet-safety-data-sheet-sds.pdf2025-05-19https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/nei/escape-lte-cfl-analysis-long-term-safety-and-efficacy-of-esketamine-nasal-spray-in-adults-with-tr.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-treatment-of-nail-psoriasis2026-03-20https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-use-in-renal-impairment2025-05-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/finegfr-cns-real-world-survival-and-patient-characteristics-of-egfr-mutated-nsclc-patients-pres.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-use-in-amyloidlight-chain-al-amyloidosis2026-03-02https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-safety-data-sheet-sds.pdf2026-01-05https://www.jnjmedicalconnect.com/products/stelara/medical-content/switching-from-other-biologics-to-stelara-in-ulcerative-colitis2026-03-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/results-from-safety-runin-cohort-1-of-the-phase-3-majestec7-study-in-patients-with-transplant-inelig.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invokana/medical-content/crushing-the-invokana-tablet-for-oral-or-enteral-feeding-tube-administration2024-11-06https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-dosing-and-administration-missed-dose2025-12-18https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/paloma-3-study2025-12-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/fostering-inclusive-language-for-genitourinary-cancer-research-a-multi-stakehold-presentation.pdf2026-02-27https://www.jnjmedicalconnect.com/products/tremfya/medical-content/concomitant-use-with-methotrexate-and-other-conventional-synthetic-dmards-in-adult-patients-with-act2026-01-23https://www.jnjmedicalconnect.com/therapeutic-areas/oncology2026-02-19https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/management-of-an-incomplete-administration-of-invega-hafyera2025-08-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/onlabel-persistence-through-24-months-among-patients-with-psoriatic-arthritis-initiating-guselkumab.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/general-safety-overview-of-spravato2026-03-11https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-darzalex-faspro-in-newly-diagnosed-multiple-myeloma-in-patients-eligible-for-autolo2025-11-07https://www.jnjmedicalconnect.com/products/balversa/medical-content/how-should-i-store-balversa2025-08-21https://www.jnjmedicalconnect.com/products/spravato/medical-content/dosing-of-spravato-partial-or-incomplete-administration2026-03-27https://www.jnjmedicalconnect.com/products/nipocalimab-investigational/medical-content/nipocalimab-overview-of-the-phase-23-energy-clinical-trial2026-03-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/real-world-comparison-of-prostate-specific-antigen-response-in-metastatic-castra-presentation.pdf2026-02-26https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-acute-deep-vein-thrombosis-treatment2025-07-14https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-cilostazol2024-09-18https://www.jnjmedicalconnect.com/products/xarelto/medical-content/real-world-evidence-of-xarelto-effects-of-body-weight2025-07-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/efficacy-of-guselkumab-in-moderately-to-severely-active-ulcerative-colitis-by-extent-of-disease-and.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/expert-consensus-on-patient-engagement-strategies-and-shared-decisionmaking-to-improve-patient-outco.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/population-pharmacokinetics-and-pharmacodynamics-modeling-of-nipocalimab-in-adolescents-aged-12-to-l.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-use-in-renal-dysfunction.pdf2025-11-27https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/pulmonary-arterial-hypertension-clinical-trial-endpoints-and-outcomes-patient-perspectives-and-prefe.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/aan-2025/audio-identifying-risk-factors2025-09-08https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/mariposa-study2026-03-06https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/use-of-invega-invega-sustenna-invega-trinza-and-invega-hafyera-in-pregnancy-or-lactation2026-03-18https://www.jnjmedicalconnect.com/products/darzalex/medical-content/what-is-the-recommended-dosing-for-darzalex-in-combination-with-lenalidomide-or-pomalidomide-and-low2026-03-11https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/concomitant-use-of-darzalex-darzalex-faspro-with-vaccines2025-05-16https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/identifying-risk-factors-for-predicting-exacerbation-and-symptom-worseninga-retrospective-cohort-st.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-adverse-event-administrationrelated-reactions-and-management-of-administrationrela2025-11-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-adult-patients-with-crohns-disease-who-are-biologicnave2026-04-02https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-early-disease-intervention-in-treatment-of-adult-patients-with-psoriasisguide-study2025-11-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/gemcitabine-intravesical-system-gemidrs-monotherapy-in-bacillus-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/guselkumab-efficacy-and-safety-in-east-asian-participants-with-moderate-to-severely-active-ulcerativ.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/phpn/real-world-adherence-and-persistence-of-upfront-therapy-in-patients-with-pulmonary-hypertension-in-t.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-west/realworld-onlabel-treatment-persistence-through-24-months-in-biologicnaive-necrosis-factor-inhibitor.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-patients-with-class-iii-obesity-bmi40-kgm22024-08-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/a-phase-1-study-of-vac85135-a-neoantigen-vaccine-regimen-targeting-calreticulin-and-jak2-mutations-i.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/cytokine-release-syndrome-in-patients-receiving-alternative-stepup-doses-of-talquetamab-for-relapsed.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-utilization-patterns-real-world-evidence2025-12-04https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/eau-2026/longitudinal-assessment-of-urine-tumor-dna-video2026-03-12https://www.jnjmedicalconnect.com/products/uptravi/medical-content/can-i-take-uptravi-if-i-am-pregnant-or-planning-to-become-pregnant2025-07-29https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/trajectory-of-response-and-remission-in-induction-nonresponders-to-esketamine-nasal-spray-a-subgroup.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec2-study-cohort-c2026-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/comorbidities-and-extraintestinal-manifestations-among-patients-with-difficulttotreat-inflammatory-b.pdf2026-01-20https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-interstitial-lung-disease-ildpneumonitis2025-07-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/clinical-outcomes-in-black-patients-with-relapsedrefractory-multiple-myeloma-following-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fsr/realworld-onlabel-treatment-persistence-through-24-months-in-biologicnaive-biologicexperienced-pati.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-density-specific-gravity-and-overfill-volume2025-10-22https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/bleximenib-or-placebo-in-combination-with-standard-induction-and-consolidation-therapy-followed-by-m.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-effect-on-lipids2026-03-13https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-occurrence-of-tuberculosis-infection2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/adaa/factors-associated-with-reaching-remission-on-esketamine-among-patients-with-treatmentresistant-depr.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/talquetamab-dosing-strategies-in-the-united-states-real-world-insights-from-over-250-patients.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-diamond-study-rapid-initiation.pdf2025-08-11https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ascp/prescriber-and-patientlevel-characteristics-associated-with-adherence-to-antipsychotics-among-patien.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/comparative-efficacy-of-ciltacabtagene-autoleucel-cilta-cel-versus-belantamab-mafodotin-belamaf-bort.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-effect-on-prostatespecific-antigen-psa-levels2025-05-19https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-density2025-07-10https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-extravasation.pdf2025-05-06https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/drug-interactions-with-invega-invega-sustenna-invega-trinza-and-invega-hafyera-general2025-06-04https://www.jnjmedicalconnect.com/products/intelence2026-01-21https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-elderly2026-03-17https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-cardiovascular-events2026-01-16https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-patients-with-pci-and-cabg2024-12-17https://www.jnjmedicalconnect.com/products/xarelto/medical-content/can-i-just-stop-taking-my-xarelto2025-07-30https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-dose-adjustments2025-10-07https://www.jnjmedicalconnect.com/products/risperdal/medical-content/risperdal-pharmacokinetics2024-07-11https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-congress/lumateperone-for-the-prevention-of-relapse-in-patients-with-schizophrenia-results-from-a-doubleblind.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/phase-3-amplitude-trial-niraparib-nira-and-abiraterone-acetate-plus-prednisone-aap-for-metastatic-ca.pdf2026-01-20https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-vaccines-in-patients-receiving-stelara2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-treatment-center-locators-outside-the-united-states2025-12-04https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/access-to-healthcare/insurance-knowledge-gaps2026-02-27https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/mgfa-20242025-08-28https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-clinically-meaningful-change-in-the-madrs-total-score2025-10-14https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-pretreatment-and-management-of-cytokine-release-syndrome-crs2025-11-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/real-world-treatment-patterns-among-patients-with-advanced-nsclc-treated-with-amivantamab.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/clarification-on-24-hour-endpoint-of-spravato-from-transform-2-study2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/effect-on-extraintestinal-manifestations-in-patients-with-crohns-disease-or-ulcerative-colitis2025-09-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/patient-level-persistence-of-on-treatment-remission-with-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/clinical-trial-comparison2025-05-13https://www.jnjmedicalconnect.com/products/spravato/medical-content/can-i-take-spravato-with-other-nasal-medications2025-09-26https://www.jnjmedicalconnect.com/media/attestation/general/neurologic-events-associated-with-immunotherapy.pdf2026-04-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/efficacy-of-erdafitinib-in-adults-with-advanced-solid-tumors-and-nonprespecified-fibroblast-growth-f.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/effectiveness-of-daratumumab-plus-bortezomib-lenalidomide-and-dexamethasone-dvrd-versus-vrd-as-front.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-discontinuation-of-premedications2025-10-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/subcutaneous-sc-after-intravenous-iv-amivantamab-in-advanced-nsclc-initial-results-from-paloma2.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-lichen-planus2026-03-04https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/summary-studies-assessing-reversal-agents-xarelto/andexanet-alfa-other-reversal-agents2025-10-16https://www.jnjmedicalconnect.com/media/attestation/products/invega-hafyera/invega-hafyera-clinical-trial.pdf2026-03-16https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/symptomatic-and-functional-remission-with-paliperidone-palmitate-3month-and-6month-formulations-in-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-sustenna-in-schizoaffective-disorder2025-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/prophylactic-tocilizumab-to-mitigate-cytokine-release-syndrome-and-outpatient-dosing-of-talquetamab.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/what-should-i-tell-my-healthcare-provider-before-receiving-invega-sustenna2025-05-13https://www.jnjmedicalconnect.com/products/remicade/medical-content/occurrence-of-tuberculosis-infection2025-10-06https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-preparation-for-intravenous-infusion-using-diluents-other-than-normal-saline-in-patients-wit2025-05-30https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-pediatric-patients2025-05-29https://www.jnjmedicalconnect.com/products/tremfya/medical-content/treatment-effect-of-tremfya-on-fatigue-in-adult-patients-with-active-psoriatic-arthritis2025-08-13https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/sid-20252025-08-28https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-bridging-therapy2026-01-05https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/how-long-does-it-take-for-invega-sustenna-to-be-removed-from-your-body2025-12-17https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/stability-of-invega-sustenna-invega-trinza-and-invega-hafyera-once-needle-attached2025-07-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/health-literacy/assessing-health-literacy2026-02-27https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-combination-with-a-biologic-in-the-treatment-of-crohns-disease-or-ulcerative-colit2025-08-19https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/use-of-invega-trinza-in-bipolar-disorder2026-01-13https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-and-invega-trinza-educational-dose-illustrator2025-09-24https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/phpn/a-realworld-retrospective-study-evaluating-a-teambased-patient-engagement-approach-to-selexipag-init.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/symptom-severity-assessment-using-mgadl-items-and-domains-in-a-24week-phase-3-study-vivacity-of-nipo.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/wcp/adjunctive-lumateperone-42-mg-in-the-treatment-of-major-depressive-disorder-a-pooled-analysis-of-2-p.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-mixing-of-different-formulationsame-strength-vials2025-09-11https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-einstein-choice2025-07-30https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aan-2025/audio-design-of-a-digital-solution2025-09-08https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-is-the-recommended-dosing-for-darzalex-faspro-in-combination-with-bortezomib-thalidomide-and-de2025-07-29https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-administration-setting012026-03-26https://www.jnjmedicalconnect.com/media/attestation/products/spravato/spravato-safety-data-sheet.pdf2026-03-23https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/erleada-publication-summary-lowentritt-et-al-2025-realworld-os-comparison-with-abiraterone-acetate.pdf2025-06-24https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-gastrointestinal-serious-adverse-events-in-adult-patients-with-plaque-psorias2025-12-05https://www.jnjmedicalconnect.com/products/balversa/medical-content/how-does-balversa-work2025-11-21https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/dosing-interval-of-invega-hafyera-every-24-weeks-versus-every-26-weeks2025-12-15https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-of-spravato-with-auvelity-dextromethorphan-hbr-and-bupropion-hcl2026-03-25https://www.jnjmedicalconnect.com/products/zytiga2026-01-21https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/what-are-the-possible-side-effects-of-tecvayli2026-03-09https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/guselkumab-pharmacokinetics-and-immunogenicity-in-pediatric-psoriasis.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/preventing-infusionrelated-reactions-with-intravenous-amivantamab-primary-results-from-skippirr-a-ph.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/impact-of-baseline-hot-flashes-on-sleep-metrics-during-initial-treatment-in-libe.pdf2026-02-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/absolute-lymphocyte-count-as-a-key-biomarker-for-monitoring-safety-after-ciltacabtagene-autoleucel.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/erleada-comparison-of-erleada-with-zytiga.pdf2026-02-23https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-pharmacokinetics2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/uptravi/uptravi-safety-data-sheet-sds.pdf2026-01-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/finegfrprint-a-retrospective-observational-study-to-investigate-treatments-and-outcomes-in-patients.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/realworld-comparison-of-prostatespecific-antigen-response-in-black-patients-with-metasta-poster.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/how-will-i-receive-tecvayli2025-09-11https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-dose-escalation-during-tremfya-maintenance-therapy-in-ulcerative-colitis2025-06-04https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/symptom-severity-assessment-using-quantitative-myasthenia-gravis-items-and-domains-in-a-24week-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/realworld-characteristics-and-safety-and-effectiveness-of-talquetamab-among-patients-with-relapsed-o.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/educational-dose-illustrator2025-06-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/influence-of-sex-on-the-therapeutic-persistence-of-guselkumab-in-psoriatic-disease-a-retrospective.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-study-design-of-compass2024-11-19https://www.jnjmedicalconnect.com/media/attestation/products/intelence/intelence-repackaging.pdf2026-03-19https://www.jnjmedicalconnect.com/products/spravato/medical-content/dosing-of-spravato-post-administration-monitoring2025-06-09https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-in-use-stability2025-10-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/homologous-recombination-repair-alterations-nextgeneration-sequencing-testing-and-time-pls.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/real-world-evidence-with-tremfya-in-adult-patients-with-plaque-psoriasis-retrospective-studies2026-03-25https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/drug-interactions-with-invega-invega-sustenna-invega-trinza-and-invega-hafyera-general2025-06-04https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-patients-with-hepatic-impairment2026-02-13https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-maternal-and-fetal-outcomes2026-01-22https://www.jnjmedicalconnect.com/media/attestation/medinfohtmlimages/inlexzo/us-sr-13894/janssen-inlexzo-evidence-table-abbreviations.pdf2026-01-22https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/safety-profile-of-nipocalimab-a-new-neonatal-fragment-crystallizable-receptor-blocker-in-the-phase-3.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokana/medical-content/what-should-i-know-about-the-management-of-yeast-infections-while-taking-invokana2025-11-03https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/psych-elevate-20242025-09-08https://www.jnjmedicalconnect.com/products/opsumit/medical-content/does-opsumit-contain-lactose2025-07-30https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/impact-of-generalized-myasthenia-gravis-on-pregnancy-outcomes-findings-from-a-healthcare-claims-data.pdf2026-01-20https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-publication-summary-daneshmand-et-al-2026-penelope2026-04-03https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-rhabdomyolysis.pdf2024-10-15https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/elevate-dermatology-summer-conference-20252025-08-29https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-hepatotoxicity2026-01-09https://www.jnjmedicalconnect.com/products/xarelto/medical-content/do-i-need-to-stop-xarelto-before-a-surgeryprocedure2025-08-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/dosing-patterns-and-early-safety-and-effectiveness-outcomes-in-patients-with-multiple-myeloma-treate.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-density.pdf2025-02-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/daratumumab-plus-bortezomib-lenalidomide-and-dexamethasone-in-patients-with-newly-diagnosed-multiple.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-step-up-dosing-schedule-real-world-evidence2025-10-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/a-phase-1-firstinhuman-openlabel-multicenter-trialinprogress-of-the-safety-tolerability-and-prelimin.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-guttate-psoriasis2026-03-13https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-concomitant-use-with-chemotherapy2026-01-13https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-use-of-closed-system-transfer-devices-in-clinical-trials2025-08-06https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/identifying-risk-factors-for-exacerbation-and-symptom-worseninga-retrospective-observational-cohort.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-patients-with-cardiomyopathy2024-07-24https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-seizure-disorders2025-12-03https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/phpn/delphi-study-to-elicit-consensus-on-best-practice-for-prior-authorization-in-pulmonary-arterial-hype.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/effect-of-guselkumab-subcutaneous-induction-and-maintenance-on-symptoms-of-moderately-to-severely-ac.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/stability-of-stelara-iv-infusion-formulation-after-dilution-in-normal-or-half-normal-saline2025-10-07https://www.jnjmedicalconnect.com/media/attestation/products/tracleer/tracleer-film-coated-tablet-storage-and-stability-information.pdf2024-11-14https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/serostatus-testing-patterns-among-individuals-with-myasthenia-gravis-and-the-influence-of-social-det.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/missed-dose-of-xarelto2025-01-28https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-comparison-to-tnf-inhibitors-in-the-treatment-of-adult-patients-with-active-psoriatic-arthr2025-11-06https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-titan-study012026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/pregnancy-outcomes-in-maternal-exposure-to-guselkumab-review-of-cases-reported-t.pdf2026-02-23https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-capsule-crushing-chewing-or-splitting2026-03-18https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-blood-brain-barrier-and-central-nervous-system-involvement2025-07-02https://www.jnjmedicalconnect.com/products/darzalex/pivotal-clinical-trial-publications2026-03-11https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-conversion-to-invega-sustenna2025-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/real-world-characteristics-and-treatment-patterns-of-transplant-eligible-patients-with-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/disease-burden-in-patients-with-generalized-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/products/balversa/medical-content/can-i-take-balversa-if-i-am-pregnant-breastfeeding-or-if-i-have-a-partner-that-can-become-pregnant2025-08-05https://www.jnjmedicalconnect.com/products/risperdal/medical-content/oral-solution-of-risperdal-beverage-and-food-compatibility2026-03-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/investigating-unmet-needs-among-advanced-therapynaive-patients-with-crohns-disease-treated-with-riza.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec-3-study2026-04-03https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-management-of-hypersensitivity-reactions-in-patients-with-generalized-myasthenia-gravis2026-01-30https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-vial-overfill2026-03-04https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-latex-content2025-07-11https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/language-and-communication/cross-cultural-communication-skills-checklist2026-02-27https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/pharmacokinetics-of-risperdal-consta2024-11-14https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/opsynvi-background-therapy2026-02-19https://www.jnjmedicalconnect.com/products/tremfya/medical-content/one-press-patient-controlled-injector-instructions-for-use/injection2025-12-08https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/ecnp/efficacy-of-adjunctive-lumateperone-42-mg-treatment-across-depression-and-anhedonia-symptoms-in-majo.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/adverse-event-of-invega-trinza-dyslipidemia2025-08-18https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-90-mg-dose-in-adult-patients-with-plaque-psoriasis-weighing-100-kg-or-less2026-02-18https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-how-should-i-store-procrit.pdf2025-10-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/effects-of-subcutaneous-guselkumab-induction-and-maintenance-on-histologic-outcomes-in-patients-with.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-monumental3-mmy3002-study2025-07-02https://www.jnjmedicalconnect.com/media/attestation/products/spravato/cardiac-safety-of-esketamine-nasal-spray-in-treatmentresistant-depression-results-from-the-clinical.pdf2026-01-26https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad/pharmacokinetics-of-guselkumab-in-super-responders-and-longterm-psoriasis-disease-control-insights-f.pdf2026-01-07https://www.jnjmedicalconnect.com/products/procrit2026-01-21https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/inlexzo-how-will-i-receive-inlexzo.pdf2025-09-12https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant/rybrevant-safety-data-sheet-sds.pdf2025-05-19https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/what-are-the-possible-side-effects-of-inlexzo2025-09-10https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/mmy3014-perseus-study2025-11-18https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-retreatment2025-07-18https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/use-of-rybrevant-faspro-in-head-neck-cancer-origami4-study2026-02-26https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-pregnancy-or-lactation2026-03-13https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/administration-of-simponi-aria-at-doses-greater-than-2-mgkg-in-adult-patients-with-active-psoriatic2025-09-02https://www.jnjmedicalconnect.com/media/attestation/products/remicade/impact-of-rapid-infliximab-infusions-on-access-at-a-large-academic-tertiary-medical-center.pdf2026-01-23https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/concomitant-use-of-invega-sustenna-with-antipsychotics2025-12-18https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-mechanism-of-action2026-03-18https://www.jnjmedicalconnect.com/products/carvykti/medical-content/adverse-event-neurological-events2026-03-12https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/assessment-of-patient-reported-outcomes-from-the-phase-3-vivacity-mg3-study-of-nipocalimab-in-gmg.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-healthcare-resource-utilitzation-hcru-following-outpatient-op-or-inpatient-ip-administrati.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/clinical-pharmacology-strategies-to-support-dose-optimization-of-the-recommended-phase-2-dose-regime.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/effect-of-guselkumab-subcutaneous-induction-and-maintenance-on-symptoms-of-moderately-to-severely-ac.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/enhanced-effectiveness-of-guselkumab-as-first-line-biologic-therapy-in-psoriasis-poster.pdf2026-03-27https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-rhinitis-or-nasal-congestion2025-10-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/consistently-high-55year-progressionfree-survival-pfs-rates-in-patients-with-and-without-bulky-basel.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/montgomerysbergdepression-rating-scale-anhedonia-factor-score-following-esketamine-nasal-spray-monot.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi2026-03-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/subcutaneous-after-intravenous-amivantamab-in-advanced-nsclc-initial-results-from-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-seizures2026-03-13https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-use-in-the-treatment-of-multiple-myeloma-with-central-nervous-system-involvement2025-06-11https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-use-in-overweight-or-obese-patients2026-03-10https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/suo-2025/gemcitabine-video2025-12-04https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/impact-of-guselkumab-in-real-life-on-sleep-quality-measured-using-a-wearable-device-in-patients.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-dosage-modifications2026-03-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/spectrem-guselkumab-efficacy-across-multiple-highimpact-sites-in-participants-with-low-bsa-moderate.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/concomitant-use-of-invega-sustenna-with-invega-trinza2025-12-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/outcomes-in-highrisk-subgroups-after-fixedduration-ibrutinib-venetoclax-for-chronic-lymphocytic-leu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal/medical-content/use-of-risperdal-in-children-and-adolescents-with-autistic-disorder2025-06-02https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-density2025-08-04https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/safety-profile-of-nipocalimab-a-new-neonatal-fragment-crystallizable-receptor-blocker-in-the-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro2026-03-19https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-combination-with-capmatinib2025-05-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/a-phase-1b-study-of-the-meninkmt2a-inhibitor-bleximenib-jnj75276617-in-combination-with-venetoclax-a.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/analysis-of-longterm-efficacy-of-nipocalimab-in-myasthenia-gravis-openlabel-extension-of-the-vivacit.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/efficacy-and-safety-of-subcutaneous-guselkumab-rescue-therapy-in-patients-with-moderately-to-severel.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-voyager-pad2025-09-11https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aad-innovation-academy-20252025-08-28https://www.jnjmedicalconnect.com/products/nipocalimab-investigational/medical-content/nipocalimab-mechanism-of-action2026-03-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aacr/identification-of-fibroblast-growth-factor-receptors-fgfrs-alterations-alts-at-dna-and-rnalevel-by-o.pdf2026-02-17https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-digital-ulcers-associated-with-systemic-sclerosis2026-01-21https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-management-of-infections-in-the-majestec-1-study2026-03-18https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-stem-cell-collection2025-11-11https://www.jnjmedicalconnect.com/products/xarelto/medical-content/dose-of-xarelto-for-dvt-or-pe-treatment-reinitiation-after-interruption-of-therapy2026-02-27https://www.jnjmedicalconnect.com/products/risperdal/medical-content/adverse-event-of-risperdal-vision-disorders2025-11-24https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/management-bleeding/einstein-treatment-dvt-pe2025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/efficacy-and-safety-of-ciltacabtagene-autoleucel-lenalidomide-maintenance-in-newly-diagnosed-multip.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/amcp-nexus/an-economic-model-assessing-costs-relapses-and-antipsychotic-adherence-of-switching-medicaid-benef.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-maximum-dose2025-08-05https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-alternative-step-up-dosing-in-the-monumental-1-study2025-10-28https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-overview-of-the-epic-clinical-trial2025-11-12https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/longterm-efficacy-and-safety-of-guselkumab-through-week-96-after-intravenous-or-subcutaneous-inducti.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/chest/characteristics-treatment-patterns-and-outcomes-of-patients-with-pulmonary-arterial-hypertension-by.pdf2026-01-20https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-long-term-use2026-03-13https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/does-taking-simponi-aria-increase-my-risk-for-cancer2025-06-03https://www.jnjmedicalconnect.com/products/tecvayli2026-03-05https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-elevate/efficacy-and-safety-of-esketamine-nasal-spray-as-monotherapy-in-adult-patients-with-treatmentresista.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-adverse-event-neuroleptic-malignant-syndrome.pdf2025-11-04https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/adaa/efficacy-and-safety-of-esketamine-nasal-spray-as-monotherapy-in-adults-with-treatmentresistant-depre.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-occurrence-and-management-of-ataxia-andor-balance-disorders2025-10-24https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/rheumatology-convergence-congress-20252025-10-26https://www.jnjmedicalconnect.com/products/stelara/medical-content/effects-of-stelara-on-endoscopic-and-histologic-outcomes-in-crohns-disease-uniti-clinical-trial-prog2025-06-16https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-combination-therapy-in-pulmonary-arterial-hypertension2025-10-15https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il23i-in-participants-with-a.pdf2026-01-07https://www.jnjmedicalconnect.com/email2026-04-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/subcutaneous-daratumumab-plus-lenalidomide-versus-lenalidomide-alone-as-maintenance-therapy-in-newly.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eha/increased-allcause-mortality-among-patients-diagnosed-with-warm-autoimmune-haemolytic-anaemia-compar.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-management-of-hypersensitivity-or-infusion-reactions-in-adult2026-01-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/inferring-pdl1-status-from-he-images-using-digital-pathology-to-identify-patients-responsive-to-anti.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/patient-reported-outcomes-from-amplitude-a-randomized-placebocontrolled-phase-3-trial-of-niraparib-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-cardiovascular-or-cerebrovascular-conditions2026-02-05https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/suo-20242025-08-28https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/tar-200-102-study2026-03-19https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ats/realworld-retrospective-cohort-study-of-oral-selexipag-in-methamphetamineassociated-pulmonary-arteri.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/use-of-tremfya-in-patients-with-active-psoriatic-arthritis-and-imaging-confirmed-sacroiliitis2026-02-09https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-use-of-zytiga-in-patients-with-cardiovascular-disease.pdf2025-01-01https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/benefitrisk-of-guselkumab-compared-to-placebo-in-the-treatment-of-moderately-to-severely-active-ulce.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-treatment-of-ulcerative-colitis-anthemuc2026-03-24https://www.jnjmedicalconnect.com/products/tremfya/medical-content/clinical-remission-through-week-12-in-crohns-disease2026-02-13https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/opsynvi-adverse-event-anemiahemoglobin-decrease2026-02-12https://www.jnjmedicalconnect.com/products/invokana/medical-content/adverse-event-of-invokana-diabetic-ketoacidosis2025-04-28https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/team-phenomenal-hope-20242025-08-28https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/jadpro-2024/subcutaneous-amivantamab-and-lazertinib-as-first-line-video2025-08-29https://www.jnjmedicalconnect.com/products/jnj-81201887/medical-content/phase-1-clinical-trials2026-02-26https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-alcohol2024-05-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/spectrem-guselkumab-demonstrates-consistent-complete-clearance-at-week-16-across-special-sites-in-pa.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-passage-across-blood-brain-barrier2025-09-16https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-issues-notice-for-cadd-infusion-sets.pdf2025-06-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/rapid-and-deep-prostatespecific-antigen-psa-response-to-apalutamide-plus-adt-correlates-with-improve.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/realworld-utilization-and-outcomes-with-pacific-regimen-in-stage-iii-unresectable-nonsmall-cell-lung.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/amivantamab-plus-chemotherapy-vs-chemotherapy-in-egfrmutant-advanced-nsclc-after-disease-progression.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-clinical-study-overview2025-11-05https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-outcomes-following-adjustments-in-dosing-frequency2026-03-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/firstline-treatment-in-patients-with-transplantineligible-newly-diagnosed-multiple-myeloma-by-age-fr.pdf2026-02-17https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/does-simponi-aria-contain-latex2025-09-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/corticosteroid-sparing-effects-of-treatment-with-guselkumab-in-patients-with-moderately-to-severely.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/dosing-of-risperdal-consta-combining-dosage-strengths2025-06-18https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-tar-200-103-study2026-03-19https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-combination-with-pomalidomide-and-dexamethasone-in-multiple-myelom2026-03-10https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-use-in-high-risk-smoldering-multiple-myeloma2025-12-03https://www.jnjmedicalconnect.com/media/attestation/products/spravato/spravato-escape-trd-one-pager01.pdf2026-01-05https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/ibd-patient-preference-study-comparing-monotherapy-and-dual-biologic-therapy-among-primary-and-secon.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/nei/trd-4005-4-month-esk-monotherapy-analysis-encore-efficacy-and-safety-of-esketamine-nasal-spray-as.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/why-is-there-a-risk-evaluation-and-mitigation-strategy-rems-program-with-spravato2025-06-30https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-how-does-spravato-work2026-01-23https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/dosage-and-administration-of-intravesical-therapies-for-bcgur-nmibc-with-cis-papillary-tumors-infog.pdf2025-09-22https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/nutrition-and-diet2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/aanem/interim-results-for-myasthenia-gravisresource-utilization-epidemiology-survival-treatment-patterns.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-occurrence-of-hypogammaglobulinemia012026-02-02https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/auriga-study2025-12-09https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-administration-setting012026-03-26https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rhapp/efficacy-and-safety-of-nipocalimab-an-antifcrn-monoclonal-antibody-in-primary-sjogrens-disease-resul.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/switching-patients-with-generalized-myasthenia-gravis-from-other-neonatal-fragment-crystallizable-re2025-11-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/talquetamab-a-gprc5dcd3-bispecific-antibody-in-combination-with-pomalidomide-in-patients-with-relaps.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsumit/medical-content/right-ventricular-remodeling-in-pah-repair2025-07-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/visible-post-inflammatory-pigmentation-journeys-exploring-the-impact-of-pigmentation.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/aan-20262026-03-20https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/ats/optimising-thresholds-for-the-detection-of-pulmonary-hypertension-ph-and-precapillary-ph-using-autom.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/eha-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/products/icotrokinra/oral-icotrokinra-for-plaque-psoriasis-in-adults-and-adolescents.pdf2026-02-18https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/what-is-the-recommended-dosing-for-opsynvi-in-the-treatment-of-pulmonary-arterial-hypertension2025-04-15https://www.jnjmedicalconnect.com/products/xarelto/medical-content/long-term-use-of-xarelto-for-vte-prophylaxis2025-07-15https://www.jnjmedicalconnect.com/products/xarelto/medical-content/realworld-evidence-of-xarelto-prophylaxis-of-dvt-in-patients-undergoing-knee-or-hip-replacement-sur2024-05-21https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-colorectal-cancer-origami-1-study2026-01-14https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/updated-comparative-effectiveness-of-talquetamab-vs-realworld-physicians-choice-of-treatment-in-pati.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-pah-associated-with-congenital-heart-disease2025-12-02https://www.jnjmedicalconnect.com/products/talvey/pivotal-clinical-trial-publications2025-12-29https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/adaa-20262026-03-25https://www.jnjmedicalconnect.com/products/stelara/medical-content/re-induce-with-intravenous-infusion-of-stelara-during-maintenance-therapy-in-crohns-disease2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ash/sentiment-analysis-applied-to-digital-conversations-among-warm-autoimmune-hemolytic-anemia-waiha-pat.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/real-world-treatment-patterns-among-patients-with-generalized-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/prezcobix-safety-information-renal-effects.pdf2025-04-08https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-dose-modifications2025-06-06https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-resistance.pdf2025-07-08https://www.jnjmedicalconnect.com/media/attestation/products/invega-sustenna/paliperidone-palmitate-1month-safety-data-sheet-sds.pdf2026-03-23https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-dosage-and-administration-combination-with-carboplatin-and-pemetrexed-papillon-and-marip2025-09-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/phase-3-randomized-study-of-teclistamab-plus-daratumumab-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/effect-of-food-on-xarelto2025-01-28https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-can-i-eat-or-drink-around-the-time-of-my-spravato-dose2025-11-10https://www.jnjmedicalconnect.com/media/attestation/products/risperdal/risperdal-oral-solution-safety-data-sheet-sds.pdf2025-04-16https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/realworld-change-in-depressive-symptoms-among-patients-with-treatmentresistant-depression-initiated.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/can-i-take-rybrevant-faspro-if-i-am-pregnant-or-breastfeeding2025-12-18https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-central-serous-retinopathyretinal-pigment-epithelial-detachment2025-07-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rwcs/visible-guselkumab-impact-on-psoriatic-arthritis-at-week-16-in-participants-with-moderate-to-severe.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/general/visible-cohort-b-guselkumab-demonstrated-scalp-clearance-through-week-48-in-participants-with-modera.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-switching-from-other-biologics-or-small-molecules-to-tremfya-in-ulcerative-colitis2025-09-22https://www.jnjmedicalconnect.com/products/prezista/pivotal-clinical-trial-publications2025-12-23https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/rhapp-20252025-09-18https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-effects-on-cognition2025-10-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/flasco/amivantamab-plus-lazertinib-vs-osimertinib-in-firstline-egfrmutant-advanced-nsclc-longer-followup-of.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/tracleer/tracleer-dispersible-tablet-safety-data-sheet-sds.pdf2025-11-17https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-is-the-recommended-dosing-for-darzalex-faspro-alone-to-treat-multiple-myeloma2026-03-25https://www.jnjmedicalconnect.com/products/risperdal/medical-content/dosing-conversion-to-invega-sustenna-from-oral-antipsychotics2026-02-25https://www.jnjmedicalconnect.com/products/spravato/medical-content/how-will-i-take-spravato2025-10-06https://www.jnjmedicalconnect.com/media/attestation/products/lazcluze/infographic-of-mariposa-final-os-with-amivantamab-lazertinib-moa.pdf2026-01-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/winter-clinical-hawaii/spectrem-skin-clearance-results-through-week-48-with-guselkumab-in-participants-with-low-body-surfac.pdf2026-01-16https://www.jnjmedicalconnect.com/products/xarelto/medical-content/how-should-i-store-xarelto-tablets2025-06-27https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/post-hoc-analysis-of-clinically-relevant-anti-vaccine-and-virus-antibodies-in-patients-treated-with.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/effect-of-esketamine-nasal-spray-monotherapy-on-emotional-blunting-in-adult-patients-with-treatmentr.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-compass-data2025-07-29https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-use-in-autistic-disorder.pdf2026-02-13https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-renal-impairment2025-10-30https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-alcyone-study2026-01-27https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/ascp/esketamine-nasal-spray-versus-quetiapine-for-treatment-resistant-depression.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/guselkumab-re-treatment-after-withdrawal-rapid-regain-of-disease-control-in-sup-poster.pdf2026-03-27https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-rems-program-audit2026-02-11https://www.jnjmedicalconnect.com/media/attestation/general/visible-cohort-a-guselkumab-demonstrated-skin-clearance-through-week-48-in-participants-with-moderat.pdf2026-01-07https://www.jnjmedicalconnect.com/products/remicade/medical-content/shortened-infusion-duration-of-remicade2025-06-03https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/adverse-event-of-invega-sustenna-hyperglycemia-and-diabetes-mellitus2026-03-18https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-pediatric-ulcerative-colitis2026-03-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/clinical-validity-of-foundationone-cdx-assay-to-identify-hrr-positive-or-brca-po.pdf2026-02-26https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-treatment-of-fontan-circulation2026-01-06https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-monumental-2-study-cohort-d2025-12-09https://www.jnjmedicalconnect.com/media/attestation/products/tracleer/tracleer-reformulation-and-administration-of-film-coated-tablets.pdf2025-02-05https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-treatment-of-congestive-heart-failure2025-08-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/final-analysis-of-fixedduration-ibrutinib-venetoclax-for-chronic-lymphocytic-leukemia-cllsmall-lymp.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/clinical-overview-of-risperdal-consta2024-05-23https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/health-literacy/overview2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/highlevel-improvements-in-psoriasis-area-and-severity-index-with-icotrokinra-in-participants-with-mo.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/icotrokinra-demonstrated-superior-responses-compared-with-placebo-and-deucravacitinib-in-the-treatme.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/nanos-20262026-03-19https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ddw-20252025-08-28https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-qualityadjusted-time-without-symptoms-or-toxicity-analysis-qtwist2025-10-03https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-sustenna-in-elderly2025-08-14https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ats/qualitative-interviews-of-physicians-managing-patients-with-methamphetamineassociated-pulmonary-arte.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-adverse-event-hepatic-safety2025-12-11https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-elevated-liver-enzymes-in-adult-patients-with-plaque-psoriasis-or-psoriatic-a2025-09-17https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-sustenna-invega-trinza-invega-hafyera-management-of-breakthrough-psychotic-symptoms2026-03-18https://www.jnjmedicalconnect.com/products/stelara/isi-english2025-03-10https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/fall-clinical-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-elevate/association-of-antipsychotic-medication-nonadherence-with-allcause-mortality-in-newly-treated-adults.pdf2026-02-17https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-immunoglobulin-light-chain-al-amyloidosis2026-03-12https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-occurrence-of-skin-related-adverse-events-in-crohns-disease-and-ulcerative-colitis2025-10-13https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/paloma-2-study2025-12-18https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/weight-and-metabolic-changes-in-patients-treated-with-esketamine-nasal-spray-versus-quetiapine-exten.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/what-should-i-do-if-i-miss-a-dose-of-tremfya2025-08-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/outpatient-step-up-dosing-and-safety-with-talquetamab-a-real-world-mayo-clinic-study.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-overview-of-pharmacologypharmacokinetics-in-adult-patients-with-psoriasis-or-psoriatic-arth.pdf2025-12-29https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-reduction-in-the-risk-of-recurrence-of-dvt-and-pe2024-09-11https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/use-of-risperdal-consta-in-bipolar-disorder2024-12-09https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eha/incidence-prevalence-clinical-characteristics-and-treatment-patterns-of-patients-with-warm-autoimmun.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/updated-comparative-effectiveness-of-talquetamab-vs-realworld-physicians-choice-of-treatment-in-loco.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad/icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-the-interleukin23receptor-for-the-treatm.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/outcomes-healthcare-resource-utilization-and-costs-of-patients-receiving-definitive-pls.pdf2026-01-20https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/tar-200-101-study2026-03-19https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-mechanism-of-action2026-03-13https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/carvykti-safety-data-sheet-sds.pdf2025-09-16https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/apapp/delphi-study-investigating-the-clinical-use-of-oral-selexipag-to-treat-pulmonary-arterial-hypertensi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-renal-and-urinary-disorders2026-03-12https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-how-should-i-store-simponi.pdf2025-05-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/life-years-gained-from-the-fda-accelerated-approval-program-in-slides.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/sid/phase-3-results-from-an-innovative-trial-design-of-treating-plaque-psoriasis-involving-difficulttotr.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aacr/differential-preclinical-activity-of-bruton-tyrosine-kinase-inhibitors-against-btk-resistanceassocia.pdf2026-01-20https://www.jnjmedicalconnect.com/products/talvey/medical-content/can-talvey-cause-loss-of-taste2025-10-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/rwcs/realworld-onlabel-treatment-persistence-through-24-months-in-biologicnaive-and-biologicexperienced-p.pdf2026-02-11https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-event-respiratory-depression012025-08-22https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/ats/preplanned-study-design-adaptations-in-unisus-a-phase-3-conclusions-randomized-superiority-study-com.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/tar-200-monotherapy-in-patients-with-bacillus-calmette-guerinunresponsive-high-risk-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/can-i-crush-split-or-chew-opsynvi2025-04-15https://www.jnjmedicalconnect.com/products/invokana/medical-content/use-of-invokana-in-npo-or-fasting-patients2025-11-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-west/real-world-on-label-treatment-persistence-through-24-months-in-biologic-naive-17a-inhibitors.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-hepatic-safety2025-12-02https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-effect-on-prostate-specific-antigen-levels2025-12-23https://www.jnjmedicalconnect.com/products/spravato/medical-content/real-world-use-spravato-treatment-patterns2025-09-23https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/use-of-invega-hafyera-in-renal-impairment2025-06-03https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-crushing-and-splitting-tablets2025-11-03https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-can-i-take-caplyta-if-i-am-pregnant-plan-to-become-pregnant-breastfeeding-or-plan-to-breast2026-01-14https://www.jnjmedicalconnect.com/media/attestation/products/darzalex-faspro/darzalex-faspro-what-is-the-recommended-dosing-for-darzalex-faspro-in-combination-with-bortezomib-l.pdf2026-03-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/the-renal-activity-index-for-lupus-identifies-and-predicts-complete-renal-remission-or-absence-of-ki.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/efficacy-and-safety-of-nipocalimab-vs-efgartigimod-in-a-randomized-openlabel-phase-3b-interventi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-stem-cell-collection2025-11-11https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-use-in-patients-with-comorbid-multiple-sclerosis2026-03-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/pooled-efficacy-and-safety-of-teclistamab-in-217-patients-with-tripleclass-exposed-relapsedrefractor.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/rhapp/visible-guselkumab-demonstrated-significant-scalp-psoriasis-clearance-and-scalp-itch-improvements-at.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/stem-cell-sc-yield-and-transplant-with-daratumumab-bortezomib-lenalidomide-and-dexamethasone-in-tran.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/pcc/schulman-et-al-20182025-10-16https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-event-of-spravato-dysgeusia2025-08-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/hopa/preventing-moderate-to-severe-dermatologic-adverse-events-in-firstline-egfrmutant-advanced-nsclc-tre.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/darzalex/darzalex-generation-2-safety-data-sheet-sds.pdf2026-01-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/guselkumab-maintenance-treatment-improves-healthrelated-quality-of-life-in-patients-with-moderately.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/efficacy-of-subcutaneous-guselkumab-in-moderately-to-severely-active-ulcerative.pdf2026-02-23https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-patients-with-parkinsons-disease2026-03-18https://www.jnjmedicalconnect.com/products/akeega/medical-content/dosage-and-administration2026-02-25https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-management-of-sleep-disturbance.pdf2025-10-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/suo/moonrise1-phase-3-study-of-tar210-erdafitinib-intravesical-targeted-releasing-system-versus-intraves.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-nasal-disorders2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-what-are-the-possible-side-effects-of-zytiga.pdf2025-09-26https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-in-prostate-cancer2026-01-19https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/ascp/lumateperone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-and-anxious-distress.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-in-combination-with-biologics-in-patients-with-plaque-psoriasis2026-03-20https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-lenalidomide-discontinuation2025-11-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/impact-of-disease-duration-on-clinical-and-endoscopic-responses-at-1-year-in-pat.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-longterm-effectiveness-and-safety-outcomes-among-patients-receiving-teclistamab-for-the-tr.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/jadpro-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/patientreported-outcomes-in-the-phase-3-cartitude4-study-of-ciltacabtagene-autoleucel-vs-standard-of.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/efficacy-and-safety-of-erdafitinib-in-patients-with-advanced-or-metastatic-cholangiocarcinoma-and-fg.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/deep-psa-decline-in-the-chinese-subgroup-of-libertas-a-phase-3-study-of-apalutapresentation.pdf2026-02-26https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-peripheral-edema-and-decrease-in-serum-albumin2025-11-14https://www.jnjmedicalconnect.com/media/attestation/products/lazcluze/amilaz-dose-modification-infographic.pdf2026-01-05https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-use-in-combination-with-an-alternative-corticosteroid.pdf2025-12-29https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-active-psoriatic-arthritis-discover12026-01-23https://www.jnjmedicalconnect.com/products/xarelto/medical-content/dosing-and-administration-compatibility-of-xarelto-oral-suspension-with-ng-or-g-tube2025-12-08https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/realworld-less-frequent-dosing-schedule-of-teclistamab-in-patients-with-relapsed-or-refractory-multi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-repackaging-stability.pdf2024-08-08https://www.jnjmedicalconnect.com/media/attestation/products/intelence/symtuza-prezcobix-prezista-intelence-edurantmedia-statementlegal-actioncounterfeit-products.pdf2025-05-08https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-injection-site-reactionpain2025-08-26https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-density-of-single-dose-prefilled-syringe-and-single-dose-prefilled-smartject-autoinjector.pdf2024-11-26https://www.jnjmedicalconnect.com/products/risperdal/medical-content/adverse-event-of-risperdal-management-of-risperidone-induced2025-07-31https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/aanem-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/erleada-sequencing-of-erleada-with-zytiga.pdf2026-01-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/efficacy-and-safety-of-subcutaneous-guselkumab-rescue-therapy-in-patients-with-moderately-to-severel.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/inferring-fgfr-status-from-he-images-using-digital-pathology-to-identify-patients-for-earlystage-bla.pdf2026-01-20https://www.jnjmedicalconnect.com/products/stelara/pivotal-clinical-trial-publications2025-12-26https://www.jnjmedicalconnect.com/products/inlexzo/procedural-videos-and-information/video-insertion-removal-procedure-anatomically-male-patient2025-09-25https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-with-monoamine-oxidase-inhibitors2025-10-30https://www.jnjmedicalconnect.com/media/attestation/products/erleada/erleada-what-are-the-possible-side-effects-of-erleada.pdf2025-06-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/treatment-with-firstline-ibrutinib-improves-overall-survival-in-patients-with-chronic-lymphocytic-le.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-dermatologic-adverse-reactions2025-10-10https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/characteristics-and-clinical-outcomes-of-patients-with-treatment-resistant-depression.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-invega-sustenna-invega-trinza-invega-hafyera-drug-interactions-general.pdf2025-06-04https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-adults-with-cancer-associated-thrombosis2024-11-19https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-capillary-leak-syndrome.pdf2024-10-21https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-instructions-for-use-one-press-patient-controlled-injector.pdf2025-10-01https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/comparison-of-pharmacodynamic-and-mechanistic-response-of-guselkumab-subcutaneous-and-intravenous-in.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/ascp-20242025-08-29https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-effect-on-inflammatory-cardiovascular-risk-biomarkers-in-adult-patients-with-plaque-psorias2025-04-29https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-combination-with-pomalidomide-and-dexamethasone-in-multiple-myelom2026-03-10https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-what-is-the-dosing-schedule-of-tremfya-for-plaque-psoriasis.pdf2025-10-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/is-there-a-way-to-reverse-the-effects-of-xarelto2025-10-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/safety-and-efficacy-of-pasritamig-pas-docetaxel-doce-in-participants-with.pdf2026-02-26https://www.jnjmedicalconnect.com/products/spravato/medical-content/drug-interactions-of-spravato-general2025-10-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-use-in-patients-with-hepatic-impairment-with-generalized-myasthenia-gravis2025-11-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/sunrise5-a-phase-3-randomized-openlabel-study-of-tar200-compared-with-intravesical-chemotherapy-afte.pdf2026-01-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-cartitude2-mmy2003-cohort-d-use-in-patients-with-cr-after-frontline-asct2025-10-01https://www.jnjmedicalconnect.com/products/darzalex/medical-content/conversion-between-formulations2025-07-22https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-treatment-of-scalp-psoriasis2026-03-19https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-potential-for-abuse-and-diversion2026-03-11https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/neuroscience-digital-knowledge-library2026-03-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-ankylosing-spondylitis-or-axial-spondyloarthritis2026-02-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/discovery-of-jnj89853413-a-firstinclass-cd33xv2-tcell-engager-for-the-treatment-of-acute-myeloid-leu.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/preventing-moderate-to-severe-dermatologic-adverse-events-in-firstline-egfrmutant-advanced-nsclc-pls.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/background-and-conversion-from-erzofri2026-02-02https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-the-treatment-of-hidradenitis-suppurativa2025-08-12https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/rybrevant-dosage-and-administration-missed-dose2025-07-31https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-management-of-hypersensitivity-or-infusion-reactions-in-adult-patients-with-crohns-disease2025-12-01https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/efficacy-of-nipocalimab-in-open-label-extension-in-patients-transitioned-from-placebo-results-from-v.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-pediatric-crohns-disease2026-03-31https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/extraintestinal-manifestations-in-participants-with-moderately-to-severely-activ.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/characterization-of-serum-inflammatory-proteins-in-response-to-guselkumab-or-ustekinumab-induction-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-monumental-2-study-cohort-e2025-12-19https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/rwcs-20262026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/impact-of-prior-tumor-necrosis-factor-inhibitor-treatment-and-baseline-psoriatic-arthritis-disease-a.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/asco-gi/amivantamab-with-or-without-chemotherapy-in-rightsided-metastatic-colorectal-cancer-updated-results.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-colorectal-cancer-origami-2-study2025-06-03https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ash-20242025-08-28https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-perioperative-use2025-05-28https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-stelara-ustekinumab-tremfya-air-bubble-in-prefilled-syringe-and-prefilled-syringebased.pdf2025-10-03https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/adaa/factors-associated-with-fulfillment-of-esketamine-prescription-among-patients-with-treatmentresistan.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/disease-recovery-evaluation-and-modification-dream-study-and2025-04-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/efficacy-and-safety-of-erdafitinib-in-adults-with-nsclc-and-prespecified-fibroblast-growth-factor-re.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-valvular-disease2025-07-25https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-oros-technology.pdf2024-11-06https://www.jnjmedicalconnect.com/media/attestation/products/imaavy/safety-data-sheet-for-imaavy-nipocalimabaahu.pdf2026-03-18https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-use-in-patients-with-a-history-of-malignancy2025-09-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/real-world-less-frequent-dosing-of-teclistamab-in-patients-with-relapsedrefractory-multiple-myeloma.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-dosing-dosing-over-72-mg-per-day-in-adults.pdf2025-08-11https://www.jnjmedicalconnect.com/media/attestation/products/darzalex/darzalex-generation-1-safety-data-sheet-sds.pdf2026-04-01https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/psych-congress-np-institute/first-onset-and-duration-of-treatmentemergent-adverse-events-in-patients-with-major-depressive-disor.pdf2026-03-19https://www.jnjmedicalconnect.com/products/stelara/medical-content/treatment-of-adult-patients-with-ulcerative-colitis-unifi-clinical-trial-program2026-02-05https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/should-i-mention-any-medications-i-am-taking-to-my-provider-before-receiving-simponi-aria2026-01-26https://www.jnjmedicalconnect.com/products/tremfya/medical-content/can-i-receive-vaccines-while-taking-tremfya2026-03-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aua/moonrise1-phase-3-study-of-tar210-an-erdafitinib-intravesical-delivery-system-versus-intravesical-ch.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rhapp/safety-of-guselkumab-in-inflammatory-bowel-disease-up-to-1-year-integrated-safety-analysis-of-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/adverse-event-of-xarelto-thrombocytopenia2024-11-15https://www.jnjmedicalconnect.com/products/talvey/medical-content/monumental-12026-01-23https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-stampede-trial.pdf2025-12-30https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/simponi-aria-stability-of-prepared-infusions-dilution-with-5-dextrose-in-water-solution2025-11-10https://www.jnjmedicalconnect.com/products/invokana/medical-content/adverse-event-increased-urination-and-select-urine-chemistry2025-05-08https://www.jnjmedicalconnect.com/products/carvykti/medical-content/what-are-the-possible-side-effects-of-carvykti2025-10-21https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/ats/effect-on-exercise-capacity-and-longterm-safety-and-tolerability-of-macitentan-and-tadalafil-as-a-si.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-15-mg-tablet-safety-data-sheet-sds.pdf2025-05-02https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-elevate/lumateperone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-and-anxious-distress.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-adverse-event-weight-change2025-12-03https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-use-of-lower-infusion-volumes2025-11-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ascpt/pharmacokinetics-bridging-of-icotrokinra-jnj77242113-oral-solution-and-tablet-formulations.pdf2026-02-17https://www.jnjmedicalconnect.com/products/uptravi/medical-content/crushing-and-reformulation-of-uptravi2025-04-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/efficacy-of-nipocalimab-a-novel-neonatal-fragment-crystallizable-receptor-blocker-as-measured-using.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-use-in-geriatric-patients2025-09-12https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant/an-infographic-including-prophylaxis-information-for-venous-thromboembolism-vte-risk-assessment-and.pdf2025-09-09https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant/rybrevant-what-are-the-possible-side-effects-of-rybrevant.pdf2025-11-17https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/acg-20242025-08-28https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/ecnp-20252025-09-30https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-emaginecartitude6-mmy3005-study2025-08-30https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il-23i-in-participants-wit.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/icotrokinra-demonstrated-superior-responses-compared-with-placebo-and-deucravacitinib-in-the-treatme.pdf2026-02-17https://www.jnjmedicalconnect.com/products/erleada/medical-content/can-i-crush-split-or-mix-erleada-240-mg-tablet-with-orange-juice-applesauce-or-noncarbonated-water012025-12-17https://www.jnjmedicalconnect.com/products/xarelto2026-02-18https://www.jnjmedicalconnect.com/media/attestation/products/sporanox-capsules/sporanox-capsules-dosage-and-administration-opening-capsule.pdf2024-12-15https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/how-patients-with-depression-and-their-providers-navigate-anhedonia-an-ethnographic-evaluation-of-di.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/absolute-lymphocyte-count-as-a-key-biomarker-for-monitoring-safety-after-ciltacabtagene-autoleucel-i.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-onset-of-action-in-bipolar-depression2026-03-18https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-cartitude-4-study2026-03-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/amivantamab-plus-chemotherapy-vs-chemotherapy-as-firstline-treatment-among-patients-with-egfr-exon-2.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/treatment-with-stelara-in-adult-patients-with-acute-severe-ulcerative-colitis2026-01-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/treatment-of-plaque-psoriasis-involving-highimpact-areas-with-icotrokinra-a-targeted-oral-peptide-th.pdf2026-02-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/density-and-overfill-volume-of-tremfya-200-mg20-ml-solution-for-intravenous-infusion2026-02-04https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/how-does-opsynvi-work2025-04-29https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/insights-on-oral-therapies-for-psoriasis-a-medical-science-liaison-administered-questionnaire.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-east/guselkumab-for-treatment-of-juvenile-psoriatic-arthritis-data-extrapolation-from-studies-in-adjacent.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/impact-of-previous-bcma-exposure-evidence-from-practice-outside-of-clinical-trials-to-inform-talquet.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/prezcobix-675mg150mg-tablets-safety-data-sheet-sds.pdf2025-08-28https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-nail-psoriasis2025-10-15https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/pha-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aacr/amivantamab-efficacy-in-wild-type-egfr-nsclc-tumors-correlates-with-levels-of-ligand-expression.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/pha/prior-authorization-restrictiveness-negatively-impacts-time-to-receipt-of-endothelin-receptor-antago.pdf2026-01-20https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-occurrence-and-management-of-hematologic-adverse-events2026-03-03https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-events-dyskinesia2026-03-17https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-eisenmenger-syndrome2025-05-15https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/teclistamab-stepup-dosing-and-less-frequent-dosing-schedule-in-the-realworld-setting-an-analysis-of.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-pentoxifylline2024-09-17https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-use-in-patients-with-renal-impairment2025-08-12https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-hematologic-events.pdf2025-12-23https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/access-to-healthcare/decision-support-for-patients2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/burden-of-prominent-anhedonia-in-major-depressive-disorder-reflected-in-polypharmacy.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/amivantamab-plus-capmatinib-in-advanced-nonsmall-cell-lung-cancer-nsclc-harboring-met-alterations-re.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/treatment-of-atopic-dermatitis-with-stelara2025-10-15https://www.jnjmedicalconnect.com/media/attestation/products/talvey/operationalization-of-bispecific-therapies-in-multiple-myeloma.pdf2025-01-29https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/ishlt/survival-in-pulmonary-arterial-hypertension-for-669-patients-treated-with-selexipag-in-clinical-prac.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-effect-on-body-composition.pdf2025-08-04https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-impact-of-weight-on-efficacy-in-the-treatment-of-adult-patients-with-crohns-disease-or-ulce2026-03-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/eau/symptoms-healthrelated-quality-of-life-and-burden-among-patients-with-highri.pdf2026-03-12https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-retreatment-of-rheumatoid-arthritis-after-a-drug-free-interval2024-11-22https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/what-should-i-avoid-while-receiving-rybrevant2025-11-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fsr/inhibition-of-structural-damage-progression-with-guselkumab-in-participants-with-active-psa-results.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/intelence/intelence-tablet-dispersion.pdf2025-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/characteristics-treatment-patterns-and-outcomes-of-patients-with-multiple-myeloma-retreated-with-dar.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/nsc-20242025-08-28https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-metastatic-nsclc-with-met-mutations-or-amplifications2025-06-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/first-worldwide-real-life-data-on-fixed-duration-ibrutinibvenetoclax-treatment-for-previously-untrea.pdf2026-01-07https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/use-of-simponi-aria-without-methotrexate-in-the-treatment-of-rheumatoid-arthritis2025-11-16https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/video-rybrevant-chrysalis-study-overview2026-02-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/mgfa-international-20252025-09-08https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-use-of-erleada-in-patients-taking-warfarin2026-03-27https://www.jnjmedicalconnect.com/products/xarelto/medical-content/real-world-evidence-of-xarelto-graham-study2025-07-30https://www.jnjmedicalconnect.com/products/stelara/medical-content/can-i-take-stelara-if-i-am-breastfeeding-planning-to-breastfeed-pregnant-or-planning-to-become-pregn2025-07-14https://www.jnjmedicalconnect.com/media/attestation/products/sporanox-oral-solution/sporanox-bioavailability-effect-of-food.pdf2026-02-12https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-daratumumab-and-hyaluronidase2025-09-12https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-pharmacokinetics-of-symtuza.pdf2025-08-25https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/dosing-of-invega-trinza-conversion-from-invega-sustenna-administered-every-3-weeks-to-invega-trinza2025-05-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il-23i-in-participants-wit.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-effect-on-blood-pressure2026-03-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/ciltacabtagene-autoleucel-vs-standard-of-care-in-patients-with-functional-highrisk-multiple-myeloma.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/outcomes-healthcare-resource-utilization-and-costs-of-patients-receiving-definitive-poster.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-ventricular-thrombus2024-11-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/longterm-followup-from-majestec1-china-cohort-of-teclistamab-in-patients-with-relapsedrefractory-mul.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-specialty-distributors2025-09-24https://www.jnjmedicalconnect.com/media/attestation/products/zavesca/zavesca-safety-data-sheet-sds.pdf2025-11-17https://www.jnjmedicalconnect.com/products/remicade/medical-content/reconstitutiondilution-of-remicade-in-045-sodium-chloride2025-01-11https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-outpatient-administration2026-03-10https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/comprehensive-analysis-of-motor-endplate-pathology-in-achr-ab-positive-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/a-randomized-openlabel-study-on-the-effect-of-nipocalimab-on-vaccine-responses-in-healthy-participan.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-pediatric-patients2026-02-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/jadpro/amivantamab-plus-chemotherapy-vs-chemotherapy-in-egfrmutated-advanced-nonsmall-cell-lung-cancer-afte.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-colorectal-cancer-origami-3-study2025-06-03https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/dosing-of-risperdal-consta-deltoid-administration2025-08-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/dynamic-frailty-analysis-of-transplantineligible-tie-patients-with-ndmm-in-the-phase-3-maia-and-ceph.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/antipsychotic-use-and-risk-of-breast-cancer-in-women-with-schizophrenia2025-12-24https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-safety-information-skin-rash.pdf2025-03-03https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/what-should-i-avoid-while-receiving-invega-sustenna2025-05-13https://www.jnjmedicalconnect.com/products/nipocalimab-investigational/medical-content/nipocalimab-clinical-studies-in-chronic-inflammatory-demyelinating-polyneuropathy-cidp2026-03-09https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-adverse-event-falls2025-11-14https://www.jnjmedicalconnect.com/products/talvey/medical-content/tecvayli-and-talvey-majestec-7-study2026-03-02https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-libertas-study2026-03-03https://www.jnjmedicalconnect.com/media/attestation/medinfohtmlimages/imaavy/us-sr-13537/janssen-imaavy-evidence-table-abbreviations.pdf2025-12-22https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/isds/guselkumab-demonstrates-effectiveness-regardless-of-disease-duration-week-76-results-from-the-real.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-palmoplantar-psoriasis2025-12-22https://www.jnjmedicalconnect.com/media/attestation/products/icotrokinra/targeted-oral-peptide-icotrokinra-for-psoriasis-involving-high-impact-sites.pdf2026-02-18https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/stigma-and-mental-health/core-principles-to-reduce-stigmatizing-language2026-02-27https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-renal-insufficiency-pharmacokinetics-and-pharmacodynamics2025-10-08https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/efficacy-of-nipocalimab-in-openlabel-extension-in-patients-transitioned-from-placebo-results-from.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/realworld-evidence-of-firstline-therapy-in-transplant-eligible-multiple-myeloma-patients-insights-fr.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-dosing-plasma-concentrations.pdf2024-09-05https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/access-to-healthcare/overview2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/nei/lumateperone-for-the-prevention-of-relapse-in-patients-with-schizophrenia-results-from-a-doubleblind.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/esmo-20242025-08-28https://www.jnjmedicalconnect.com/products/opsumit/medical-content/efficacy-and-safety-of-opsumit-in-patients-with-chronic-thromboembolic-pulmonary-hypertension2025-09-30https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-dosage-and-administration-restarting-after-prolonged-interruptions2025-05-08https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/biomarker-correlates-of-clinical-outcomes-from-a-global-phase-1b-study-of-jnj-90014496-cd20cd19-bi-s.pdf2026-01-11https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-trinza-paliperidone-palmitate-3month032026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/comparison-of-pharmacodynamic-serum-il22-and-the-mechanistic-tissue-molecular-changes-between-guselk.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-sustenna-invega-trinza-invega-hafyera-management-of-breakthrough-psychotic-symptoms2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-treatment-of-ulcerative-colitis-dose-increase-above-100-mg-every-4-weeks-or-dosing-interval.pdf2025-11-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/amivantamab-plus-lazertinib-vs-osimertinib-in-firstline-1l-egfrmutant-egfrm-advanced-nsclc-final-ove.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/real-world-patient-characteristics-treatment-patterns-and-outcomes-among-relapsedrefractory-multiple.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-gem-tectal-study2025-08-04https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/comparative-efficacy-of-nipocalimab-and-other-fcrn-blocker-therapies-in-generalized-myasthenia-gravi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-specialty-distributors2026-01-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/bleximenib-in-combination-with-intensive-chemotherapy-supplemental-materials.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-mmy2012-lyra-study2025-06-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/rwcs/efficacy-and-safety-of-guselkumab-in-participants-with-active-psoriatic-arthritis-and-inadequate-res.pdf2026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/acnp/remission-with-lumateperone-42-mg-adjunctive-to-antidepressant-therapy-in-patients-with-major-depres.pdf2026-01-15https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/language-and-communication/strategies-for-listening-and-learning2026-02-27https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-patients-undergoing-surgery2025-11-26https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-differences-from-oral-risperidone.pdf2025-06-05https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-occurrence-of-neurotoxicity-including-icans2026-02-02https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/seltorexant-versus-quetiapine-extended-release-as-adjunctive-treatment-in-major-depressive-disorder.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-initial-triple-versus-initial-dual-oral-combination-therapy-triton2025-07-30https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-headache-in-adult-patients-with-moderate-to-severe-plaque-psoriasis-or-active2025-09-08https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/wclc-2025/validation-analysis-of-met-ihc-video2025-09-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/subcutaneous-vs-intravenous-amivantamab-patient-satisfaction-and-resource-utilization-results-from-t.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/crossstudy-comparison-of-ibrutinib-in-combination-with-venetoclax-iv-vs-acalabrutinib-in-combination.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/longterm-use-of-oral-corticosteroids-and-overall-survival-among-patients-with-myasthenia-gravis-a-na.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/storage-and-stability-of-darzalex-faspro-vials-at-freezing-temperatures2025-09-23https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/amcp-nexus-20252025-10-27https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-sexual-function2026-03-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/asco-gi/amivantamab-with-or-without-chemotherapy-in-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-what-is-spravato2026-01-09https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-effect-on-ocular-manifestations-in-patients-with-generalized-myasthenia-gravis2025-08-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eha/a-systematic-review-in-primary-and-secondary-warm-autoimmune-haemolytic-anemia-an-outcomefocused-ana.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rhapp/icotrokinra-a-novel-targeted-oral-peptide-in-patients-with-psoriatic-disease-exploratory-assessments.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-sustenna-dosing-conversion-to-invega-sustenna-from-oral-antipsychotics.pdf2026-02-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/early-intervention-with-guselkumab-is-associated-with-greater-efficacy-and-higher-rates-of-complete.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-nppa-summer/visible-cohort-b-guselkumab-improves-scaling-itch-and-shedding-or-flaking-through-week-48-in-partici.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/use-in-major-depressive-disorder2026-03-16https://www.jnjmedicalconnect.com/products/invokana/medical-content/use-of-invokana-in-patients-on-special-diets2025-04-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aacr/molecular-subtyping-and-immunohistochemistry-validation-identifies-muscle-invasive-bladder-cancer-su.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/low-remission-recapture-after-ustekinumab-dose-optimization-in-crohns-disease-results-of-the-randomi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-use-in-adolescents-with-adhd.pdf2026-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/winter-clinical-hawaii/spectrem-guselkumab-patientreported-outcomes-across-multiple-highimpact-sites-in-participants-with-l.pdf2026-01-16https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-once-everythreeweeks-q3w-dosing-in-chronic-kidney-disease.pdf2024-06-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/crisprcas9-library-screens-identified-atp2a2-as-an-in-vivo-specific-tumor-suppressor-in-myeloid-neop.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/language-and-communication2026-02-27https://www.jnjmedicalconnect.com/products/darzalex/medical-content/what-is-the-recommended-dosing-for-darzalex-in-combination-with-bortezomib-melphalan-and-prednisone2025-07-03https://www.jnjmedicalconnect.com/media/attestation/products/spravato/spravato-comparison-of-spravato-to-atypical-antipsychotics-ipdf.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-tablet-crushing-chewing-or-splitting.pdf2024-06-18https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/what-should-i-avoid-while-receiving-rybrevant-faspro2025-12-18https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aanem-20242025-08-28https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/does-lazcluze-contain-lactose2025-06-12https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-mechanism-of-action2026-03-02https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/apex-guselkumab-response-and-inhibition-of-structural-damage-progression-in-act-poster.pdf2026-03-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/patient-perspectives-and-preferences-for-step-up-dosing-and-treatment-with-teclistamab-and-talquetam.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-occurrence-of-gastrointestinal-adverse-events-in-patients-with-plaque-psoriasis2026-03-21https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/ascp/efficacy-and-safety-of-esketamine-nasal-spray-as-monotherapy-in-adults-with-treatmentresistant-depre.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/does-opsynvi-contain-lactose2025-04-15https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/latex-content-of-invega-sustenna-invega-trinza-and-invega-hafyera2025-05-20https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-of-darzalex-darzalex-faspro-in-newly-diagnosed-multiple-myeloma-in-patients-eligible-for-autolo2025-11-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-renal-insufficiency-cad-and-pad2025-07-25https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-9-mg-safety-data-sheet-sds.pdf2025-05-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/updated-efficacy-and-safety-results-of-jnj-5322-a-novel-next-generation-bcmagprc5dcd3-trispecific-an.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/safety-and-efficacy-of-ustekinumab-in-paediatric-ulcerative-colitis-uc-results.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/updated-comparative-effectiveness-of-talquetamab-vs-realworld-physicians-choice-of-treatment-in-loco.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/specialty-distributors-and-specialty-pharmacy2026-03-10https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/comparison-of-invega-sustenna-to-conventional-antipsychotics2026-03-18https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/adverse-event-of-invega-sustenna-serious-skin-reactions2025-11-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/treatment-patterns-and-molecular-testing-patterns-in-a-usbased-cohort-of-newly-diagnosed-and-relapse.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/impact-and-insights-of-psoriasis-on-quality-of-life-and-shared-decision-making-among-us-adolescents.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/adverse-event-of-invega-trinza-hyperglycemiadiabetes2025-10-01https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/stability-of-invega-sustenna-refrigeratedfrozen-excursion2025-07-03https://www.jnjmedicalconnect.com/resources/rems2026-02-10https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-treatment-of-hidradenitis-suppurativa2025-03-28https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/realworld-comparative-effectiveness-of-longacting-injectable-and-oral-antipsychotics-among-us-medica.pdf2026-02-17https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-pharmacokinetics-of-opsumit-vs-other-endothelin-receptor-antagonists2026-01-21https://www.jnjmedicalconnect.com/products/risperdal/medical-content/adverse-event-of-risperdal-pituitary-tumors2025-08-05https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-dosage-adjustment-to-every-8-weeks-in-adult-patients-with-plaque-psoriasis2025-06-16https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/does-darzalex-faspro-contain-preservatives2026-02-03https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-effect-on-drug-screening.pdf2025-02-13https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-pharmacokinetics2025-11-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/effect-of-gender-and-follow-up-time-in-damage-accrual-data-from-a-latin-america-lupus-cohort.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/gu-20252025-08-28https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/simponi-aria-occurrence-of-liver-enzyme-elevations2025-12-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/comparison-of-realworld-response-and-remission-among-patients-with-treatmentresistant-depression-tre.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/dermatologyeducationfoundationnppa/phase-3-results-from-an-innovative-trial-design-of-treating-plaque-psoriasis-involving-difficulttotr.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/pvri-20252025-08-28https://www.jnjmedicalconnect.com/products/spravato/medical-content/return-or-disposal-of-spravato2026-01-13https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-pharmacokinetics-influence-of-food.pdf2025-12-31https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/tar-200-monotherapy-in-patients-with-bacillus-calmette-guerinunresponsive-papillary-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/products/balversa2026-01-21https://www.jnjmedicalconnect.com/media/attestation/products/talvey/talvey-monumental-1-study-ipdf.pdf2026-03-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/isds/guselkumab-pharmacokinetics-and-immunogenicity-in-pediatric-psoriasis-phase-3-protostar-study.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-use-in-patients-with-hepatic-impairment2025-09-11https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-trinza-differences-from-invega-sustenna2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/rwcs-20252025-08-28https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/use-of-risperdal-consta-in-comorbid-substance-abuse-disorder2024-08-09https://www.jnjmedicalconnect.com/products/akeega/medical-content/what-are-the-possible-side-effects-of-akeega2025-12-15https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/carvykti-ciltacabtagene-autoleucel-training-module-select-adverse-reactions-including-cytokine-relea.pdf2025-12-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/longterm-5-year-remission-and-survival-after-treatment-with-ciltacabtagene-autoleucel-in-cartitude1.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/fatigue-assessed-by-neuroqol-in-phase-3-vivacitymg3-trial-of-nipocalimab-vs-placebo-in-generalized-m.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-sustenna-in-recently-diagnosed-patients-with-schizophrenia2026-04-02https://www.jnjmedicalconnect.com/products/risperdal/medical-content/adverse-event-of-risperdal-sexual-dysfunction2025-03-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/efficacy-and-safety-of-erdafitinib-in-adults-with-breast-cancer-and-prespecified-fibroblast-growth-f.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-effect-on-albumin-in-patients-with-generalized-myasthenia-gravis2025-11-10https://www.jnjmedicalconnect.com/products/tremfya/medical-content/switching-adult-patients-with-active-psoriatic-arthritis-from-other-biologics-to-tremfya2025-07-30https://www.jnjmedicalconnect.com/products/icotyde/medical-content/what-should-i-do-if-i-miss-a-dose-of-icotyde2026-03-18https://www.jnjmedicalconnect.com/products/sporanox-oral-solution2026-01-21https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ims-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/molecular-differentiation-of-guselkumab-and-ustekinumab-in-moderately-to-severely-active-crohns-dise.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/how-should-i-store-lazcluze2025-06-12https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-dose-escalation-during-tremfya-maintenance-therapy-in-crohns-disease2026-02-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/winter-clinical-hawaii/durable-inhibition-of-structural-damage-progression-and-improvements-in-joint-disease-activity-with.pdf2026-01-16https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-nail-toxicity2025-10-10https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/computer-vision-endoscopy-scoring-for-ulcerative-colitis-disease-severity-arges.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/amivantamab-plus-folfox-or-folfiri-in-metastatic-colorectal-cancer-results-from-origami1-a-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/dosage-and-administration-for-the-intravenous-use-of-uptravi2026-03-10https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-combination-of-zytiga-with-radium-ra-223-dichloride-in-mcrpc.pdf2025-12-23https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/adverse-events-of-invega-trinza-general2026-03-11https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/socu-20252025-10-03https://www.jnjmedicalconnect.com/media/attestation/products/lazcluze/lazcluze-safety-data-sheet-sds-80-mg-tablets.pdf2025-08-26https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/conversion-of-invega-trinza-to-invega2025-12-18https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-adverse-event-hypersensitivity-reactions2025-07-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/icotrokinra-a-novel-targeted-oral-peptide-in-patients-with-psoriatic-disease.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/biomarker-testing-patterns-among-patients-newly-diagnosed-with-prostate-cancer-in-a-community-slides.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/exposure-response-er-relationships-of-icotrokinra-inpresentation.pdf2026-03-27https://www.jnjmedicalconnect.com/call-me-now2026-04-01https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-crohns-disease-galaxi-program2026-03-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/gulliver-study-treatment-of-facial-psoriasis-andor-genital-psoriasis2025-06-10https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/induction-efficacy-of-subcutaneous-guselkumab-vs-advanced-therapies-in-moderatelytoseverely-active-c.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/use-of-tremfya-in-patients-undergoing-surgery2025-09-01https://www.jnjmedicalconnect.com/media/attestation/products/darzalex-faspro/darzalex-faspro-what-is-the-recommended-dosing-for-darzalex-faspro-to-treat-highrisk-smoldering-mul.pdf2026-03-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/firstline-ibrutinib-plus-venetoclax-vs-chlorambucil-plus-obinutuzumab-in-elderly-or-comorbid-patient.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-dosing-discontinuation-or-withdrawal-of-therapy.pdf2025-05-06https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/what-should-i-tell-my-provider-before-receiving-rybrevant2026-01-28https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/summary-studies-assessing-reversal-agents-xarelto/rfviia2025-10-16https://www.jnjmedicalconnect.com/products/xarelto/medical-content/what-should-i-mention-to-my-healthcare-provider-before-starting-xarelto2025-06-27https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-oros-technology.pdf2025-05-20https://www.jnjmedicalconnect.com/products/invokana/medical-content/comparison-of-invokana-to-other-sglt2-inhibitors2024-10-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/results-from-safety-runin-cohort-1-of-the-phase-3-majestec7-study-in-patients-with-transplant-inelig.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/lazertinib-vs-osimertinib-in-1l-egfrmutant-advanced-nsclc-a-randomized-doubleblind-exploratory-analy.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-immunogenicity-in-patients-with-plaque-psoriasis2026-03-19https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/smfm-2026/hdfn-patient-journey-video2026-01-23https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/open-label-extension-study-of-the-double-blind-non-inferiority-study2026-01-22https://www.jnjmedicalconnect.com/media/attestation/products/risperdal-consta/risperdal-consta-safety-data-sheets-sds.pdf2025-06-04https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-fragile-patients2024-09-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/real-world-characteristics-and-outcomes-of-newly-diagnosed-multiple-myeloma-patients-receiving-autol.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-portopulmonary-hypertension2025-07-08https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-key-inclusion-and-exclusion-criteria-in-the-monumental-1-study-protocol2025-07-03https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/long-term-safety-and-efficacy-of-esketamine-nasal-spray-after-a-lapse-in-maintenance-treatment.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/rhapp/comparison-of-onlabel-treatment-persistence-in-realworld-patients-with-psoriatic-arthritis-receiving.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/economic-burden-of-myasthenia-gravis-exacerbation-and-crisis-from-us-payer-perspective.pdf2026-01-20https://www.jnjmedicalconnect.com/products/uptravi/medical-content/how-does-uptravi-work2025-08-14https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/can-lazcluze-cause-skin-problems2025-11-14https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-insertion-rates-of-inlexzo2025-09-11https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-occurrence-of-infections-in-patients-with-plaque-psoriasis2026-03-21https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-safety-data-sheet-sds-for-250-mg-tablets.pdf2025-05-05https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/asco-gi-2025/gi-2025-video2025-09-08https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-what-should-i-do-if-i-miss-a-dose-of-erleada2025-06-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/deep-prostatespecific-antigen-decline-among-early-participants-in-libertas-a-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-peripheral-artery-disease-and-nonvalvular-atrial-fibrillation2025-11-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/real-world-treatment-patterns-among-patients-with-advanced-nsclc-treated-with-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-number-needed-to-treatharm-in-clinical-trials2025-07-25https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-grapefruit-juice2025-01-23https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/phpn/patient-characteristics-and-treatment-patterns-in-patients-initiated-with-or-transitioned-to-maciten.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/design-of-a-digital-solution-to-improve-myasthenia-gravis-patient-symptom-tracking-in-routine-clinic.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-sprinkle-capsules-safety-data-sheet-sds-25-mg.pdf2025-05-01https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-occurrence-of-hematologic-events012026-01-30https://www.jnjmedicalconnect.com/products/tremfya/medical-content/can-tremfya-cause-allergic-reactions2025-09-22https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/andexanet-alfa-prt064445/comparative-analysis-andexanetalfa-pcc2025-10-16https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/inlexzo-evidence-and-value-summary.pdf2026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/subsequent-treatments-and-outcomes-in-bacillus-calmetteguerin-unresponsive-patients-with-highrisk-no.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex-faspro/pivotal-clinical-trial-publications2026-03-11https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-dosing-conversion-tofrom-another-antipsychotic.pdf2025-03-24https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/mariposa-study2026-03-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/long-term-progression-free-survival-benefit-with-ciltacabtagene-autoleucel-in-standard-risk-relapsed.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-renal-impairment-and-dialysis2026-01-05https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-effect-on-fertility2026-03-18https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/survival-outcomes-of-multiple-myeloma-patients-video2025-12-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/independent-medical-education2026-03-06https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/higher-anhedonia-is-associated-with-poorer-clinical-and-humanistic-outcomes-among-us-adults-with-maj.pdf2026-01-20https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/does-rybrevant-faspro-contain-preservatives2025-12-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/effectiveness-of-bridging-therapy-corresponds-to-improved-outcomes-after-ciltacabtagene-autoleucel-p.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/eau-2026/subsequent-treatment-patterns-and-outcomes-among-patients2026-03-12https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/clinical-trial-comparison2025-05-13https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-missed-dose.pdf2025-09-05https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-use-in-patients-with-tic-disorders.pdf2025-02-21https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/does-simponi-aria-contain-preservatives2026-02-05https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/storage-and-stability-of-darzalex-faspro-vials-at-room-temperature2025-09-23https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-carotid-or-coronary-artery-disease-and-nonvalvular-atrial-fibrillation2024-08-22https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ishlt/longterm-survival-and-safety-with-selexipag-in-pulmonary-arterial-hypertension-pah-10year-results-fr.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ash/design-of-a-phase-3-multicenter-randomized-openlabel-study-of-nipocalimab-or-ivig-in-pregnancies-at.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/ecnp/lumateperone-for-the-prevention-of-relapse-in-patients-with-schizophrenia-results-from-a-doubleblind.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/treatment-of-eisenmenger-syndrome-with-uptravi2025-11-17https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/team-phenomenal-hope/qualitative-interviews-of-physicians-managing-patients-with-methamphetamine-associated-pulmonary-art.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/mapping-out-the-patient-journey-of-generalized-myasthenia-gravis-insights-and-challenges.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/pharmacoeconomic-data-of-xarelto-stroke-risk-reduction-in-atrial-fibrillation2025-11-20https://www.jnjmedicalconnect.com/media/attestation/products/balversa/balversa-safety-data-sheet-sds-5-mg-tablets.pdf2025-11-04https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/does-rybrevant-contain-preservatives2025-08-05https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-skippirr-study2026-01-23https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-nausea-and-vomiting2025-06-10https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/use-of-simponi-aria-without-methotrexate-in-the-treatment-of-psoriatic-arthritis2025-08-01https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/odac-dermatology/maintenance-of-response-with-icotrokinra-a-targeted-oral-peptide-for-the-treatment-of-moderatetoseve.pdf2026-02-17https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-of-spravato-with-benzodiazepines2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/socu/visible-cohort-b-guselkumab-scalp-clearance-results-through-week-100-in-participants-with-moderateto.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/how-should-i-use-stelara2025-07-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/icotrokinra-a-firstinclass-novel-targeted-oral-peptide-in-patients-with-psoriatic-disease-explorator.pdf2026-02-17https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-is-the-recommended-dosing-for-darzalex-faspro-in-combination-with-bortezomib-and-dexamethasone2025-07-30https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-trimm3-mmy1005-study2025-06-26https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/intravenous-and-subcutaneous-guselkumab-induction-are-both-efficacious-in-patien.pdf2026-02-23https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-thor-2-study2026-03-16https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-effect-on-weight.pdf2025-08-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/real-world-clinical-outcomes-among-patients-with-localized-prostate-cancer-under-presenation.pdf2026-02-26https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/cinp-20252025-08-28https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/use-of-rybrevant-in-geriatric-patients2025-10-01https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-use-in-newly-diagnosed-multiple-myeloma-in-patients-ineligible-for-autologous-stem-cell-tr2026-02-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/suo/sunrise5-a-phase-3-randomized-openlabel-study-of-tar200-compared-with-intravesical-chemotherapy-afte.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/rybrevant-lazcluze-cocoon-study2025-12-08https://www.jnjmedicalconnect.com/disease-state/schizophrenia/video-kody-green-q-and-a2026-03-26https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-adverse-event-alopecia.pdf2024-08-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/efficacy-of-intravenous-and-subcutaneous-guselkumab-induction-by-weight-and-body.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/socu/visible-cohort-b-longterm-patientreported-outcomes-through-week-100-in-participants-with-moderatetos.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/guselkumab-shows-better-long-term-effectiveness-and-drug-survival-compared-to-se-poster.pdf2026-03-27https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/flasco-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/efficacy-and-safety-of-subcutaneous-guselkumab-in-east-asian-participants-with-moderately-to-severel.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ascp/efficacy-and-safety-of-esketamine-nasal-spray-as-monotherapy-in-adults-with-treatmentresistant-depre.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/homologous-recombination-repair-alterations-nextgeneration-sequencing-testing-and-time-poster.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-conversion-from-invega-sustenna-to-another-antipsychotic-including-other-formulations-of-ris2025-10-14https://www.jnjmedicalconnect.com/products/talvey/medical-content/trimm2-mmy1002-study-talvey-and-darzalex2025-11-06https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-mechanism-of-action2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/maui-derm-caribbean/durable-inhibition-of-structural-damage-progression-and-improvements-in-joint-disease-activity-with.pdf2026-01-14https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-faspro-in-high-risk-multiple-myeloma-in-clinical-trials2025-12-12https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-reports-of-peripheral-edema2025-10-29https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/how-will-i-receive-invega-trinza2025-07-11https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-interference-with-immunofixation-assays2025-08-06https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/asco-gi-20252025-08-29https://www.jnjmedicalconnect.com/products/akeega/pivotal-clinical-trial-publications2025-12-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/efficacy-safety-and-pharmacokinetics-of-golimumab-in-pediatric-patients-with-moderatelytoseverely-ac.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-comorbid-parkinsons-disease2025-11-17https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-use-of-symtuza-in-patients-with-renal-impairment.pdf2025-06-24https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-hepatocellular-carcinoma2026-04-03https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/ats/provider-preferences-regarding-the-use-of-combination-erapde5i-for-the-treatment-of-pulmonary-arteri.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/longterm-use-of-oral-corticosteroids-and-overall-survival-among-patients-with-myasthenia-gravis-a-na.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/one-year-persistence-and-effectiveness-of-guselkumab-or-tnfi-as-secondline-treatment-after-receiving.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-treatment-discontinuation.pdf2026-02-27https://www.jnjmedicalconnect.com/products/erleada/medical-content/video-mixing-erleada-240mg-tablet-with-orange-juice-applesauce-additional-water2026-02-10https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/uegw-20252025-10-06https://www.jnjmedicalconnect.com/products/carvykti/pivotal-clinical-trial-publications2025-12-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/paloma2subcutaneous-amivantamab-administered-every-4-weeks-q4w-plus-lazertinib-in-firstline-egfr-mut.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-women-during-pregnancy2026-02-16https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-retreatment-with-zytiga-in-metastatic-castration-resistant-prostate-cancer.pdf2025-12-23https://www.jnjmedicalconnect.com/products/jnj-81201887/medical-content/parasol-phase-2-clinical-trial2025-04-30https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-measuring-ustekinumab-drug-levels-in-adult-patients-with-crohns-disease-realworld-evidence2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-what-is-the-dosing-schedule-of-tremfya-for-ulcerative-colitis-uc.pdf2025-09-26https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-how-supplied2024-06-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/less-frequent-teclistamab-dosing-in-responders-modeling-and-simulation-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsynvi2026-03-24https://www.jnjmedicalconnect.com/products/spravato/medical-content/individual-items-of-the-madrs-in-the-spravato-transform-2-trial2025-02-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/rhapp/pregnancy-outcomes-in-women-exposed-to-guselkumab-review-of-cases-reported-to-the-manufacturers-glob.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/leveraging-ai-to-characterize-mental-health-experiences-throughout-the-myasthenia-gravis-diagnosis-j.pdf2026-01-20https://www.jnjmedicalconnect.com/products/risperdal/medical-content/risperdal-oral-solution-storage-and-handling-conditions2024-04-15https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-urine-drug-screen2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/first-line-ibrutinib-plus-venetoclax-versus-chlorambucil-plus-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/dosing-of-spravato-tapering-upon-discontinuation2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ispor/a-budget-impact-analysis-of-introducing-opsynvi-for-the-treatment-of-adult-patients-diagnosed-with-p.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-highrisk-smoldering-multiple-myeloma2025-12-24https://www.jnjmedicalconnect.com/products/erleada/medical-content/akeega-comparison-of-akeega-with-erleada2025-05-24https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-comparison-of-akeega-with-enzalutamide2025-06-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/pharmacokinetics-and-exposure-response-relationships-of-guselkumab-intravenous-o.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/comparison-of-pharmacodynamic-and-mechanistic-response-of-guselkumab-subcutaneous-and-intravenous-in.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-healthcare-resource-utilization-cost-outcomes-and-treatment-patterns2025-09-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/humanistic-burden-of-sjogrens-disease-a-systematic-review-of-treatment-efficacy-on-health-related.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/can-rybrevant-faspro-cause-skin-problems2025-12-18https://www.jnjmedicalconnect.com/chat2025-04-30https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-dosage-adjustments-in-adult-patients-with-plaque-psoriasis2026-01-09https://www.jnjmedicalconnect.com/products/risperdal/medical-content/adverse-event-of-risperdal-elevated-prolactin-levels-in-adults2025-03-13https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-interference-with-immunofixation-assays2026-02-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/gemcitabine-intravesical-system-in-combination-with-cetrelimab-versus-chemoradiotherapy.pdf2026-02-27https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-stability-of-unopened-vials.pdf2025-07-15https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/opsynvi-the-a-due-phase-3-trial2026-04-03https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-in-elderly-patients-65-years-of-age-and-older-with-plaque-psoriasis2026-03-20https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-ar-v7-anomalies2025-08-07https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-pharmacokinetics-of-concerta.pdf2026-03-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/safety-and-efficacy-of-talquetamab-teclistamab-in-patients-with-relapsedrefractory-multiple-myeloma.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/symptomatic-improvement-with-intravenous-guselkumab-induction-therapy-is-observe.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-3-mg-tablet-safety-data-sheet-sds.pdf2025-05-02https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-combination-with-immunomodulators-5asas-and-corticosteroids-in-ulcerative-colitis2025-08-19https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-dosing-interval-adjustment-during-every-8-weeks-maintenance-therapy-in-adult-patients-with2025-06-24https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-dosing-lower-dose2026-03-17https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/asco-gu-20262026-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/ecnp/longterm-adjunctive-lumateperone-treatment-in-major-depressive-disorder-results-from-a-sixmonth-open.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-events-of-spravato-nausea-and-vomiting2026-01-22https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/guselkumab-induction-therapy-results-in-molecular-resolution-of-inflammation-in-moderately-to-severe.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/wcpd-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/clinical-outcomes-of-teclistamab-among-majestec1-eligible-and-ineligible-population-in-the-realworld.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-elevated-gamma-glutamyltransferase2025-06-30https://www.jnjmedicalconnect.com/media/attestation/products/edurant/edurant-pharmacokinetic-food-effects.pdf2025-07-31https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-retreatment-in-adult-patients-with-active-psoriatic-arthritis-after-a-drug-free-interval2025-08-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aacr/amoydx-essential-ngs-panel-lc-10-one-solution-covering-tumor-tissue-and-plasma-for-detection-of-egfr.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aan-2025/audio-identifying-risk-factors2025-11-18https://www.jnjmedicalconnect.com/products/spravato/medical-content/maintenance-dose-of-spravato2026-01-30https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/wsaua-20252025-11-02https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/use-of-lazcluze-in-patients-with-renal-impairment2025-08-21https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/can-i-breastfeed-while-taking-opsynvi2025-04-15https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-somnolence-and-sedation2026-04-01https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-occurrence-of-malignancies-in-pediatric-and-young-adult-patients2025-01-17https://www.jnjmedicalconnect.com/products/darzalex/medical-content/how-does-darzalex-work2026-03-24https://www.jnjmedicalconnect.com/products/invokana2026-01-21https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/maui-derm-nppa-fall-20252025-09-22https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/variables-associated-with-remission-in-patients-treated-with-esketamine-nasal-spray-or-quetiapine-ex.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-drug-interactions2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/cardiac-risk-factors-and-cardiac-events-in-patients-with-newly-diagnosed-amyloid-light-chain-al-amyl.pdf2026-01-11https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-occurrence-of-infusion-related-reactions2025-07-01https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-extravasation2025-06-05https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/baseline-characteristics-and-nutrition-in-patients-with-moderately-to-severely-active-inflammatory-b.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/xarelto/xarelto-safety-data-sheet-sds-for-15-mg-tablets.pdf2025-09-16https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2026/mda/efficacy-and-safety-of-nipocalimab-vs-efgartigimod-pls.pdf2026-03-06https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-psoriasis-or-psoriatic-arthritis-with-comorbid-crohns-disease-or2025-06-11https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/aan-2025/audio-design-of-a-digital-solution2025-09-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/validation-and-characterization-of-six-distinct-sle-molecular-subtypes-using-two-large-patient-cohor.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/evaluating-the-effectiveness-of-amivantamab-plus-lazertinib-in-chrysalis2-vs-egfr-tki-monotherapy-in.pdf2026-01-20https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/adverse-event-of-risperdal-consta-neuroleptic-malignant-syndrome2025-08-21https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-trinza-conversion-to-invega-sustenna2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/dermatologyeducationfoundationnppa/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il23i-in-participants-with-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-and-darzalex-faspro-understanding-and-mitigating-interference-with-blood-compatibility-tes2025-07-16https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-comorbid-autism-spectrum-disorder2025-12-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/efficacy-and-safety-of-nipocalimab-an-antifcrn-monoclonal-antibody-in-primary-sjogrens-disease-resul.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-mechanism-of-action2026-02-04https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-drug-drug-and-pharmacokinetic-interaction-studies2025-07-31https://www.jnjmedicalconnect.com/products/tremfya/medical-content/use-of-tremfya-in-adult-patients-with-comorbid-metabolic-syndrome2026-02-25https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-drug-interactions2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/effects-of-guselkumab-on-cdapsa-disease-activity-state-and-its-association-with-longterm-radiographi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/real-world-data-of-xarelto-vs-apixaban-based-on-body-weight2025-04-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/teclistamab-daratumumab-and-pomalidomide-in-patients-with-relapsedrefractory-multiple-myeloma-result.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/conversion-between-formulations2025-07-22https://www.jnjmedicalconnect.com/products/erleada/medical-content/use-of-erleada-in-combination-with-zytiga2025-06-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/moonrise1-phase-3-study-of-tar210-an-intravesical-erdafitinib-releasing-system-versus-intravesical-c.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/jnj87801493-cd20xcd28-a-potential-firstinclass-cd20-targeted-cd28-costimulatory-bispecific-antibody.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/ascp/a-retrospective-study-of-realworld-outcomes-for-esketamine-nasal-spray-among-patients-with-treatment.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/cvct/dose-rationale-for-unisus-an-ongoing-event-driven-phase-iii-superiority-study-evaluating-macitentan.pdf2026-01-20https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-what-is-the-dose-of-caplyta2026-01-14https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/impact-of-dose-reductions-on-the-efficacy-of-erdafitinib-in-patients-with-advanced-or-metastatic-uro.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-sensitivity-to-light-in-an-extension-line.pdf2026-03-06https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/pha/delphi-study-investigating-the-clinical-use-of-oral-selexipag-to-treat-pulmonary-arterial-hypertensi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-elevate/lumateperone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-results-from-a-randomi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/doubleblind-and-openlabel-extension-results-from-a-phase-3-trial-of-seltorexant-adjunctive-to-antide.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-administration-via-a-feeding-tube2025-06-18https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/summary-studies-assessing-reversal-agents-xarelto/apcc2025-10-16https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-giant-cell-arteritis2026-01-30https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-adverse-event-hematologic-events-in-patients-with-newly-diagnosed-multip2025-11-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/realworld-comparison-of-prostatespecific-antigen-response-in-metastatic-castrationsensitive-pls.pdf2026-02-26https://www.jnjmedicalconnect.com/products/risperdal/medical-content/what-are-the-possible-side-effects-of-risperdal2025-07-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aacr/initial-results-from-a-phase-1-study-of-an-a2a-receptor-antagonist-administered-as-monotherapy-and-i.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/masterclass-in-dermatology/spectrem-guselkumab-effects-on-uncontrolled-psoriatic-arthritis-in-participants-with-moderate-low-bo.pdf2026-02-18https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/adverse-event-of-invega-sustenna-weight-change2025-11-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/efficacy-and-safety-of-esketamine-nasal-spray-as-monotherapy-in-adults-with-treatmentresistant-depre.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-fistulizing-crohns-disease2026-03-30https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/earlier-use-of-guselkumab-is-projected-to-yield-longterm-sustained-remission-in-patients-with-modera.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/nei/long-term-safety-and-efficacy-of-esketamine-nasal-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/racial-and-ethnic-differences-in-pah-care-insights-from-a-multicenter-study-in-the-united-states.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-pediatric-patients-with-plaque-psoriasis-or-psoriatic-arthritis2025-08-20https://www.jnjmedicalconnect.com/products/erleada/medical-content/video-mixing-erleada-60-mg-tablets-with-applesauce_hcp2026-02-10https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/masterclass-in-dermatology/solstice-efficacy-of-guselkumab-in-participants-with-active-psoriatic-arthritis-and-inadequate-respo.pdf2026-02-18https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-pharmacokinetics2026-02-25https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-long-term-metabolic-effects2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/preclinical-analysis-of-ciltacabtagene-autoleucel-combination-strategies-with-t-cell-bispecifics-and.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/nei/efficacy-and-safety-of-esketamine-nasal-spray-as-monotherapy-in-adults-with-treatmentresistant-depre.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-dosage-and-administration012026-01-12https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/lazcluze-dosage-and-administration-administration-via-a-feeding-tube2025-08-01https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/visible-guselkumab-impact-on-psoriatic-arthritis-at-week-16-in-participants-with-moderatetosevere-ps.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsumit/medical-content/what-should-i-do-if-i-miss-a-dose-of-opsumit2025-07-28https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-effect-of-body-mass-index2026-02-27https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-safety-data-sheet-sds-for-150-mg-tablets.pdf2026-01-05https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/wfsbp/efficacy-of-lumateperone-42-mg-in-the-treatment-of-major-depressive-disorder-a-pooled-analysis-of-ph.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/what-are-the-possible-side-effects-of-spravato2025-10-26https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/cinp/efficacy-of-lumateperone-42-mg-in-the-treatment-of-major-depressive-disorder-a-pooled-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-use-in-pregnancy-and-lactation-in-patients-with-generalized-myasthenia-gravis2026-02-13https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-use-in-jehovahs-witnesses.pdf2025-07-04https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-breast-cancer2025-06-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad/guselkumab-for-the-treatment-of-moderatetosevere-plaque-psoriasis-in-pediatric-patients-results-of-a.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/realworld-analysis-of-talquetamab-in-heavily-pretreated-and-highrisk-patients-with-relapsedrefractor.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/administration-of-spravato-by-a-healthcare-professional2026-02-26https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/dosing-partial-or-divided-dose-administration-of-invega-hafyera2026-03-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/depth-of-response-to-immunotherapy-is-associated-with-survival-outcomes-in-oligoprogressive-nsclc-a.pdf2026-01-20https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-use-of-uptravi-in-pulmonary-arterial-hypertension-treatment-in-patients-undergoing-renal-di2026-01-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/characteristics-and-treatment-patterns-of-nontransplanted-patients-with-newly-diagnosed-multiple-mye.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/indirect-treatment-comparisons-of-daratumumabpomalidomidedexamethasone-and-pomalidomidebortezomibdex.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/treatment-discontinuation-in-patients-with-inflammatory-bowel-disease-ibd-receiving-biologic-therapi.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-retreatment2025-07-18https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-malignancy2026-01-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/circulating-tumor-cells-as-a-biomarker-to-identify-highrisk-transplant-eligible-myeloma-patients-tre.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-sustenna-in-bipolar-disorder2025-08-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-high-impact-site-skin-clearance-and-itch-plspdf.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-mmy2004-griffin-study2025-07-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/suo/safety-and-tolerability-of-tar200-monotherapy-in-patients-with-bacillus-calmetteguerin-bcgunresponsi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/what-is-the-recommended-dosing-of-xarelto-for-the-treatment-of-blood-clots-in-the-veins-of-your-legs2025-07-30https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-comorbid-glaucoma2025-06-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/updated-efficacy-and-safety-results-of-subcutaneous-daratumumab-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aacr/extending-enpp3-expression-inference-from-tissue-microarrays-to-whole-tissue-sections-building-a-cas.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-drug-interactions-general.pdf2024-10-29https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-ichthyosis2025-08-12https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-occurrence-of-herpes-zoster-infections-in-adult-patients2026-02-03https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/characteristics-and-antipsychotic-treatment-pathways-of-patients-with-schizophrenia-who-received-onc.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/inhibition-of-structural-damage-progression-with-guselkumab-in-participants-with-active-psoriatic-ar.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/how-does-rybrevant-faspro-work2025-12-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/comparison-of-onlabel-treatment-persistence-in-realworld-patients-with-psoriatic-arthritis-receiving.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/comparison-of-tremfya-to-ixekizumab-in-the-treatment-of-adults-with-moderate-to-severe-plaque-psoria2026-01-11https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-vte-prevention-in-hip-and-other-fractures2025-02-13https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/ecnp-20242025-08-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-rw-burden-of-infection-among-tripleclassexposed-tce-patients-pts-with-relapsedrefractory-m.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-sequencing-of-erleada-with-enzalutamide2026-02-23https://www.jnjmedicalconnect.com/products/stelara/medical-content/outcomes-based-on-disease-location-in-the-treatment-of-crohns-disease2025-11-26https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/what-should-i-tell-my-healthcare-provider-before-starting-lazcluze2026-03-04https://www.jnjmedicalconnect.com/products/balversa/medical-content/does-balversa-interact-with-other-medicines2025-12-11https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-outpatient-administration-real-world-evidence2026-01-09https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-skin-disorders2025-10-31https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/phase-3-study-of-teclistamab-tec-in-combination-with-lenalidomide-len-and-tec-alone-versus-len-alone.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/jadpro-2024/effect-of-amivantamab-dose-interruptions-on-video2025-08-29https://www.jnjmedicalconnect.com/products/erleada/medical-content/can-i-take-erleada-if-i-have-a-partner-that-is-pregnant-or-breastfeeding2025-07-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad/visible-cohort-b-guselkumab-demonstrated-scalp-clearance-and-improved-healthrelated-quality-of-life.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ash/prevalence-and-demographics-of-autoimmune-hemolytic-anemia-in-the-united-states.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec2-study-cohort-d2026-03-02https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-use-in-ocular-myasthenia-gravis2025-10-30https://www.jnjmedicalconnect.com/products/opsumit2026-03-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/guselkumab-binding-to-cd64-il23producing-myeloid-cells-enhances-potency-for-neutralizing-il23-signal.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-gluten-content2025-05-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/dose-adjustment-outcomes-in-patients-with-waldenstrom-macroglobulinemia-treated-with-ibrutinib.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/comparison-of-invega-trinza-to-other-long-acting-therapies2025-10-01https://www.jnjmedicalconnect.com/products/akeega/medical-content/use-of-akeega-in-patients-without-homologous-recombination-repair-hrr-alterations2025-08-22https://www.jnjmedicalconnect.com/products/akeega/medical-content/video-akeega-magnitude-gene-by-gene-analysis2026-03-09https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-of-darzalex-and-darzalex-faspro-in-extramedullary-disease2025-06-26https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/use-of-risperdal-consta-and-risperdal-in-pregnancy-or-lactation2026-02-19https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/concomitant-use-of-invega-sustenna-invega-trinza-or-invega-hafyera-with-covid19-vaccines2025-08-14https://www.jnjmedicalconnect.com/products/stelara/medical-content/using-stelara-intravenous-infusion-during-maintenance-therapy-in-crohns-disease2025-11-17https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-patient-outcomes-and-experiences2025-09-15https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ascpt/adme-profiling-of-targeted-oral-peptide-jnj77242113-icotrokinra.pdf2026-02-17https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/what-are-the-possible-side-effects-of-rybrevant-faspro2025-12-18https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-occurrence-and-management-of-infections-and-hypogammaglobulinemia2026-03-06https://www.jnjmedicalconnect.com/products/spravato/medical-content/how-long-does-it-take-for-spravato-to-start-working2025-05-01https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/guselkumab-induction-therapy-results-in-molecular-resolution-of-inflammation-in-moderately-to-severe.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/every-4-week-dosing-of-spravato2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/maui-derm-hawaii/psoriasis-treatment-choices-patient-perspectives-and-preferences-a-multicountry-qualitative-study.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/real-world-evidence-of-ustekinumab-on-health-related-quality-of-life-in-patients.pdf2026-02-23https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/macitentan-containing-products-rems-update2026-03-12https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-syringe-stability.pdf2025-07-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/reallife-outcomes-in-patients-pts-with-bcmaexposed-relapsedrefractory-multiple-myeloma-rrmm-treated.pdf2026-01-20https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/use-of-lazcluze-reproductive-potential-and-lactation2025-08-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/outcomes-of-outpatient-stepup-dosing-sud-of-teclistamab-and-talquetamab-in-patients-with-relapsedref.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/progressionfree-survival-after-first-subsequent-therapy-pfs2-in-papillon2026-01-19https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/perinatal-treatment-patterns-in-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-primordium-study2026-02-26https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-management-of-infections-in-the-majestec-3-study2026-03-04https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-perforation-of-the-bladder2025-09-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/updated-efficacy-and-safety-results-of-jnj-5322-supplemental-materials.pdf2026-01-07https://www.jnjmedicalconnect.com/products/prezista2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/daratumumab-plus-bortezomib-lenalidomide-and-dexamethasone-dvrd-in-patients-with-newly-diagnosed-mul.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/kit-components-of-invega-sustenna2025-11-10https://www.jnjmedicalconnect.com/products/tremfya/medical-content/one-press-patient-controlled-injector-instructions-for-use/overview2025-12-08https://www.jnjmedicalconnect.com/products/talvey/medical-content/temperature-excursion-guidelines-for-talvey-vials2025-07-18https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-pharmacokinetics.pdf2025-12-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/phase-1-safety-efficacy-pharmacokinetics-pk-and-pharmacodynamics-pd-of-pas.pdf2026-02-26https://www.jnjmedicalconnect.com/products/stelara/medical-content/stability-of-iv-formulation-of-stelara-in-d5w2026-02-26https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-of-darzalex-darzalex-faspro-in-polyneuropathy-organomegaly-endocrinopathy-monoclonal-gammopathy2025-06-02https://www.jnjmedicalconnect.com/products/balversa/medical-content/ragnar-study2025-07-18https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-esophageal-cancer2025-06-23https://www.jnjmedicalconnect.com/media/attestation/products/xarelto/xarelto-can-i-crush-or-split-xarelto-tablets.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/cost-per-responder-model-of-daratumumab-bortezomib-lenalidomide-and-dexamethasone-dvrd-for-transplan.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-drug-interaction-anticonvulsants-and-mood-stabilizers.pdf2024-06-18https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-of-darzalex-darzalex-faspro-in-combination-with-bortezomib-lenalidomide-and-dexamethasone-in-mu2026-01-08https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-adverse-event-infections2026-03-02https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-stability.pdf2026-02-27https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-hydrashift-24-daratumumab-immunofixation-assay012026-01-23https://www.jnjmedicalconnect.com/products/tremfya/medical-content/occurrence-of-arthralgia-in-the-treatment-of-adult-patients-with-plaque-psoriasis2025-08-11https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-of-darzalex-faspro-in-underweight-or-obese-patients2025-04-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/trial-in-progress-realitec2-an-international-retrospective-study-of-clinical-outcomes-in-patients-wi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-pityriasis-rubra-pilaris2025-07-21https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-of-darzalex-darzalex-faspro-in-combination-with-cyclophosphamide-and-bortezomib-and-dexamethaso2025-08-07https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-use-of-symtuza-for-the-treatment-of-covid-19.pdf2025-05-08https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-ulcerative-colitis-quasar-program2026-03-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/realworld-treatment-patterns-and-clinical-outcomes-in-bacillus-calmetteguerin-bcg-pls.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/longterm-benefits-in-patientreported-outcomes-and-time-to-next-antimyeloma-therapy-of-ciltacabtagene.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/ascp/longterm-adjunctive-lumateperone-treatment-in-major-depressive-disorder-results-from-a-sixmonth-open.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/infectious-disease-and-vaccines2026-02-19https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-effect-on-cardiovascular-outcomes-randomized-clinical-trials2025-11-25https://www.jnjmedicalconnect.com/products/icotyde/medical-content/can-i-receive-icotyde-if-i-am-pregnant-planning-to-become-pregnant-breastfeeding-or-planning-to-brea2026-03-19https://www.jnjmedicalconnect.com/products/tremfya/pivotal-clinical-trial-publications2025-12-29https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-use-in-continuous-renal-replacement-therapy-crrt.pdf2025-11-18https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-effect-on-anxiety2026-03-18https://www.jnjmedicalconnect.com/products/akeega/medical-content/use-of-akeega-in-metastatic-castrationresistant-prostate-cancer-mcrpc2025-10-23https://www.jnjmedicalconnect.com/products/inlexzo2026-01-23https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/lazcluze-dosage-and-administration-crushing-and-splitting-tablets2025-08-01https://www.jnjmedicalconnect.com/products/invokana/medical-content/heart-failure-outcomes-of-invokana-clinical-trials2025-04-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/daratumumab-plus-bortezomib-lenalidomide-and-dexamethasone-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-effect-on-mania-in-bipolar-disorder2026-03-13https://www.jnjmedicalconnect.com/products/talvey2026-01-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/firstinhuman-study-of-jnj79635322-jnj5322-a-novel-nextgeneration-trispecific-antibody-in-patients-wi.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-use-in-patients-with-renal-impairment.pdf2024-10-07https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-routes-of-administration-minimizing-pain-at-the-site-of-subcutaneous-injection.pdf2025-07-23https://www.jnjmedicalconnect.com/products/stelara/medical-content/the-use-of-stelara-in-the-treatment-of-crohns-disease-with-strictures-or-stenoses2026-02-09https://www.jnjmedicalconnect.com/products/spravato/medical-content/switching-from-iv-ketamine-to-spravato-or-vice-versa2025-06-11https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-adverse-event-ocular-adverse-reactions2025-06-03https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-switching-from-other-biologics-or-advance-therapy-to-tremfya-in-crohns-disease2025-11-20https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-pharmacokinetics2026-02-19https://www.jnjmedicalconnect.com/products/remicade/pivotal-clinical-trial-publications2025-12-24https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-switching-from-or-to-generic-formulations-of-topamax.pdf2026-03-23https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-pediatric-patients2026-02-12https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-open-bottle-stability2025-11-14https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-dosing-and-administration-in-pediatric-patients2024-11-19https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-dosage-and-administration-partial-or-incomplete-administration2025-07-16https://www.jnjmedicalconnect.com/media/attestation/products/talvey/talvey-safety-data-sheet-sds.pdf2026-02-05https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/renal-impairment2025-06-16https://www.jnjmedicalconnect.com/products/risperdal-consta/pivotal-clinical-trial-publications2025-12-24https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/aquila-study2025-12-30https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-how-do-i-use-tremfya-100mgml-pen.pdf2025-10-09https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-pediatric-and-young-adult-patients2026-03-16https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-elevate/longterm-efficacy-and-safety-of-esketamine-nasal-spray-as-monotherapy-a-post-hoc-analysis-of-the-sus.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/fcdc-20252025-10-24https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-permitted-medications-in-cartitude-1-and-cartitude-42026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/ibd-gaps-inflammatory-bowel-disease-guidelines-alignment-in-clinical-practice-su.pdf2026-02-23https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-non-csr-ocular-disorders2025-07-23https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-latex-content2026-03-11https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-concomitant-use-of-erleada-with-relugolix2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/gpcc-2026/real-world-comparison-of-achieving-undetectable-prostate-specific-antigen-response-video2026-02-02https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-low-or-high-body-weight2025-10-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/realworld-treatment-patterns-and-clinical-outcomes-in-bacillus-calmetteguerin-bcg-poster.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec5-mmy2003-study-tecvaylibased-regimens2025-10-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-east/longitudinal-evaluation-of-neutrophiltolymphocyte-ratio-in-guselkumabtreated-patients-with-psoriatic.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-in-patients-with-comorbid-multiple-sclerosis2026-02-11https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/aepc-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/updated-analysis-of-survival-and-treatment-evolution-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/mechanisms-of-acquired-resistance-to-firstline-amivantamab-plus-lazertinib-vs-osimertinib-updated-an.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/exploring-super-responders-who-remained-treatment-free-for-more-than-3-years-after-guselkumab-withdr.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/realworld-talquetamab-utilization-patterns-and-dose-schedules-in-the-united-states-an-analysis-using.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-use-in-patients-with-renal-impairment2025-09-12https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-sustenna-invega-trinza-and-invega-hafyera-considerations-for-use-of-lais-during-covid19-pand2025-06-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/longterm-followup-from-the-phase-12-majestec1-trial-of-teclistamab-in-patients-with-relapsedrefracto.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/retreatment-of-adult-patients-with-plaque-psoriasis-with-stelara-after-a-drug-free-interval2025-12-19https://www.jnjmedicalconnect.com/products/invega2026-01-21https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-safety-information-lactic-acidosis-or-severe-hepatomegaly-with-steatosis.pdf2025-06-06https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/safety-and-efficacy-of-ustekinumab-in-indian-patients-with-moderate-to-severe-crohns-disease.pdf2026-02-23https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/aua-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/products/opsumit/opsumit-safety-data-sheet-sds.pdf2025-12-09https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/utility-and-sensitivity-of-wett-sa53-video2025-12-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/predictors-of-psoriasis-relapse-after-guselkumab-withdrawal.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/jadpro/subcutaneous-amivantamab-and-lazertinib-as-firstline-treatment-in-patients-with-advanced-egfrmutated.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ideom/spectrem-guselkumab-efficacy-across-multiple-highimpact-sites-in-participants-with-low-bsa-moderate.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/cvct-20252025-12-10https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/access-to-healthcare/patient-support-tips2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aacr/prevalence-of-fibroblast-growth-factor-receptor-fgfr-alterations-and-programmed-deathligand-1-pdl1-e.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/final-analysis-of-fixedduration-ibrutinib-venetoclax-for-chronic-lymphocytic-leukemia-cllsmall-lymp.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/efficacy-and-safety-of-subcutaneous-guselkumab-rescue-therapy-in-patients-with-moderately-to-severel.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/andexanet-alfa-prt064445/milling-et-al-20232025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/dosing-patterns-and-early-safety-and-effectiveness-outcomes-in-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-use-in-adult-patients-with-crohns-disease-or-ulcerative-colitis-and-comorbid-primary-sclero2026-02-24https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-compromised-respiratory-function2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/phase-1-study-of-intratumoral-administration-of-jnj-87704916.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/akeega/akeega-safety-data-sheet-sds-100-mg500-mg-tablets.pdf2025-08-12https://www.jnjmedicalconnect.com/products/darzalex/medical-content/can-darzalex-be-used-in-patients-with-sorbitol-allergy2025-09-10https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-dosing-rationale-in-treatmentresistant-depression2026-01-07https://www.jnjmedicalconnect.com/media/attestation/medinfohtmlimages/spravato/us-sr-12423/janssen-spravato-evidence-table-abbreviations.pdf2026-02-04https://www.jnjmedicalconnect.com/products/tremfya/medical-content/use-of-vaccines-in-patients-receiving-tremfya2025-12-02https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-perianal-and-fistulizing-crohns-disease-in-adult-patients-realworld-evidence2026-03-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/higher-teclistamab-stepup-dosing-in-patients-with-relapsed-or-refractory-multiple-myeloma-rrmm-resul.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant/cocoon-final-analysis-infographic.pdf2025-12-11https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/comparison-of-invega-sustenna-or-invega-trinza-to-once-monthly-or-once-every-two-months-subcutaneous2026-03-10https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-locally-advanced-or-metastatic-urothelial-carcinoma2026-03-16https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-management-of-elevated-lipids-in-patients-with-generalized-myasthenia-gravis2025-10-13https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec4-mmy3003emn30-study2025-11-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/endoscopic-patient-clustering-to-investigate-differential-treatment-effects-of-guselkumab-and-usteki.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/masterclass-in-dermatology/visible-guselkumab-impact-on-psoriatic-arthritis-through-week-100-in-participants-with-moderatetosev.pdf2026-02-18https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-adverse-events-general-in-patients-with-multiple-myeloma2025-11-11https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/side-effect-management-with-indwelling-idrs-in-the-treatment-of-bladder-cancer-deck.pdf2026-03-11https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-crushing-splitting-tablets2025-11-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-ulcerative-colitis-in-adults-after-prior-biologic-exposure-realworld-evidence2025-11-11https://www.jnjmedicalconnect.com/products/invokamet/medical-content/invokamet-splitting-cutting-or-dividing-the-tablet2024-11-14https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-occurrence-of-infusion-related-reactions-in-patients-with-generalized-myasthenia-gravis2025-07-09https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-specialty-distributors-and-specialty-pharmacy2025-09-16https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ccr-west-20252025-09-17https://www.jnjmedicalconnect.com/products2025-08-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ipcu/comparison-of-real-world-overall-survival-in-subgroups.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-1-study2026-03-16https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-geriatric-patients2025-10-01https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-dosage-and-administration-lower-dosing.pdf2026-02-11https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/use-of-invega-trinza-in-patients-with-early-illness-schizophrenia2025-05-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-intravenous-vs-subcutaneous-daratumumab-administration-in-multiple-myelom2026-02-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/efficacy-of-subcutaneous-guselkumab-induction-therapy-by-baseline-demographics-and-concomitant-medic.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-renal-impairment2025-06-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/efficacy-and-safety-of-apalutamide-in-metastatic-castration-sensitive-prostate-cancer-patients-with.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-and-invega-trinza-pharmacodynamics2025-12-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/spda-fall/visible-cohort-b-guselkumab-scalp-clearance-results-through-week-100-in-participants-with-moderateto.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-use-in-pediatric-patients-with-juvenile-psoriatic-arthritis2025-11-19https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-thrombotic-events-in-the-treatment-of-adult-patients-with-psoriasis-or-psoria2026-02-17https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/mmy3019-cepheus-study2025-11-03https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/health-beliefs-and-practices2026-02-27https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-postpartum-depression2026-01-01https://www.jnjmedicalconnect.com/media/attestation/products/elmiron/elmiron-capsules-100-mg-safety-data-sheet-sds.pdf2025-06-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/ciltacabtagene-autoleucel-vs-standard-of-care-in-patients-with-functional-highrisk-multiple-myeloma.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-effect-on-extraintestinal-manifestations-in-adult-patients-with-crohns-disease-or-ulcerativ2026-03-10https://www.jnjmedicalconnect.com/products/spravato/medical-content/direct-absorption-of-spravato-to-cns-no-data2025-11-14https://www.jnjmedicalconnect.com/products/erleada/medical-content/what-should-i-tell-my-healthcare-provider-before-taking-erleada2026-03-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aua/sunrise2-a-phase-3-multicenter-randomized-study-evaluating-the-efficacy-of-tar200-in-combination-wit.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/comparative-effectiveness-of-teclistamab-vs-realworld-physicians-choice-of-carfilzomibandor-pomalido.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/safety-of-guselkumab-in-inflammatory-bowel-disease-up-to-1-year-integrated-safety-analysis-of-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/what-should-i-avoid-while-receiving-invega-hafyera2025-11-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-miami/sustained-improvements-in-psoriasis-area-and-severity-index-and-in-percent-body-surface-area-of-psor.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/erleada/lay-summary-lowentritt-et-al-ecop-2024-rwe-h2h-os-apa-vs-abi.pdf2025-03-05https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il23i-in-participants-with-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-mechanism-of-action2025-09-08https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-tuberculosis-screening-during-pivotal-clinical-trials-in-the-treatment-of-adult-patients-wi2026-03-09https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/simponi-aria-stability-of-prepared-infusions-dilution-with-09-sodium-chloride-solution2025-07-23https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/partnering-with-patients-and-caregivers-to-guide-the-development-of-impactful-study-engagement-tools.pdf2026-01-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/is-there-a-risk-of-becoming-dependent-on-spravato2025-08-04https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/disease-burden-associated-with-prominent-anhedonia-in-patients-with-major-depressive-disorder-mdd-fr.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/stelara/safety-data-sheet-for-stelara-ustekinumab.pdf2025-12-12https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/nipocalimab-effect-on-immunoglobulin-g-subclasses-in-patients-with-generalized-myasthenia-gravis.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-overdose2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/guselkumab-efficacy-and-safety-in-east-asian-participants-with-moderate-to-severely-active-crohns-di.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-renal-insufficiency-venous-thromboembolism-in-adult-patients2024-12-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-overview-of-voyage-2-clinical-trial2026-03-26https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-missed-dose2026-01-29https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/prezcobix-use-in-pregnancy.pdf2025-06-02https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-use-of-prophylactic-tocilizumab2026-01-30https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/elcc-20252025-09-08https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-every-two-week-dosing-in-treating-anemia-in-patients-with-cancer.pdf2024-09-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/daratumumab-bortezomib-lenalidomide-and-dexamethasone.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/how-do-i-store-tremfya-pen2026-03-03https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-adverse-event-cytokine-release-syndrome-crs2026-03-13https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-metastasisfree-survival-mfs2025-08-07https://www.jnjmedicalconnect.com/products/invokana/medical-content/effect-of-invokana-on-renal-protection2025-01-14https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/realworld-timetonexttreatment-and-timetocastrationresistance-among-patients-with-me-presentation.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/evolution-of-treatment-patterns-and-survival-outcomes-in-european-patients-with-multiple-myeloma-fro.pdf2026-01-20https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-during-lactation2026-03-19https://www.jnjmedicalconnect.com/products/xarelto/medical-content/can-i-take-xarelto-with-supplements-or-multivitamins2025-10-15https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/language-and-communication/learn-model2026-02-27https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-renal-insufficiency-end-stage-renal-disease-hemodialysis2025-06-30https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravatoclinical-data-in-black-andor-african-american-patients-with-treatmentresistant-depression2025-08-06https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-occurrence-of-hypersensitivity-or-infusion-reactions-in-adult-patients-with-crohns-disease2025-11-25https://www.jnjmedicalconnect.com/products/opsumit/medical-content/how-does-opsumit-work2025-10-01https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-hepatic-adverse-events-and-use-in-patients-with-hepatic-impairment2025-10-22https://www.jnjmedicalconnect.com/products/spravato/medical-content/management-of-spravato-induced-high-blood-pressure-or-hypertension2025-12-18https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-use-in-the-treatment-of-multiple-myeloma-with-central-nervous-system-involvement2025-07-22https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/comparative-effectiveness-of-ibrutinib-flexible-dosing-treatment-strategies-on-time-to-next-treatmen.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/duration-of-therapy-in-patients-with-waldenstrom-macroglobulinemia-undergoing-dose-reductions-of-fir.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/isds/efficacy-and-safety-of-icotrokinra-a-novel-targeted-oral-peptide-in-adolescents-with-moderate-to-s.pdf2026-02-17https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-dosing-plasma-concentrations2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/efficacysafety-of-ciltacabtagene-autoleucel-lenalidomide-maintenance-in-patients-with-multiple-myelo.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aanem-20252025-10-29https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/patient-and-caregiver-resources2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/phpn/structured-expert-elicitation-to-generate-estimates-for-the-administrative-workload-associated-with.pdf2026-01-20https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-use-in-patients-with-seronegative-generalized-myasthenia-gravis2026-02-09https://www.jnjmedicalconnect.com/products/tremfya/medical-content/how-do-i-dispose-of-tremfya-after-my-injection2025-09-05https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/montelukast-medication2025-07-21https://www.jnjmedicalconnect.com/products/stelara/medical-content/occurrence-of-cytomegalovirus-in-adult-patients-receiving-stelara2025-07-29https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/early-systemic-and-skin-pharmacodynamic-effects-of-icotrokinra-in-participants-with-moderatetosevere.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/daratumumab-bortezomib-lenalidomide-and-dexamethasone-dvrd-vs-vrd-in-transplantineligibletransplantd.pdf2026-01-07https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/simponi-aria-treatment-of-inflammatory-eye-disease2026-01-26https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/visible-guselkumab-impact-on-psoriatic-arthritis-through-week-48-in-participants-with-moderatetoseve.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-alternative-maintenance-dosing-interval2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/earlier-use-of-longacting-injectable-paliperidone-palmitate-versus-oral-antipsychotics-in-patients-w.pdf2026-02-17https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-step-up-dosing-real-world-evidence2025-12-02https://www.jnjmedicalconnect.com/media/attestation/products/erleada/lay-summary-shore-et-al-ecop-2024-rwe-h2h-os-apa-vs-enz.pdf2025-03-05https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-in-adolescentpediatric-populations2025-09-03https://www.jnjmedicalconnect.com/products/botaretigene-sparoparvovec/medical-content/immunogenicity2026-03-02https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-once-every-two-weeks-dosing-in-chronic-kidney-disease.pdf2025-07-04https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rhapp/guselkumab-for-treatment-of-juvenile-psoriatic-arthritis-data-extrapolation-from-studies-in-adjacent.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokamet/medical-content/crushing-the-invokamet-tablet-for-oral-or-enteral-feeding-tube-administration2024-12-02https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/nei/lumateperone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-and-anxious-distress.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/dosing-of-risperdal-consta-alternate-administration-interval2025-04-24https://www.jnjmedicalconnect.com/products/erleada/medical-content/use-of-erleada-in-biochemically-relapsed-or-recurrent-prostate-cancer2025-06-24https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-latex-content.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/preclinical-analysis-of-ciltacabtagene-autoleucel-combination-strategies-with-t-cell-bispecifics-and.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/efficacy-and-safety-of-icotrokinra-a-novel-targeted-oral-peptide-il23rinhibitor-in-adolescents-with.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/pharmacodynamic-signatures-and-correlatives-of-response-in-patients-with-relapsedrefractory-multiple.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/initiation2025-06-16https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-events-extrapyramidal-symptoms2026-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/rp2d-determination-of-bleximenib-in-combination-with-venaza-phase-1b-study-in-nd-rr-aml-with-kmt2an.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-nppa-summer/icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-the-interleukin23receptor-for-the-treatm.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/guselkumab-maintenance-dose-regimens-in-patients-with-high-disease-activity-and-severity.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/impact-of-subcutaneous-guselkumab-induction-therapy-on-molecular-inflammation-in-patients-with-ulcer.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccd/visible-cohort-b-guselkumab-demonstrated-scalp-clearance-and-improved-healthrelated-quality-of-life.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/patient-centered-tools/nsclc-pda2026-02-04https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-adverse-event-prolactin-effects2025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/daratumumab-bortezomib-lenalidomide-and-dexamethasone-vs-bortezomib-lenalidomide-and-dexamethasone.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aibd/unsupervised-machine-learning-to-identify-distinct-response-patterns-to-guselkumab-in-participants-w.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/inlexzo-matchingadjusted-indirect-comparison-maic-infographic.pdf2026-02-24https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-real-world-and-pre-approval-access-program-outcomes2026-02-26https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-comorbid-autism-spectrum-disorder2025-11-10https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/mgfa-20252025-10-29https://www.jnjmedicalconnect.com/products/xarelto/medical-content/adverse-event-comparison-of-major-bleeding-events-in-patients-with-nvaf-receiving-doacs2025-07-31https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-presto-study2025-10-30https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ipcu-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-safety-outcomes-and-healthcare-resource-utilization-hcru-during-outpatient-inpatient-and-h.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/occurrence-of-alopecia-in-adult-patients-with-crohns-disease-or-ulcerative-colitis-treated-with-stel2025-07-24https://www.jnjmedicalconnect.com/products/opsumit/medical-content/macitentan-containing-products-rems-update2026-03-12https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-immune-thrombocytopenia2025-06-27https://www.jnjmedicalconnect.com/products/darzalex/medical-content/montelukast-medication2025-07-21https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-suicide2026-03-17https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/mda-20262026-03-16https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/ats/selexipag-in-pulmonary-arterial-hypertension-associated-with-connective-tissue-disease-pahctd-realwo.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-how-will-i-receive-invega-hafyera2025-12-18https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/andexanet-alfa-prt064445/phase-2-study2025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/socu/the-power-of-photos-leveraging-clinical-photos-from-the-visible-study-to-create-an-image-library-for.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/comparative-efficacy-of-carvykti-in-cartitude4-versus-alternative-treatments-from-daratumumab-clinic.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/adverse-event-of-invega-sustenna-cardiovascular-effects2025-11-26https://www.jnjmedicalconnect.com/media/attestation/products/imaavy/imaavy-what-are-the-possible-side-effects-of-imaavy.pdf2026-03-26https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-preparation-and-stability-of-3000-to-15000-ng-per-ml-from-vials-containing-15-mg.pdf2025-06-19https://www.jnjmedicalconnect.com/products/darzalex/medical-content/minimal-residual-disease-in-multiple-myeloma2025-08-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-adverse-event-hemophagocytic-lymphohistiocytosismacrophage-activation-syndrome-hlhmas2026-03-30https://www.jnjmedicalconnect.com/products/stelara/medical-content/how-do-i-dispose-of-stelara2025-07-11https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-tolerability-testing2025-12-24https://www.jnjmedicalconnect.com/products/invokana/medical-content/splitting-cutting-or-dividing-the-invokana-tablet2024-11-06https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-manufacturing-process2026-03-24https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/ispor-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/phase-3-study-of-tar210-intravesical-erdafitinib-releasing-system-vs-intravesical-chemotherapy-in-pa.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/adverse-event-of-risperdal-consta-prolactin-effects2024-11-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/survival-outcomes-of-multiple-myeloma-patients-previously-exposed-to-bcma-targeted-therapies-in-the.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/tracleer/tracleer-safety-data-sheet-sds.pdf2025-11-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/jadpro/amivantamab-plus-lazertinib-vs-osimertinib-in-firstline-egfrmutant-advanced-nsclc-longer-followup-of.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-atrial-thrombus2024-05-31https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-storage-and-stability-of-diluted-solution-at-room-temperature2026-01-26https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aan-20262026-03-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-adverse-event-seizures2025-11-11https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-invega-sustenna-invega-trinza-and-invega-hafyera-in-pregnancy-or-lactation2026-03-18https://www.jnjmedicalconnect.com/products/spravato/medical-content/tolerance-of-spravato-to-antidepressant-effect2025-09-11https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/team-phenomenal-hope/practical-considerations-for-managing-transitions-from-parenteral-prostacyclin-agents-to-oral-ip-rec.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ims-20252025-10-28https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-congress/longterm-adjunctive-lumateperone-treatment-in-major-depressive-disorder-results-from-a-sixmonth-open.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-occurrence-of-headaches-in-patients-with-plaque-psoriasis2026-03-19https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-what-is-caplyta2026-01-14https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ecop/realworld-headtohead-analysis-of-overall-survival-in-patients-with-metastatic-castration-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokana/medical-content/effect-of-invokana-on-serum-electrolytes2024-05-31https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-general2026-04-01https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-events-of-spravato-suicidal-ideation-and-behavior-in-clinical-trials-of-major-depressive-di2026-04-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/predicting-disease-remission-in-ulcerative-colitis-patients-early-results-from-the-presager-study.pdf2026-02-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/can-tremfya-cause-injection-site-reactions2026-03-16https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-density-of-reconstituted-solution2024-10-15https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/visible-cohort-b-guselkumab-demonstrated-scalp-clearance-through-week-48-in-participants-with-modera.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/apapp/patient-preferences-regarding-the-use-of-combination-erapde5i-for-the-treatment-of-pulmonary-arteria.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-immunogenicity-in-adult-patients-with-ulcerative-colitis-or-crohns-disease2025-09-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/teclistamab-in-a-large-cohort-of-100-asian-patients-with-tripleclass-exposed-multiple-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-comparison-to-risankizumab-in-the-treatment-of-adult-patients-with-crohns-disease-sequence2026-01-21https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-use-in-patients-with-hepatic-impairment2026-03-25https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/team-phenomenal-hope/qualitative-interviews-of-patients-with-methamphetamine-associated-pulmonary-arterial-hypertension-u.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-hidradenitis-suppurativa2025-09-30https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-and-darzalex-faspro-understanding-and-mitigating-interference-with-blood-compatibility-tes2025-07-16https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/capp/structured-expert-elicitation-to-generate-estimates-for-the-administrative-workload-associated-with.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/guselkumab-pharmacokinetics-and-exposureresponse-relationships-are-consistent-following-intravenous.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-cou-aa-302-study.pdf2025-07-15https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/optimization-of-car-t-cell-utilization-infographic.pdf2026-01-12https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant/infographic-on-the-dosage-administration-of-amivantamab-iv-in-the-mariposa-mariposa2-and-papillon-s.pdf2025-12-15https://www.jnjmedicalconnect.com/products/invega-trinza/pivotal-clinical-trial-publications2025-02-21https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-adverse-event-suicidal-ideation-and-behavior-in-treatmentresistant-depression-clinical-tr2026-03-24https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-5-study2025-09-10https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/interference-with-determination-of-complete-response2025-07-30https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/unsupervised-machine-learning-to-identify-distinct-response-patterns-to-guselkum.pdf2026-02-23https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/esmo-20252025-10-02https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-occurrence-of-posterior-reversible-encephalopathy-syndrome-pres2026-03-11https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/safety-data-sheet-for-tremfya-guselkumab-subcutaneous-injection.pdf2025-09-05https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ipcu-2025/head-to-head-video2025-09-08https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-latitude-study.pdf2026-02-13https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-partial-or-divided-dose-administration-of-invega-sustenna2025-05-20https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/how-will-i-receive-invega-sustenna2025-07-11https://www.jnjmedicalconnect.com/products/balversa/medical-content/how-should-i-take-balversa2025-12-10https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/educational-infographics/characterizing-real-world-evidence2025-03-24https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-missed-dose-in-patients-with-generalized-myasthenia-gravis2026-04-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/survival-differences-in-transplant-ineligible-multiple-myeloma-patients-in-japan-and-taiwan-explorin.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/clinical-burden-of-patients-diagnosed-with-major-depressive-disorder-with-versus-without.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/nanos-20262026-03-19https://www.jnjmedicalconnect.com/products/tremfya/medical-content/occurrence-of-uveitis-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis2025-08-20https://www.jnjmedicalconnect.com/products/invokana/medical-content/comparison-of-invokana-to-dapagliflozin2026-02-13https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-stomatitis2025-11-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/phase-2-study-of-talquetamab-teclistamab-in-patients-with-relapsedrefractory-multiple-myeloma-and-e.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/development-of-a-patient-friendly-lung-cancer-lexicon.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/comparison-of-xarelto-to-clopidogrel-use-in-cad-or-pad2024-10-01https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-bioequivalence-of-240-mg-and-60-mg-tablet-formulations2026-02-12https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-injection-volume2026-03-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/origami2-a-randomized-phase-3-study-of-amivantamab-vs-cetuximab-both-in-combination-with-folfox-or-f.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/daratumumab-bortezomiblenalidomidedexamethasone-in-patients-with-transplantineligible-or-transplant.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-malignancies-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis2025-09-09https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/patient-and-caregiver-experiences-of-symptom-instability-and-unpredictability-from-a-myasthenia-grav.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-lactose-intolerance2025-06-02https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-rationale-maintenance-dose2026-01-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-east/a-novel-composite-endpoint-including-low-peripheral-joint-disease-activity-state-and-clearalmost-cle.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/efficacy-by-baseline-disease-characteristics-of-intravenous-and-subcutaneous-guselkumab-induction-th.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/oral-dosing-syringe-for-xarelto-oral-suspension2025-12-08https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/real-world-evidence-on-patient-reported-outcomes-among-newly-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/edurant/edurant-use-in-pregnancy.pdf2026-01-06https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-is-the-recommended-dosing-for-darzalex-faspro-in-combination-with-bortezomib-cyclophosphamide-a2025-07-31https://www.jnjmedicalconnect.com/products/symtuza2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-east/onlabel-persistence-through-24-months-among-patients-with-psoriatic-arthritis-initiating-guselkumab.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/adverse-event-of-invega-trinza-prolactin-effects2025-09-16https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/adverse-event-neuroleptic-malignant-syndrome-and-invega-sustenna-invega-trinza-and-invega-hafyera2026-04-01https://www.jnjmedicalconnect.com/products/spravato/medical-content/does-spravato-nasal-spray-kit-contain-latex2025-09-01https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-mode-of-delivery2025-09-15https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-long-term-efficacy-and-relapse-prevention-in-schizophrenia2026-03-18https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-dosage-modifications2025-12-30https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-injection-set-materials-and-manufacturers2025-07-21https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-mechanism-of-action-and-molecular-profile2025-11-04https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/temperature-excursion-guidelines-for-tecvayli-vials2026-01-05https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-malignancies-in-adult-patients-with-crohns-disease-or-ulcerative-colitis2026-03-16https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/treating-insomnia-symptoms-as-part-of-major-depressive-disorder-a-crosssectional-survey-on-patient-n.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/can-tremfya-increase-my-risk-for-infection2025-10-03https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-resistance-mechanisms-in-egfr-exon-20-insertion-mutated-nsclc2025-06-17https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-cartitude2-mmy2003-cohort-e-use-in-highrisk-ndmm-transplant-not-planned2025-10-28https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-storage-of-inlexzo2026-02-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ecco-20252025-08-28https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-stability-of-reconstituted-vials2025-07-03https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-vasoreactivity-testing.pdf2026-03-06https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-management-of-infusion-related-reactions2024-11-21https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-invega-sustenna-invega-trinza-invega-hafyera-antipsychotic-use-and-risk-of-breast-cancer.pdf2025-12-24https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-adult-patients-with-crohns-disease-real-world-evidence2025-10-27https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-generalized-pustular-psoriasis2025-12-25https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-post-transcatheter-aortic-valve-replacement2025-09-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/value-of-the-treatmentfree-period-following-ciltacabtagene-autoleucel-infusion-in-patients-with-rela.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-occurrence-of-infections-in-patients-with-generalized-myasthenia-gravis2026-02-25https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/comparison-of-realworld-response-and-remission-among-patients-with-treatmentresistant-depression-tre.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/suo-2024/penelope-video2025-09-08https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/patient-and-caregiver-resources/caregiver-resources2026-02-27https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-use-as-monotherapy-in-patients-with-extramedullary-disease2025-11-04https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-pharmacokinetics-and-pharmacodynamics2025-11-05https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-dermatologic-adverse-reactions2025-10-10https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-use-in-high-risk-smoldering-multiple-myeloma2026-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/endoscopic-and-histologic-results-from-the-uniti-jr-study-of-ustekinumab-in-paed.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/treatment-positioning-model-to-evaluate-the-survival-benefit-of-ciltacabtagene-autoleucel-in-second.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-dosing-higher-dose2026-03-18https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-comorbid-fibromyalgia2026-02-09https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-monumental-1-study2026-03-03https://www.jnjmedicalconnect.com/media/attestation/products/balversa/balversa-safety-data-sheet-sds-3-mg-tablets.pdf2025-11-04https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-dosing-higher-doses.pdf2025-08-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/real-world-outcomes-in-patients-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-w.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/what-should-i-avoid-while-receiving-invega-trinza2025-05-06https://www.jnjmedicalconnect.com/products/xarelto/medical-content/clinical-trials-of-xarelto-with-andexxa2024-12-06https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-results-from-the-legend-2-study-assessing-lcar-b38m-cartcells2025-06-27https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-administration-without-androgen-deprivation-therapyadt2025-07-17https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/can-i-receive-invega-trinza-treatment-if-i-am-breastfeeding-pregnant-or-planning-to-become-pregnant2025-11-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/association-between-dose-reduction-and-duration-of-therapy-in-patients-receiving-ibrutinib-or-acalab.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-concomitant-use-with-vaccines-in-patients-with-generalized-myasthenia-gravis2026-01-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/comparison-of-prostate-specific-antigen-response-among-patients-with-metastatic-castration-sensitive.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-adverse-event-incidence-of-infections-in-patients-with-relapsedrefractor2025-11-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/talquetamab-versus-belgian-realworld-clinical-practice-in-tripleclass-exposed-relapsed-and-refractor.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/phase2-study-of-talquetamab-tal-teclistamab-tec-in-patients-pts-with-relapsed-refractory-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/xarelto/xarelto-safety-data-sheet-sds-for-10-mg-tablets.pdf2025-11-05https://www.jnjmedicalconnect.com/products/tremfya/medical-content/ustekinumabtremfya-guselkumab2025-11-03https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-use-of-akeega-with-concurrent-radiotherapy2026-04-01https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/ishlt-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-latex-content.pdf2025-09-19https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-hypersensitivity-reactions-in-adult-patients-with-plaque-psoriasis-or-psoriat2025-10-31https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-alternative-injection-site2025-08-05https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-comparison-to-other-neonatal-fragment-crystallizable-receptor-blockers-in-patients-with-gene2025-12-15https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-adverse-event-immune-effector-cellassociated-enterocolitis-iecec2026-02-03https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-treatment-of-genital-psoriasis2026-03-18https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-venous-thromboembolism-vte2025-06-15https://www.jnjmedicalconnect.com/products/risperdal-consta2026-01-21https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-preparation-and-administration-using-aseptic-technique-in-clinical-trials2025-08-06https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/pcc/levi-et-al-20042025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/corticosteroid-sparing-effects-of-treatment-with-guselkumab-in-patients-with-moderately-to-graviti-s.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-false-positive-urine-drug-screen2025-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rwcs/achievement-of-low-disease-activityremission-in-guselkumabtreated-patients-with-moderatelyhighly-act.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-use-in-patients-with-hepatic-impairment2025-11-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/clinical-biomarkers-associated-with-progression-free-survival-to-ciltacabtagene-autoleucel-in-chines.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/suo/outcomes-and-healthcare-resource-utilization-of-patients-receiving-definitive-versus-nondefinitive-t.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/pharmacokinetics-and-exposureresponse-relationships-of-guselkumab-intravenous-or-subcutaneous-induct.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokana/medical-content/100-vs-300-mg-invokana-as-a-starting-dose2024-08-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/reveal-mm-retrospective-evaluation-of-variables-in-early-assessment-and-landmark-trends-in-multiple.pdf2026-01-07https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-patients-with-hepatic-impairment2026-02-09https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/conversion-from-invega-sustenna-administered-every-3-weeks-to-invega-hafyera2025-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/talquetamab-utilization-patterns-and-dose-schedules-in-the-united-states-a-real-world-analysis.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/insights-into-nipocalimabfcrn-structure-binding-affinity-and-igg-lowering-and-comparison-with-efga.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-use-of-a-drug-holiday.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/nei/trd-3008-final-data-monotherapy-analysis-encore-long-term-safety-and-efficacy-of-esketamine-nasal.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/ciltacabtagene-autoleucel-vs-standard-of-care-in-lenalidomiderefractory-multiple-myeloma-phase-3-car.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/management-bleeding/rocket-af-nonvalvular-atrial-fibrillation2025-10-16https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-apollo-mmy3013-study2025-11-17https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-adverse-event-hematologic-events2026-03-13https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-administration-of-zytiga-via-a-feeding-tube.pdf2025-12-30https://www.jnjmedicalconnect.com/products/talvey/medical-content/what-are-the-possible-side-effects-of-talvey2025-10-13https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-pulmonary-hypertension-after-left-ventricular-assist-device-implantation2026-01-08https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-stelara-ustekinumab-tremfya-are-air-bubbles-in-the-prefilled-syringe-and-prefilled-syrin.pdf2025-11-03https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-dosage-in-patients-with-generalized-myasthenia-gravis2026-04-01https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/lazcluze-dosage-and-administration-missed-dose2025-07-31https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-use-of-zytiga-in-combination-with-enzalutamide-in-metastatic-castrationresistant-prostate-ca.pdf2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/bleximenib-dose-optimization-and-determination-of-rp2d-from-a-phase-1-study-in-relapsedrefractory-ac.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/camelot-2-a-phase-3-randomized-double-blind-placebo-controlled-study-of-bleximenib-venetoclax-and-az.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-use-of-erleada-in-patients-taking-clopidogrel2025-09-15https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/mgfa-international-20252025-08-28https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/how-is-darzalex-faspro-administered2025-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/real-world-time-to-next-treatment-and-time-to-castration-resistance-among-patients-with-me-pls.pdf2026-01-20https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-use-in-bcg-unresponsive-high-risk-nmibc-with-papillary-tumors-only2026-03-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suna/sunrise-1-updated-study-results-from-cohorts-2-and-4-presentation.pdf2026-01-20https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-cartitude2-mmy2003-cohort-a-use-in-progressive-multiple-myeloma-after-13-prior-lines-of-t2025-07-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/clinical-features-and-management-of-gprc5d-related-ae-in-chinese-relapsedrefractory-multiple-myeloma.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-safety-information-neurologicpsychiatric-adverse-effects.pdf2025-07-31https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-tuberculosis-infection-in-adult-patients-with-plaque-psoriasis-or-psoriatic-a2026-01-25https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-congress/lumateperone-treatment-for-major-depressive-episodes-with-mixed-features-in-major-depressive-disorde.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-proteus-study2026-02-25https://www.jnjmedicalconnect.com/products/invokamet-xr/pivotal-clinical-trial-publications2025-12-22https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/tar-200-monotherapy-in-patients-with-bacillus-calmette-guerinunresponsive-high-risk-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2024/acnp/safety-and-tolerability-of-lumateperone-42-mg-for-the-treatment-of-major-depressive-disorder-a-poole.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/maui-derm-np-pa-summer-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/association-of-pd-l1-expression-with-clinical-response-to-tar-200-in-the-phase-2b-sunrise-1-trial.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/ecnp/adjunctive-lumateperone-42-mg-treatment-in-major-depressive-disorder-efficacy-in-anhedonia-and-acros.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/rationale-for-dosing-regimens-of-xarelto2025-11-18https://www.jnjmedicalconnect.com/products/opsumit/pivotal-clinical-trial-publications2025-12-23https://www.jnjmedicalconnect.com/products/remicade/medical-content/how-should-i-receive-remicade2025-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/amivantamab-plus-chemotherapy-vs-chemotherapy-in-egfrmutated-advanced-nonsmall-cell-lung-cancer-afte.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-treatment-of-pulmonary-hypertension-associated-with-sickle-cell-disease2025-05-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/efficacy-and-safety-of-erdafitinib-in-patients-with-advanced-or-metastatic-cholangiocarcinoma-cca-an.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/adverse-events-of-invega-hafyera-general2025-07-21https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-dosing-missed-dose2025-06-24https://www.jnjmedicalconnect.com/media/attestation/products/caplyta/caplyta-what-are-the-possible-side-effects-of-caplyta.pdf2026-02-27https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-infusion-rate2025-10-12https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ash/a-retrospective-database-analysis-of-healthcare-resource-utilization-in-patients-with-warm-autoimmun.pdf2026-01-20https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-occurrence-of-injection-site-infiltration2025-09-15https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-monoclonal-gammopathy-of-renal-significance2025-04-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-west/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il23i-in-participants-with-a.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/capp/delphi-study-investigating-the-clinical-use-of-oral-selexipag-to-treat-pulmonary-arterial-hypertensi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsumit/medical-content/use-of-opsumit-in-pediatric-patients-with-pulmonary-arterial-hypertension2026-04-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/copernicus-a-multinational-pragmatic-phase-2-trial-of-subcutaneous-amivantamab-in-common-egfrmutated.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/other/tranexamic-acid2025-10-16https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-with-antidepressant-therapy2026-03-17https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-interstitial-lung-diseasepneumonitis2025-06-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/sid/guselkumab-pharmacokinetics-and-immunogenicity-in-pediatric-psoriasis-phase-3-protostar-study.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/switching-patients-with-plaque-psoriasis-from-other-biologics-to-tremfya2025-12-22https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-population-pharmacokinetic-simulations-and-exposure-analyses-after-switching-to-less-frequ2025-09-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/realworld-use-of-bacillus-calmettegurin-in-patients-with-highrisk-nonmuscle-invasive-bladder-cancer.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/tracleer/tracleer-use-in-pediatrics-with-pah-or-newborns-with-pphn.pdf2025-03-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/visible-cohort-b-guselkumab-demonstrated-scalp-clearance-and-improved-healthrelated-quality-of-life.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/improvements-in-patient-reported-outcomes-through-24-weeks-of-guselkumab-treatment-in-participants-w.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-dosage-and-administration2026-02-13https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2026/mda/posthoc-analysis-of-clinically-relevant-antivaccine-and-antivirus-antibodies-in-patients-treated-wit.pdf2026-03-06https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/does-rybrevant-faspro-contain-lactose2025-12-18https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-credence-comparison-to-dapa-ckd2025-05-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/early-systemic-and-skin-pharmacodynamic-effects-of-icotrokinra-in-participants-with-moderate-to-seve.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/prophylactic-interventions-for-oral-toxicities-with-the-gprc5dcd3-bispecific-antibody-talquetamab-in.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-understanding-interference-with-blood-compatibility-testing-brochure-onc2026-02-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/pharmacodynamic-profiles-of-patients-pts-with-newly-diagnosed-nd-vs-relapsedrefractory-multiple-myel.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-use-in-adult-patients-with-advanced-liposarcoma-or-leiomyosarcoma.pdf2025-10-27https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-reinduce-with-intravenous-infusion-during-the-induction-period-in-the-treatment-of-adult-pa2025-10-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/longerterm-followup-of-patients-receiving-prophylactic-tocilizumab-for-reduction-of-cytokine-release.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/adverse-event-of-xarelto-intracranial-hemorrhage2025-07-24https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/pha/patient-preferences-regarding-the-use-of-combination-erapde5i-for-the-treatment-of-pulmonary-arteria.pdf2026-01-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-active-coronavirus-covid192024-11-22https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/high-risk-smoldering-multiple-myeloma2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-hawaii/real-world-on-label-treatment-persistence-through-24-months-in-subcutaneous-interleukin-17a-inhibi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/use-of-invega-hafyera-in-patients-with-comorbid-substance-abuse2025-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/clinical-characteristics-and-treatment-patterns-of-ustekinumab-in-patients-with.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-safety-data-sheet-sds-for-75-mg-tablets.pdf2026-01-05https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-transitioning-patients-from-flolan-or-generic-epoprostenol-to-veletri.pdf2024-04-10https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/treatment-related-characteristics-among-younger-women-with-generalized-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-dosage-and-administration2025-09-23https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/carvykti-patient-wallet-card-chinese.pdf2024-09-13https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/nipocalimab-in-chronic-inflammatory-demyelinating-polyneuropathy-diagnostic-adjudication-of-the-firs.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/isds/durable-inhibition-of-structural-damage-progression-and-improvements-in-joint-disease-activity-post.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-storage-and-handling2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-use-of-zytiga-in-patients-with-diabetes.pdf2025-12-29https://www.jnjmedicalconnect.com/media/attestation/general/optimizing-biomarker-testing-across-the-patient-journey-in-oncology.pdf2025-11-10https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/latex-content-of-invega-sustenna-invega-trinza-and-invega-hafyera2025-05-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/comparative-efficacy-of-ciltacabtagene-autoleucel-video2025-12-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-clopidogrel2025-07-07https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/safety-information-for-rybrevant-faspro-dermatologic-adverse-reactions2026-03-30https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-faspro-amivantamab-and-hyaluronidaselpujrybrevant-amivantamabvmjwrybrevant-faspro-rybrevan2026-02-05https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/chest/characteristics-and-outcomes-of-patients-with-pulmonary-arterial-hypertension-and-selfreported-menta.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/does-akeega-interact-with-food-and-other-medicines2025-12-15https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-extravasation2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/mhncs/amivantamab-plus-pembrolizumab-in-previously-untreated-recurrent-metastatic-head-neck-squamous-cell.pdf2026-02-19https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/what-are-the-possible-side-effects-of-opsynvi2025-04-15https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/effectiveness-safety-and-clinical-use-of-teclistamab-in-patients-with-tripleclassexposed-multiple-my.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-severe-cutaneous-adverse-reactions.pdf2025-08-04https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-hepatitis-b-virus-reactivation2026-03-17https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ash-2025/a-us-retrospective-observational-study-video2025-12-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/efficacy-and-safety-of-guselkumab-for-ulcerative-colitis-through-week-140-of-the.pdf2026-02-23https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-use-in-combination-with-a-janus-kinase-inhibitor-in-adult-patients-with-crohns-disease-or-u2026-03-10https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-use-in-patients-with-a-history-of-transplantation2026-01-29https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/risperdal-and-risperdal-consta-adverse-events-fecal-incontinence2025-04-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/use-of-tremfya-in-nursing-mothers2026-02-11https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-diabetic-patients2024-11-28https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/jens-20252025-10-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/impact-of-subcutaneous-guselkumab-therapy-on-molecular-inflammation-in-patients-with-ulcerative-coli.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-tablets-50-mg-safety-data-sheet-sds.pdf2025-05-01https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/safety-information-for-rybrevant-faspro-administration-related-reactions2026-03-30https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-storage-and-stability-after-dilution-in-normal-saline2026-02-27https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-pharmacokinetics-and-pharmacodynamics-in-patients-with-generalized-myasthenia-gravis2026-03-04https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-synovitisacnepustulosishyperostosisosteitis-sapho-syndrome2026-02-25https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-cartitude2-mmy2003-cohort-c-use-in-relapsedrefractory-multiple-myeloma-after-prior-bcma-e2025-08-30https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-alternative-dosing-and-titration-schedule2025-11-13https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-ninety-minute-infusion2026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-characteristics-and-outcomes-of-patients-with-relapsed-or-refractory-multiple-myeloma-trea.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/fsr-20252025-10-10https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/ascp-20252025-08-28https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-management-of-severe-adverse-reactions2025-08-10https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-flexible-weekly-dosing-use-in-anemia-due-to-chemotherapy-in-patients-with-cancer.pdf2024-09-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aacr/discovery-of-wrn-helicase-inhibitors-that-covalently-engage-a-novel-induced-allosteric-site.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-safety-data-sheet-sds.pdf2025-07-23https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-drug-interactions2025-10-21https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-overview-of-the-phase-3-vivacity-mg3-clinical-trial2025-08-11https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-54-mg-tablet-safety-data-sheet-sds.pdf2025-05-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/management-strategies-and-patient-outcomes-among-localized-prostate-cancer-patients-with-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/corticosteroid-sparing-effects-of-treatment-with-guselkumab-in-patients-with-moderate-to-severely-ac.pdf2026-01-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-patient-reported-outcomes2025-10-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/talquetamab-a-gprc5dcd3-bispecific-antibody-in-combination-with-daratumumab-and-lenalidomide-in-pati.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant/infographic-of-mariposa-final-os-with-amivantamab-lazertinib-moa.pdf2026-01-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/elevatedermatologysummerconference/phase-3-results-from-an-innovative-trial-design-of-treating-plaque-psoriasis-involving-difficulttotr.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/safety-of-guselkumab-in-patients-aged-60-years-old-with-immune-mediated-inflamm.pdf2026-02-23https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-explorer-program2025-05-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis-with-a-history-of-malign2025-07-04https://www.jnjmedicalconnect.com/products/akeega/medical-content/comparison-of-akeega-with-zytiga2026-01-09https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-hawaii/onlabel-persistence-in-psoriasis-after-switching-to-guselkumab-or-il17-inhibitors-from-other-advance.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/policy-research/2025/amcp-nexus/patient-perspectives-on-employerbased-health-insurance-experiences-of-employees-with-chronic-disease.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/darzalex-faspro/darzalex-faspro-what-are-the-possible-side-effects-of-darzalex-faspro.pdf2026-03-25https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-use-of-anakinra-in-the-management-of-cytokine-release-syndrome-in-cartitude-12026-01-21https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-how-do-i-use-tremfya-200-mg2-ml-prefilled-syringe.pdf2025-06-13https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-use-in-patients-with-renal-impairment2026-02-05https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/comparative-analysis-of-relapse-rate-with-paliperidone-palmitate-6month-in-schizophrenia-randomized.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/safety-of-guselkumab-in-inflammatory-bowel-disease-up-to-1-year-integrated-safety-analysis-of-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/products/simponi2026-01-21https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/apcc/perzborn-et-al-20142025-10-16https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-pancreatic-carcinoma2025-07-01https://www.jnjmedicalconnect.com/products/stelara/medical-content/treatment-of-adult-patients-with-active-psoriatic-arthritis2025-08-06https://www.jnjmedicalconnect.com/products/invokana/medical-content/effect-of-invokana-on-hemoglobin-and-hematocrit2025-01-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/neoadjuvant-gemcitabine-intravesical-system-gemidrs-plus-cetrelimab-or-cetrel.pdf2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/rwcs/12month-persistence-and-multidomain-effectiveness-of-guselkumab-in-adults-with-active-psoriatic-arth.pdf2026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/updated-efficacy-and-safety-results-of-subcutaneous-daratumumab-plus-lenalidomide-versus-lenalidomid.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/real-world-clinical-outcomes-among-localized-prostate-cancer-patients-with-external-beam-radiation-t.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/real-world-evidence-effectiveness-and-safety-of-spravato-therapy2025-11-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/how-will-i-receive-rybrevant2025-11-13https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-psoriatic-arthritis-and-comorbid-uveitis2026-01-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/tar200-plus-cetrelimab-or-cetrelimab-alone-as-neoadjuvant-therapy-in-patients-with.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/pivotal-clinical-trial-publications2025-02-21https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-extravasation2026-03-18https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-delayed-hypersensitivity-reactions2025-09-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/realworld-effectiveness-of-belantamab-mafodotin-bcmacd3-bispecifi-antibodies-and-talquetamab-in-pati.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/treatment-patterns-and-clinical-outcomes-in-patients-with-bacillus-calmetteguerin-b-poster.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-regulatory-status2025-07-25https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-storage-and-handling2025-08-05https://www.jnjmedicalconnect.com/products/elmiron2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/superresponse-to-guselkumab-treatment-in-chinese-patients-with-moderatetosevere-psoriasis-a-posthoc.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-is-the-recommended-dosing-for-darzalex-faspro-in-combination-with-bortezomib-melphalan-and-pred2025-05-14https://www.jnjmedicalconnect.com/products/balversa/medical-content/administration-of-balversa-via-a-feeding-tube2025-11-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/persistence-and-effectiveness-across-psa-patient-subgroups-with-guselkumab-and-il-17-inhibitors-6-m.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/subcutaneous-daratumumab-bortezomiblenalidomidedexamethasone-in-transplanteligible-newly-diagnosed.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-immunogenicity-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis2026-01-29https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/acnp/efficacy-of-lumateperone-42-mg-for-the-treatment-of-major-depressive-disorder-analysis-of-demographi.pdf2026-01-14https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/eau-2026/periprocedural-prophylactic-antibiotic-use-with-gemcitabine-intravesical-system2026-03-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/realworld-treatment-patterns-efficacy-and-safety-of-daratumumabbased-regimens-in-chinese-patients-wi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/maui-derm-hawaii/maintenance-of-response-with-icotrokinra-a-targeted-oral-peptide-for-the-treatment-of-moderatetoseve.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ideom-20252025-08-28https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/real-world-characteristics-and-outcomes-video2025-12-08https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-exposure-study2025-06-10https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-mechanism-of-action2026-01-21https://www.jnjmedicalconnect.com/products/icotyde/medical-content/overview-of-the-iconic-ascend-clinical-trial2026-03-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/amivantamab-plus-paclitaxel-in-recurrentmetastatic-head-neck-squamous-cell-cancer-after-disease-pro.pdf2026-01-07https://www.jnjmedicalconnect.com/products/botaretigene-sparoparvovec/medical-content/mechanism-of-action2025-06-17https://www.jnjmedicalconnect.com/products/spravato/medical-content/what-should-i-mention-to-my-healthcare-provider-before-taking-spravato2025-09-26https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-in-combination-with-bortezomib-and-dexamethasone-in-multiple-myeloma2026-01-19https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/how-should-i-store-opsynvi2025-05-07https://www.jnjmedicalconnect.com/products/remicade/medical-content/use-of-remicade-without-methotrexate-in-the-treatment-of-rheumatoid-arthritis2025-04-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/ipcu/real-world-comparison-of-overall-survival-in-patients-with-metastatic-castration-presentation.pdf2026-02-03https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/lazcluze-dosage-and-administration2026-02-20https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-every-three-week-dosing-in-treating-anemia-in-patients-with-cancer.pdf2024-09-16https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2026/mda/longterm-safety-and-efficacy-results-of-nipocalimab-in-adolescents-with-generalized-myasthenia-gravi.pdf2026-03-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/ciltacabtagene-autoleucel-lenalidomide-maintenance-in-newly-diagnosed-multiple-myeloma-with-subopti.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/pharmacodynamic-response-of-jnj77242113-in-serum-and-skin-of-patients-with-moderatetosevere-psoriasi.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/aacr-20252025-08-28https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-the-use-of-vaccines-in-infants-exposed-in-utero-to-ustekinumab2026-01-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/updated-comparative-efficacy-of-ciltacabtagene-autoleucel-versus-idecabtagene-vicleucel-in-patients.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/lazcluze-use-of-lazcluze-as-a-single-agent-in-nsclc2025-10-21https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-thor-study2026-01-15https://www.jnjmedicalconnect.com/products/carvykti/medical-content/minimal-residual-disease-in-clinical-trials2026-03-30https://www.jnjmedicalconnect.com/media/attestation/congresses/policy-research/2025/amcp-nexus/patient-perspectives-on-health-insurance-design-experiences-of-beneficiaries-with-chronic-disease.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/sporanox-oral-solution/sporanox-administration-via-a-nasogastric-tube.pdf2026-01-30https://www.jnjmedicalconnect.com/media/attestation/products/icotrokinra/jnj77242113-a-highly-potent-selective-peptide-targeting-the-il23-receptor.pdf2026-02-18https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-credence2025-05-08https://www.jnjmedicalconnect.com/products/invokana/medical-content/adverse-event-amputation-randomized-controlled-trials2025-04-28https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/impact-of-race-and-social-determinants-of-health-on-exacerbations-in-generalized-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-reports-of-hemoglobin-decrease-and-anemia2025-09-11https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-aspirin2025-04-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/corticosteroid-sparing-effects-of-treatment-with-guselkumab-in-patients-with-moderately-to-galaxi-23.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/use-of-invega-hafyera-in-schizoaffective-disorder2025-05-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/exploratory-analysis-to-identify-responserelated-biomarkers-in-the-china-cohort-of-the-phase-12-maje.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/factors-associated-with-exacerbations-or-crises-in-generalized-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/carvykti-how-will-i-receive-carvykti.pdf2026-01-29https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-gastrointestinal-adverse-events2025-06-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/development-of-a-patient-friendly-lung-cancer-lexicon-slides.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rhapp/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il23i-in-participants-with-a.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/subcutaneous-amivantamab-plus-chemotherapy-in-egfrmutant-advanced-nonsmall-cell-lung-cancer-after-di.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/amivantamab-plus-lazertinib-vs-osimertinib-longer-follow-up-of-the-mariposa-study.pdf2026-01-20https://www.jnjmedicalconnect.com/products/stelara/medical-content/treatment-of-pouchitis2026-02-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/talquetamab-a-gprc5dcd3-bispecific-antibody-in-combination-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-passage-across-blood-brain-barrier2026-01-05https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/feasibility-of-extrarenal-systemic-lupus-erythematosus-disease-modification-in-gladel-20-a-latin-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-overview-of-frontier-program2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fsr/realworld-onlabel-treatment-persistence-through-24-months-in-biologicnaive-biologicexperienced-tnfi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-how-should-i-store-caplyta2026-01-13https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-latex-content2025-09-11https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/rybrevant-faspro-lazcluze-copernicus-study2025-12-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/talquetamab-outcomes-from-practice-outside-of-clinical-trials-the-bital-study.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-older-patients-with-multiple-myeloma012026-01-27https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-open-bottle-stability-of-symtuza-tablets.pdf2025-09-09https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/wfsbp/longterm-adjunctive-lumateperone-treatment-in-major-depressive-disorder-results-from-a-sixmonth-open.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-ingredients2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/reshaping-treatments-insights-from-the-bital-study-on-talquetamab-in-relapsed-refractory-multiple-my.pdf2026-01-07https://www.jnjmedicalconnect.com/products/balversa/medical-content/what-should-i-tell-my-healthcare-provider-before-taking-balversa2025-08-25https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-occurrence-and-management-of-neurotoxicity-including-immune-effector-cellassociated-neurotox2026-03-03https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2024/ecnp/lumateperone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-results-from-a-randomi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/video-crushing-splitting-or-mixing-of-60mg-tablet2025-08-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/esmo-2025/neoadjuvant-gemcitabine-intravesical-system-video2025-10-17https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-concomitant-use-with-intravenous-immunoglobulin-ivig-therapy2026-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/final-analysis-of-the-resonate2-study-up-to-10-years-of-followup-of-firstline-ibrutinib-treatment-in.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/gemcitabine-intravesical-system-tar-200-monotherapy-in-bacillus-calmette-guerinunresponsive-high-ris.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-dosing-preparation-and-administration2025-06-25https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-alternative-routes-of-administration2025-11-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/nbtxr3-activated-by-sbrt-in-combination-with-nivolumab-or-pembrolizumab-for-the-treatment-of-patient.pdf2026-01-20https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/dosage-and-administration-dosing-synchronization-with-chemotherapy-for-dose-delays-in-papillon-and2025-09-17https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-is-the-recommended-dosing-for-darzalex-faspro-in-combination-with-lenalidomide-and-dexamethason2026-03-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/robust-icotrokinra-systemic-and-skin-pharmacodynamic-effects-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/cartitude-4-study-infographic.pdf2025-11-12https://www.jnjmedicalconnect.com/products/stelara/medical-content/can-i-store-stelara-prefilled-syringes-at-room-temperature2025-07-11https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-comparison-to-intravesical-gemcitabine-and-gemcitabinedocetaxel2025-09-11https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-medicines-might-i-be-given-along-with-darzalex-faspro2025-10-15https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-switching-from-tremfya-to-other-biologics-in-crohns-disease-or-ulcerative-colitis2025-09-26https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/effectiveness-of-bridging-therapy-corresponds-video2025-12-06https://www.jnjmedicalconnect.com/products/uptravi/medical-content/can-i-crush-split-or-chew-uptravi-tablets2025-11-21https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-administration-equipment2024-12-13https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/dosage-strength-information2025-06-16https://www.jnjmedicalconnect.com/products/icotyde/medical-content/mechanism-of-action-and-pharmacokineticspharmacodynamics2026-03-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ipcu/a-descriptive-analysis-of-treatment-patterns-and-clinical-outcomes-in-patients-with-metastatic-castr.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/cardiovascular-and-metabolism2026-02-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rwcs/onlabel-persistence-through-24-months-in-patients-with-psoriatic-arthritis-using-guselkumab-or-subcu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-urine-drug-screen2026-03-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/realworld-onlabel-treatment-persistence-through-24-months-in-biologicnaive-and-biologicexperienc-17a.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/tar200-cetrelimab-and-cetrelimab-alone-in-patients-with-bacillus-calmet.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/general/psoriasis-toolkit-for-beauty-and-wellness-professionals.pdf2026-03-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/treatment-patterns-and-clinical-outcomes-in-patients-with-metastatic-urothelial-carcinoma-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-elevate/adjunctive-lumateperone-in-patients-with-major-depressive-disorder-results-from-an-additional-random.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-effects-on-prolactin2026-03-17https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-comorbid-attention-deficit-hyperactivity-disorder2025-06-30https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-annar-study2025-06-18https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-gen501-study2025-11-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/realworld-characteristics-of-patients-initiating-advanced-therapy-for-plaque-psoriasis-in-the-us-spe.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/sid/visible-significant-serum-cytokine-reduction-achieved-with-guselkumab-in-participants-with-psoriasis.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-comorbid-dementia-or-alzheimers-disease2025-11-14https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/does-invega-sustenna-prefilled-syringe-contain-latex2025-10-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/libertas-a-degendered-and-transgenderinclusive-phase-3-study-of-apalutamide-plus-intermittent-versus.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/maintenance-of-endoscopic-and-histologic-improvements-with-guselkumab-for-ulcerative-colitis-at-week.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/longitudinal-evaluation-of-neutrophiltolymphocyte-ratio-in-guselkumabtreated-patients-with-psoriatic.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/discovery-of-jnj-87562761-a-novel-anti-gprc5d-enhanced-effector-function-eef-antibody-with-multiple.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/rhapp/efficacy-and-safety-of-guselkumab-induction-and-maintenance-therapy-in-patients-with-moderately-to-s.pdf2026-01-07https://www.jnjmedicalconnect.com/safety-program-advisors2026-02-04https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/identifying-risk-factors-for-predicting-exacerbation-and-symptom-worseninga-retrospective-cohort-st.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-faspro-in-newly-diagnosed-multiple-myeloma-in-patients-ineligible-for-autologous-ste2026-01-06https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-open-bottle-stability.pdf2024-10-29https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-use-of-erleada-in-patients-with-hepatic-impairment2026-03-24https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-comparison-of-erleada-with-darolutamide2026-02-26https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-comorbid-anxiety-or-obsessive-compulsive-disorder2026-04-02https://www.jnjmedicalconnect.com/products/spravato/medical-content/measurement-of-plasma-levels-of-spravato2025-11-14https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/aanem/safety-and-effectiveness-of-nipocalimab-in-adolescent-participants-in-the-open-label-phase-23-vibran.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/comparison-of-invega-sustenna-or-invega-trinza-to-abilify-asimtufii-aripiprazole2026-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/longterm-safety-and-efficacy-of-nipocalimab-in-generalized-myasthenia-gravis-vivacitymg3-openlabel-e.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/transitioning-from-oral-uptravi-to-iv-uptravi2025-08-08https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-drug-interactions-in-the-monumental-1-study2025-09-08https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-elevate/longterm-adjunctive-lumateperone-treatment-in-major-depressive-disorder-results-from-a-sixmonth-open.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/video-titan-study-overview2026-02-10https://www.jnjmedicalconnect.com/media/attestation/products/sporanox-capsules/sporanox-capsules-safety-data-sheet.pdf2026-01-05https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-acis-study2026-01-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/a-global-phase-1b-study-of-jnj90014496-a-cd19cd20-bispecific-chimeric-antigen-receptor-car-tcell-the.pdf2026-01-20https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-cartitude2-mmy2003-cohort-b-use-in-early-relapse-multiple-myeloma-after-initial-therapy2025-11-21https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/elcc-2025/preventing-moderate-to-severe-dermatologic-video2025-08-29https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-invega-trinza-invega-hafyera-management-of-breakthrough-psychotic-symptoms2026-03-18https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-understanding-interference-with-blood-compatibility-testing-brochure-onc2026-02-03https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-outcomes-by-disease-location-in-crohns-disease2026-03-26https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/nei/longterm-safety-of-esketamine-nasal-spray-dosed-in-accordance-with-us-prescribing-information-in-adu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/adverse-event-of-invega-hafyera-weight-change2026-01-13https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-vial-overfill2026-02-13https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-conversion-to-invega2025-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/acnp/efficacy-of-adjunctive-lumateperone-42-mg-treatment-across-depression-and-anhedonia-symptoms-in-majo.pdf2026-01-13https://www.jnjmedicalconnect.com/products/tremfya/medical-content/can-i-take-tremfya-if-i-am-breastfeeding-planning-to-breastfeed-pregnant-or-planning-to-become-pregn2025-09-26https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/winter-clinical-hawaii-20252025-08-28https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/webinars2025-09-15https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-efficacy-outcomes-by-weight-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis2025-12-23https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-infusion-related-reactions2025-09-05https://www.jnjmedicalconnect.com/products/xarelto/medical-content/real-world-evidence-of-xarelto-stroke-risk-reduction-in-nonvalvular-atrial-fibrillation2024-09-23https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-nano-particle-technology2026-02-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/longterm-efficacy-and-safety-results-from-the-phase-12-monumental1-study-of-talquetamab-a-gprc5dcd3.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/phase-1b-study-of-bleximenib-in-combination-with-venetoclax-in-acute-myeloid-leukemia-with-kmt2a-or.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/comparison-of-lazcluze-to-osimertinib2025-11-24https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/psych-congress-np-institute-20262026-03-19https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-optec-mm165-study012025-10-17https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/adverse-event-of-risperdal-consta-postinjection-deliriumsedation-syndrome-pdss2026-01-29https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/a-phase-2b-longterm-extension-doseranging-study-of-oral-jnj77242113-for-the-treatment-of-moderatetos.pdf2026-02-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/do-tremfya-prefilled-syringes-contain-latex2025-06-17https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-combination-with-carfilzomib-lenalidomide-and-dexamethasone-in-mul2026-02-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/efficacy-and-safety-from-the-phase-12-monumental1-study-of-talquetamab-a-gprc5dcd3-bispecific-antibo.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/bleximenib-in-combination-with-intensive-chemotherapy-a-phase-1b-study-in-newly-diagnosed-acute-myel.pdf2025-12-08https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-the-treatment-of-nail-psoriasis2026-02-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/daratumumab-darabortezomiblenalidomidedexamethasone-dvrd-with-dr-maintenance-maint-in-transplantelig.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-dosing-abrupt-discontinuation-or-withdrawal2026-03-17https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-hyponatremia2025-07-21https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-crushing-splitting-or-dispersion-of-240-mg-tablet2025-05-19https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-drug-interaction-with-oral-anticoagulants.pdf2025-12-10https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-renal-insufficiency-atrial-fibrillation2025-10-09https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma2026-02-05https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/posthoc-evaluation-of-the-clinical-effects-of-nipocalimab-a-new-neonatal-fragment-crystallizable-blo.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-drug-interactions2025-06-05https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-dosage-and-administration-use-of-peripheral-vs-central-intravenous-line2025-06-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/western-section-aua/matchingadjusted-indirect-comparisons-of-tar200-vs-fdaapproved-novel-agents-in-bacillus-calmetteguer.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/use-of-invega-trinza-in-schizoaffective-disorder2026-02-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/maui-derm-hawaii/musculoskeletal-ultrasound-abnormalities-in-patients-with-psoriasis-at-high-risk-of-progression-to-p.pdf2026-02-17https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/sunrise-1-study2026-02-10https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/early-disease-efficacy-of-guselkumab-therapy-in-biologicnaive-patients-with-moderately-to-severely-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-multiple-sclerosis2025-07-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/initiating-firstline-1l-fixedduration-fd-ibrutinib-and-venetoclax-ibrven-in-patients-pts-with-chroni.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/during-maintenance-therapy2025-06-16https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant/amilaz-dose-modification-infographic.pdf2026-01-05https://www.jnjmedicalconnect.com/media/attestation/products/akeega/akeega-safety-data-sheet-sds-50-mg500-mg-tablets.pdf2025-08-12https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-guselkumab-impact-on-nail-psoriasis-and-psoriatic-arthritis-through-week-48-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-pharmacodynamics2026-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/ipcu/real-world-comparison-of-overall-survival-in-patients-with-metastatic-castration-pls.pdf2026-02-03https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-infections-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis2025-09-03https://www.jnjmedicalconnect.com/products/simponi-aria/pivotal-clinical-trial-publications2025-12-26https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant-faspro/sc-amivantamab-dosage-admin-infographic.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/clinical-validity-of-plasma-dna-testing-to-identify-brca-mutated-brca-patients-in-the.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-miami/shadows-of-inflammation-exploring-postinflammatory-pigment-changes-in-psoriasis-in-visible-a-phase-3.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/opsynvi/opsynvi-macitentan-10-mgtadalafil-20-mg-safety-data-sheet-sds.pdf2026-02-24https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-oral-suspension-preparation2024-11-06https://www.jnjmedicalconnect.com/products/darzalex/medical-content/what-are-the-possible-side-effects-of-darzalex2025-04-25https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/risperdal-consta-latex-content2024-08-21https://www.jnjmedicalconnect.com/media/attestation/products/sirturo/sirturo-20mg-safety-data-sheet-sds.pdf2026-01-16https://www.jnjmedicalconnect.com/products/akeega/isi-english2026-03-09https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-common-psychiatric-comorbidities-in-phase-3-trials-for-treatment-resistant-depression2025-12-01https://www.jnjmedicalconnect.com/media/attestation/products/icotrokinra/maintenance-of-response-with-icotrokinra-a-targeted-oral-peptide-for-the-treatment-of-moderateto.pdf2026-02-18https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/adverse-event-of-invega-trinza-upper-respiratory-tract-infection2025-10-01https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-hepatotoxicity2025-05-19https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-patients-65-years-of-age-and-older2025-05-21https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-pharmacokinetics-effect-of-food2025-07-14https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/dosing-higher-doses-of-risperdal-consta2025-01-14https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/nei/national-realworld-study-of-the-patient-journey-of-dually-eligible-medicare-enrollees-with-schizophr.pdf2026-02-17https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-darzalex-faspro-in-polyneuropathy-organomegaly-endocrinopathy-monoclonal-gammopathy2025-06-02https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ideom/icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-the-interleukin23receptor-for-the-treatm.pdf2026-02-17https://www.jnjmedicalconnect.com/products/risperdal/pivotal-clinical-trial-publications2025-12-24https://www.jnjmedicalconnect.com/products/uptravi/medical-content/how-should-i-store-uptravi-tablets2025-07-30https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-drug-interactions-with-hydroxychloroquine.pdf2024-05-15https://www.jnjmedicalconnect.com/products/xarelto/medical-content/effect-of-xarelto-on-thrombophilia-screening-assays2025-01-28https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-breast-disorders2025-09-08https://www.jnjmedicalconnect.com/products/xarelto/medical-content/adverse-event-of-xarelto-menstrual-and-uterine-bleeding2025-06-26https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-central-nervous-system-cancers2025-06-17https://www.jnjmedicalconnect.com/products/risperdal2026-01-21https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-administration-of-60-mg-tablets-via-a-feeding-tube2025-07-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/real-world-comparison-of-prostate-specific-antigen-response-in-metastatic-castra.pdf2026-02-26https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-with-bupropion2026-02-26https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/masterclass-in-dermatology/sustained-improvements-in-psoriasis-area-and-severity-index-and-in-percent-body-surface-area-of-psor.pdf2026-02-17https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-occurrence-of-headache-in-patients-with-generalized-myasthenia-gravis2026-01-29https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/dgho-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/real-world-rw-use-of-fixed-duration-fd-ibrutinibvenetoclax-ibrven-in-patients-pts-with-previously-un.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/molecular-differentiation-of-guselkumab-and-ustekinumab-in-moderately-to-severely-active-crohns-dise.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-comparison-to-oral-risperidone.pdf2026-03-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/amivantamab-plus-chemotherapy-vs-chemotherapy-as-firstline-treatment-in-egfr-exon-20-insertionmutate.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/aanem/perinatal-treatment-patterns-in-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/products/remicade/medical-content/what-are-the-possible-side-effects-of-remicade2025-05-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/infections-and-immune-reconstitution-in-the-phase-3-cartitude4-trial-of-ciltacabtagene-autoleucel-vs.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/efficacy-of-daratumumabbortezomiblenalidomidedexamethasone-dvrd-vs-daratumumablenalidomidedexamethas.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-dosing-information2025-08-06https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/aanem/leveraging-ai-to-characterize-mental-health-experiences-throughout-the-myasthenia-gravis-diagnosis-j.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/isds/pharmacokinetics-of-guselkumab-in-super-responders-and-long-term-psoriasis-disease-control-insights.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/prezcobix-800mg150mg-tablets-safety-data-sheet-sds.pdf2026-01-15https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-invega-sustenna-invega-trinza-invega-hafyera-use-in-pregnancy-or-lactation.pdf2026-03-18https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-management-of-oral-mucositis2025-06-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/longterm-efficacy-and-safety-results-from-the-phase-12-monumental1-study-of-talquetamab-tal-a-gprc5d.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-number-needed-to-treat-or-harm-post-hoc-analysis2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/risperdal/risperdal-3-mg-tablet-safety-data-sheet-sds.pdf2025-05-19https://www.jnjmedicalconnect.com/products/spravato/medical-content/comparison-of-spravato-to-electroconvulsive-therapy-ect-and-transcranial-magnetic-stimulation-tms2026-02-05https://www.jnjmedicalconnect.com/products/tremfya/medical-content/one-press-patient-controlled-injector-instructions-for-use/after-injection2025-12-08https://www.jnjmedicalconnect.com/products/remicade/medical-content/measuring-infliximab-trough-levels-during-remicade-treatment2025-09-17https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aad-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/first-line-treatment-in-patients-with-transplant-ineligible-newly-diagnosed-multiple-myeloma-by-age.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/onlabel-persistence-through-24-months-in-patients-with-psoriatic-arthritis-using-guselkumab-or-subcu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-hypersensitivity-or-infusion-reactions-in-adult-patients-with-crohns-disease2026-01-06https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/background-and-conversion-from-erzofri2026-02-02https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-blc2001-study2026-01-14https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-occurrence-of-cytokine-release-syndrome-crs2026-03-20https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-storage-and-stability-excursion-information2025-12-02https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-clinical-trials-in-major-depressive-disorder-and-active-suicidal-ideation-with-intent2025-08-12https://www.jnjmedicalconnect.com/media/attestation/products/risperdal/risperdal-4-mg-tablet-safety-data-sheet-sds.pdf2025-05-19https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/smfm-2026/understanding-fetal-and-neonatal-alloimmune-thrombocytopenia-video2026-01-23https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/odac-dermatology-20262026-01-12https://www.jnjmedicalconnect.com/products/erleada/medical-content/sequencing-of-erleada-with-docetaxel2025-12-11https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-occurrence-of-muscle-spasms-in-patients-with-generalized-myasthenia-gravis2026-01-26https://www.jnjmedicalconnect.com/products/icotyde/medical-content/what-should-i-tell-my-healthcare-provider-before-starting-icotyde2026-03-19https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/use-of-risperdal-consta-in-obese-patients2025-06-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/gpcc/real-world-comparison-of-achieving-undetectable-prostate-specific.pdf2026-02-02https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-drug-interactions-in-generalized-myasthenia-gravis2025-12-10https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-20252025-12-09https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-repackaging.pdf2025-09-09https://www.jnjmedicalconnect.com/products/spravato/medical-content/dosage-and-administration-of-spravato2026-03-18https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/how-will-i-receive-rybrevant-faspro2025-12-18https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/adverse-event-of-invega-sustenna-mortality2025-11-19https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-pediatric-patients2025-08-18https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-drug-interactions2025-09-11https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant/amilaz-nccn-nsclc-infographic.pdf2026-02-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/prophylactic-interventions-for-oral-toxicities-with-the-gprc5dcd3-bispecific-antibody-talquetamab-in.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/can-i-take-nsaids-with-xarelto2025-06-27https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/slide-deck-a-randomized-doubleblind-multicenter-noninferiority-study-comparing-paliperidone-palmitat2025-10-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/treatment-patterns-and-clinical-outcomes-in-patients-with-bacillus-calmetteguerin-b-pls.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ipcu-2025/comparison-video2025-09-08https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/can-rybrevant-cause-skin-problems2025-11-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/cluster-analysis-of-socioeconomic-and-environmental-determinants-modifying-activity-chronicity-and.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/first-worldwide-reallife-data-on-fixedduration-ibrutinibvenetoclax-treatment-for-previously-untreate.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-density-specific-gravity-and-overfill-volume2026-03-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/comparison-of-spravato-and-ketamine2026-03-11https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-prezcobix-prezista-intelence-edurantmedia-statementlegal-actioncounterfeit-products.pdf2025-05-08https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-chads2-score-in-rocket-af2024-10-15https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/disease-recovery-evaluation-and-modification-dream-study-and2025-04-30https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-venous-thromboembolism-vte2025-06-15https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-what-is-the-dosing-schedule-of-tremfya-for-crohns-disease.pdf2026-03-19https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/carvykti-evidence-and-value-summary.pdf2026-03-10https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ers/dose-rationale-for-unisus-an-ongoing-eventdriven-phase-iii-superiority-study-evaluating-macitentan-7.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-mmy3006-cassiopeia-study2025-08-01https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/use-of-rybrevant-faspro-reproductive-potential-and-lactation2025-12-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/overview-of-pharmacologypharmacokinetics-in-ulcerative-colitis-and-crohns-disease2026-03-09https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-stability-of-final-vialed-product-for-intravenous-infusion2026-01-12https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ccr-west-20242026-02-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aacr/a-phase-2b-study-of-subcutaneous-amivantamab-with-lazertinib-as-firstline-treatment-or-with-chemothe.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/concomitant-use-of-invega-sustenna-invega-trinza-or-invega-hafyera-with-covid19-vaccines2025-08-14https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant-faspro/rybrevant-faspro-safety-data-sheet-sds.pdf2025-12-17https://www.jnjmedicalconnect.com/products/balversa/medical-content/comparison-of-balversa-to-pembrolizumab2025-04-11https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/socu-20242025-08-28https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-conversion-to-invega-sustenna-from-oral-antipsychotics2026-02-25https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/maintenance-clinical-rationale2025-06-16https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-use-in-central-nervous-system-cns-metastases2026-01-13https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/use-of-invega-trinza-in-patients-with-comorbid-substance-abuse2026-02-25https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-occurrence-and-management-of-nail-toxicity2026-03-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/clinically-relevant-anti-vaccine-and-virus-antibodies-in-patients-with-sjogrens-disease-treated-wit.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/inlexzo-gemcitabine-intravesical-system-dosage-and-administration-infographic.pdf2025-09-22https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-plasma-cell-leukemia2025-10-12https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-reports-of-hemoglobin-decrease-and-anemia2025-12-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-immunogenicity-in-pediatric-patients-with-plaque-psoriasis2025-10-09https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/therapeutic-and-hospitalisation-outcomes-after-first-line-anti-tnf-in-inflammatory-bowel-disease.pdf2026-02-17https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-interaction-with-serological-testing-for-blood-banks2025-07-31https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-hawaii/the-power-of-photos-leveraging-clinical-photos-from-the-visible-study-to-create-an-image-library-for.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/what-are-the-possible-side-effects-of-invega-sustenna2025-06-13https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-occurrence-of-infections2026-02-06https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/antipsychotic-use-and-risk-of-breast-cancer-in-women-with-schizophrenia2025-12-24https://www.jnjmedicalconnect.com/media/attestation/products/invokana/invokana-100mg-safety-data-sheet-sds.pdf2025-08-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/mechanisms-of-acquired-resistance-to-firstline-amivantamab-plus-lazertinib-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/how-long-do-i-have-to-wait-before-i-can-drive-or-return-to-work-after-i-take-spravato2026-02-17https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-comparison-to-nadofaragene-firadenovec-vncg2025-09-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/a-phase-1-study-of-jnj69086420-an-225aclabeled-antibody-targeting-human-kallikrein-2-to-treat-metast.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-pharmacokinetics-bioequivalence-and-bioavailability2025-07-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-re-induce-with-intravenous-infusion-during-maintenance-therapy-in-ulcerative-colitis2025-07-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/qcs/elevating-the-patient-voice-understanding-treatment-preferences-in-patients-with-advanced-slides.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/guselkumab-pharmacokinetics-and-exposureresponse-relationships-are-consistent-following-intravenous.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/baseline-characteristics-of-patients-with-moderatetosevere-plaque-psoriasis-treated-with-guselkumab.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/conversion-from-another-antipsychotic-to-invega-trinza2025-12-16https://www.jnjmedicalconnect.com/products/risperdal/medical-content/use-of-risperdal-consta-and-risperdal-in-pregnancy-or-lactation2026-02-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/longterm-5-year-remission-and-survival-after-treatment-with-ciltacabtagene-autoleucel-ciltacel-in-ca.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-combination-with-ixazomib-in-multiple-myeloma2026-01-11https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ers/realworld-evidence-on-individualised-selexipag-dosing-in-pulmonary-arterial-hypertension-pah.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/guselkumab-improves-healthrelated-quality-of-life-as-measured-by-promis29-in-participants-with-moder.pdf2026-01-07https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/simponi-aria-administration-equipment2025-11-18https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-alternative-dosing-of-inlexzo2025-09-11https://www.jnjmedicalconnect.com/products/erleada/medical-content/poster-summary-hadaschik-et-al-2023-psma-pet-study-in-patients-with-nmcrpc2025-05-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/daratumumab-darabortezomiblenalidomidedexamethasone-dvrd-with-dr-maintenance-maint-in-transplantelig.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/should-xarelto-be-administered-with-food-in-adults2025-07-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/prevalence-and-severity-of-hot-flashes-and-their-association-with-prostate-specific-antigen-response.pdf2026-01-07https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/simponi-aria-treatment-of-rheumatoid-arthritis2026-01-27https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-comparison-of-erleada-with-zytiga2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/endoscopic-patient-clustering-to-investigate-differential-treatment-effects-of-guselkumab-and-usteki.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/nei/adjunctive-lumateperone-42-mg-in-the-treatment-of-major-depressive-disorder-a-pooled-analysis-of-2-p.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-stability-of-final-vialed-product-for-intravenous-infusion2025-08-05https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-lazcluze-cocoon-study2025-12-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-nppa-summer/spectrem-guselkumab-efficacy-and-patient-reported-outcomes-across-multiple-high-impact-sites.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/capp/comorbidities-among-patients-with-pulmonary-arterial-hypertension-in-the-time-to-therapy-activation.pdf2026-01-20https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/treatment-of-active-psoriatic-arthritis-with-simponi-aria-in-patients-2-years-of-age-and-older2025-07-24https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/characteristics-and-treatment-patterns-of-nontransplanted-video2025-12-08https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/can-lazcluze-cause-blood-clots2025-11-13https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/symtuza-prezcobix-prezista-intelence-edurantmedia-statementlegal-actioncounterfeit-products.pdf2025-05-08https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/nutrition-and-diet/tips-for-providers2026-02-27https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/am-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/symptom-and-quality-of-life-benefits-of-achieving-deep-remission-a-realworld-study-of-patients-with.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/hopa-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/realworld-data-on-the-use-of-subcutaneous-daratumumab-plus-bortezomib-thalidomide-and-dexamethasone.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/western-section-aua/nurse-and-advanced-practice-provider-perspectives-on-gemcitabine-intravesical-system-treatment-of-hi.pdf2026-01-20https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-preparation-and-administration-using-aseptic-technique-in-clinical-trials2025-07-22https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-overdose.pdf2025-12-05https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-pregnancy-and-lactation2025-10-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/how-do-i-store-stelara-vials-and-prefilled-syringes2025-07-14https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/clinical-validity-of-foundationone-cdx-assay-to-identify-hrr-positive-or-brca-presentation.pdf2026-02-26https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-interaction-with-serological-testing-for-oncologists2025-07-31https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/radiographic-progression-without-psa-progression-rpd-in-advanced-prostate-cancer-patientsslides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/an-analysis-of-digital-conversations-to-understand-perceptions-toward-the-dosing-and-administration.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/pharos-a-realworld-multicountry-european-study-on-patients-with-highrisk-localised-and-locally-advan.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/ascp/the-association-between-adherence-to-esketamine-nasal-spray-therapy-dosing-regimen-and-changes-in-de.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-dosing-dosing-over-72-mg-per-day-in-adolescents.pdf2026-03-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/maui-derm-hawaii/visible-cohort-b-scalp-clearance-and-patientreported-outcome-results-with-guselkumab-through-week-10.pdf2026-01-25https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-concomitant-use-of-symtuza-with-paxlovid.pdf2025-08-13https://www.jnjmedicalconnect.com/products/akeega/medical-content/how-should-i-take-akeega2025-12-15https://www.jnjmedicalconnect.com/products/intelence/isi-english2025-08-20https://www.jnjmedicalconnect.com/products/carvykti/medical-content/can-i-receive-vaccines-if-i-receive-carvykti2026-04-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/real-world-disease-burden-and-treatment-patterns-among-triple-class-exposed-patients-with-relapsedre.pdf2026-01-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/real-world-insights-into-the-patient-experience-and-gender-disparities-during-treatment-for-high-ris.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/retreatment-of-ulcerative-colitis-with-stelara-after-a-drug-free-interval2025-12-04https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-latex-content2025-11-12https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-combination-with-tnf-inhibitors-for-the-treatment-of-psoriatic-arthritis-in-adult-pa2026-03-26https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/efficacy-and-safety-of-guselkumab-for-ulcerative-colitis-through-week-92-of-the-quasar-longterm-exte.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-trinza-clinical-overview2026-04-01https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/sunrise-1-cohort-4-infographic.pdf2026-01-06https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-measuring-ustekinumab-drug-levels-in-patients-with-crohnsdisease-uniti-clinical-trial-progr2026-03-11https://www.jnjmedicalconnect.com/media/attestation/products/prezista/symtuza-prezcobix-prezista-intelence-edurantmedia-statementlegal-actioncounterfeit-products.pdf2025-05-08https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/less-frequent-teclistamab-dosing-in-responders-modeling-and-simulation-data-from-the-majestec1-study.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-renal-impairment2026-03-16https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/team-phenomenal-hope/delphi-study-to-elicit-consensus-on-best-practice-for-prior-authorization-in-pulmonary-arterial-hype.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/efficacy-of-nipocalimab-in-adult-patients-with-moderate-to-severe-ocular-manifestations-of-gmg-in-ph.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-alternative-dosing-other-than-200-mg-once-daily-in-patients-with-plaque-psoriasis2026-03-19https://www.jnjmedicalconnect.com/products/xarelto/medical-content/does-xarelto-oral-suspension-contain-lactose2025-07-25https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-dosage-and-administration2026-03-12https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-is-the-recommended-dosing-for-darzalex-faspro-in-combination-with-carfilzomib-and-dexamethasone2025-05-14https://www.jnjmedicalconnect.com/media/attestation/medinfohtmlimages/caplyta/us-sr-13895/janssen-caplyta-evidence-table-abbreviations.pdf2026-01-16https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/team-phenomenal-hope/real-world-adherence-and-persistence-of-upfront-therapy-in-patients-with-pulmonary-hypertension-in-t.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/economic-burden-of-myasthenia-gravis-exacerbation-and-crisis-from-us-payer-perspective.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-use-for-post-exposure-prophylaxis.pdf2025-09-09https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/independent-medical-education2025-10-21https://www.jnjmedicalconnect.com/products/simponi/isi-english2025-03-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-nsaids2026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/maintenance-of-response-with-icotrokinra-a-targeted-oral-peptide-for-the-treatment-of-moderatetoseve.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-alternative-dexamethasone-dosing.pdf2025-01-23https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-hyponatremia2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-use-in-adults-with-adhd.pdf2024-11-06https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-adverse-event-urinary-tract-infections2024-08-29https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-rybrevant-dosage-and-administration-intravenous-to-subcutaneous-switch2026-02-13https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/pha/managing-patient-expectations-when-treated-with-oral-selexipag-for-pulmonary-arterial-hypertension-p.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-faspro-in-underweight-or-obese-patients2025-04-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/efficacy-and-safety-of-subcutaneous-guselkumab-induction-therapy-in-patients-with-moderately-to-seve.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-concomitant-use-with-vaccines-in-patients-with-plaque-psoriasis2026-03-19https://www.jnjmedicalconnect.com/products/xarelto/medical-content/american-geriatric-society-2023-beers-criteria2024-11-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/association-of-psma-pet-results-at-biochemical-recurrence-bcr-with-metastasis-free-survival-mfs-by-c.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/assessment-of-patient-reported-outcomes-from-the-phase-3-vivacity-mg3-study-of-nipocalimab-in-gmg.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-occurrence-of-arthralgia-in-adults-patients-with-crohns-disease2026-02-26https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-immunogenicity-in-adult-patients-with-crohns-disease-or-ulcerative-colitis2025-09-08https://www.jnjmedicalconnect.com/products/edurant/isi-english2025-02-26https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/nei/risk-of-relapse-with-pp1m-versus-the-most-commonly-utilized-oaps-in-the-us-in-adults-with-schizophre.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-treatment-of-acute-respiratory-distress-syndrome-ards.pdf2024-11-18https://www.jnjmedicalconnect.com/products/uptravi/medical-content/what-is-the-recommended-dosing-for-uptravi-intravenous-injection-for-pulmonary-arterial-hypertension2025-07-24https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-of-darzalex-in-plasmablastic-lymphoma2025-08-08https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/use-of-risperdal-consta-in-renal-dysfunction2025-05-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/from-onset-to-insights-longitudinal-assessment-of-disease-activity-flares-and-damage-accrual-in-pati.pdf2026-02-17https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-subcutaneous-formulation-of-stelara-as-induction-treatment-in-ulcerative-colitis2025-08-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad/spectrem-guselkumab-demonstrates-consistent-significant-clearance-across-the-full-range-of-low-body.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-27-mg-tablet-safety-data-sheet-sds.pdf2025-05-02https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/apapp/expert-consensus-on-the-definition-of-methamphetamine-associated-pulmonary-arterial-hypertension-met.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/esmo-2025/amivantamab-in-recurrent-metastatic-head-video2025-10-24https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-management-of-neurotoxic-events2025-11-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/visible-cohort-a-guselkumab-demonstrated-skin-clearance-and-improved-healthrelated-quality-of-life-t.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/healthcare-resource-utilization-and-costs-associated-with-exacerbation-or-crisis-in-generalized-myas.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/amivantamab-plus-chemotherapy-vs-chemotherapy-in-egfrmutant-advanced-nsclc-after-progression-on-osim.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-comparison-of-akeega-with-talazoparib2025-07-23https://www.jnjmedicalconnect.com/resources/congress-materials2026-03-11https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-dermatology-bibliography2026-03-18https://www.jnjmedicalconnect.com/products/imaavy/medical-content/what-should-i-do-if-i-miss-a-dose-of-imaavy2025-05-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/real-world-characteristics-and-outcomes-of-newly-diagnosed-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/how-should-i-store-xarelto-oral-suspension2025-07-15https://www.jnjmedicalconnect.com/products/invokana/medical-content/use-of-invokana-in-patients-with-a-solitary-kidney2025-06-06https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/adverse-reaction-of-invega-hafyera-upper-respiratory-tract-infection2025-08-29https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-pleiades-study2026-04-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-treatment-patterns-effectiveness-and-safety-of-daratumumabbased-regimens-in-chinese-patien.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/factors-associated-with-myasthenia-gravis-activities-of-daily-living-score-in-a-realworld-united.pdf2026-01-20https://www.jnjmedicalconnect.com/products/imaavy/pivotal-clinical-trial-publications2025-12-22https://www.jnjmedicalconnect.com/media/attestation/general/visible-guselkumab-pooled-safety-across-all-skin-tones-through-week-48.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/overdose-of-spravato2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/longer-sustained-remission-in-crohns-disease-with-guselkumab-versus-ustekinumab-treatment-projection.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/nei/antipsychotic-utilization-healthcare-resource-use-costs-and-quality-of-care-in-patients-with-schi.pdf2026-02-17https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/apcc/sheikhtaha-et-al-20232025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/histologic-and-combined-histologic-and-endoscopic-outcomes-after-guselkumab-maintenance-therapy-in-p.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-west/icotrokinra-in-patients-with-psoriatic-disease-exploratory-assessments-from-a-phase-2-psoriasis-stud.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-latex-content.pdf2024-07-02https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/can-rybrevant-faspro-cause-eye-problems2025-12-18https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/ats-20252025-08-28https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-patients-with-hepatic-impairment2026-03-24https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-the-treatment-of-bipolar-depression-and-major-depressive-disorder-with-mixed-feature2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/efficacy-of-guselkumab-in-moderately-to-severely-active-crohns-disease-according-to-induction-respon.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/dosing-of-risperdal-consta-partial-dose-administration2025-04-24https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/use-of-lazcluze-in-geriatric-patients2025-08-21https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/adverse-event-invega-hafyera-and-movement-disorders2025-08-26https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ecop-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/aepc/macitentan-in-pediatric-pulmonary-arterial-hypertension-results-from-the-phase-3-randomized-controll.pdf2026-01-07https://www.jnjmedicalconnect.com/resources/real-world-evidence/real-world-evidence-publications/rwe-publications-heme2025-09-11https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-hematologic-toxicities-with-combination-treatment2025-06-10https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/stigma-and-mental-health2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/safety-and-efficacy-results-of-nipocalimab-in-adolescents-with-generalized-myasthenia-gravis-during.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-chrysalis-study2026-03-23https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/chest/expert-consensus-exploring-the-definition-of-a-diseasemodifying-therapy-and-the-data-requirements-to.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/acc-20262026-03-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-east/visible-guselkumab-impact-on-psoriatic-arthritis-through-week-48-in-participants-with-moderatetoseve.pdf2026-01-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-apheresisleukapheresis-in-cartitude-1-and-cartitude-42026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/a-systematic-literature-review-on-the-economic-burden-of-sjogrens-disease.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/does-spravato-increase-my-risk-for-suicidal-thoughts-and-actions2025-06-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-pharmacokinetics-and-pharmacodynamics2025-06-02https://www.jnjmedicalconnect.com/products/tremfya/medical-content/comparison-of-tremfya-to-adalimumab-in-the-treatment-of-plaque-psoriasis2025-10-01https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/symptom-severity-assessment-using-quantitative-myasthenia-gravis-items-and-domains-in-a-24week-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/dosage-and-administration-of-spravato-duration-of-therapy2025-06-16https://www.jnjmedicalconnect.com/media/attestation/products/erleada/apalutamide-titan-hrqol-deck-rp-rd.pdf2025-12-08https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ipcu-2025/a-descriptive-analysis-video2025-09-08https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/clinical-overview-of-invega-sustenna2026-01-22https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-how-does-zytiga-work.pdf2025-10-27https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-treatment-of-hand-and-foot-psoriasis2026-03-19https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-concomitant-use-with-intravenous-immunoglobulin-ivig-therapy2026-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad-innovation-academy/unmet-needs-of-adults-with-psoriasis-and-clinicians-treating-psoriasis-in-the-us.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invokana/pivotal-clinical-trial-publications2025-12-22https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/cinp/efficacy-of-lumateperone-42-mg-in-the-treatment-of-major-depressive-disorder-a-pooled-poster.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-use-of-symtuza-in-pregnancy.pdf2025-03-26https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-use-in-gastrointestinal-conditions.pdf2025-03-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/realworld-treatment-patterns-and-clinical-outcomes-among-patients-with-diffuse-large-bcell-lymphoma.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/clinical-burden-and-treatment-satisfaction-in-a-realworld-survey-of-patients-diagnosed-with-major-de.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/preventing-moderatetosevere-dermatologic-adverse-events-in-firstline-egfrmutant-advanced-nsclc-treat.pdf2026-01-20https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/what-should-i-do-if-i-miss-a-dose-of-opsynvi2025-04-15https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-event-of-spravato-dissociative-effectsperceptual-disturbances2026-02-19https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-3-study2025-09-22https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-non-small-cell-lung-cancer2025-07-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/using-stelara-iv-infusion-during-maintenance-therapy-in-ulcerative-colitis2025-11-24https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/retreatment-of-rheumatoid-arthritis-with-simponi-aria-after-a-drug-free-interval2026-01-15https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-apa-rp-study2025-08-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/health-beliefs-and-practices/overview2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/efficacy-and-safety-of-firstline-ibrutinib-plus-venetoclax-in-patients-with-mantle-cell-lymphoma-who.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-study-design-of-rocket-af2024-05-23https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-darzalex-faspro-in-combination-with-carfilzomib-and-dexamethasone-in-multiple-myelo2025-07-30https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-adverse-event-mania2025-12-11https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/through-the-patient-lens-the-diagnostic-journey-from-connective-tissue-disease-to-pulmonary-arterial.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/phase-3-results-from-an-innovative-trial-design-of-treating-plaque-psoriasis-involving-difficult-to.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-hawaii/spectrem-guselkumab-demonstrates-consistent-significant-clearance-at-week-16-across-the-full-range-o.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/patterns-of-management-and-multidisciplinary-care-in-highvery-high-and-intermedi.pdf2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/chronic-lymphocytic-leukemia-cll-and-small-lymphocytic-lymphoma-sll-patient-demographics-and-patient.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ipcu-20262026-02-02https://www.jnjmedicalconnect.com/products/xarelto/medical-content/real-world-evidence-use-of-xarelto-in-renal-insufficiency-atrial-fibrillation2024-10-08https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-elevate/earlier-use-of-longacting-injectable-paliperidone-palmitate-versus-oral-antipsychotics-in-patients-w.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokamet2025-03-04https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-cartitude-1-subgroup-analysis2025-06-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/retreatment-of-plaque-psoriasis-with-tremfya-in-adult-patients-after-a-drug-free-interval2026-02-18https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-how-long-can-i-use-spravato2026-01-23https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-faspro-daratumumab-and-hyaluronidase2025-09-12https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-what-is-the-dose-of-caplyta-for-patients-with-liver-disease2026-02-13https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/refining-the-conceptual-model-of-patient-experiences-in-chronic-inflammatory-demyelinating-polyneuro.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/general/schizophrenia-finding-hope-and-healing-through-treatment.pdf2026-01-26https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/efficacy-and-safety-of-icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-il23-receptor-act.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/apapp/10year-data-on-oral-selexipag-longterm-survival-safety-and-dosing-insights-in-pulmonary-arterial-hyp.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/sid/visible-pioneering-transcriptomic-analysis-of-psoriasis-in-skin-of-color.pdf2026-02-17https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-palmoplantar-psoriasis2026-01-19https://www.jnjmedicalconnect.com/media/attestation/congresses/cardiovascular-and-metabolism/2024/ash/effectiveness-and-safety-of-rivaroxaban-versus-warfarin-in-patients-with-pulmonary-embolism-and-righ.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/seltorexant-adjunctive-to-antidepressants-in-adults-with-major-depressive-disorder-with-insomnia-sym.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-talisman-study2025-12-17https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-in-patients-with-comorbid-eating-disorders2025-07-03https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-dosage-strengths-and-volume-of-injection2026-02-24https://www.jnjmedicalconnect.com/products/erleada/medical-content/does-erleada-interact-with-other-medicines2025-12-22https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/dosing-of-invega-sustenna-and-invega-trinza-educational-dose-illustrator2025-09-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/retrospective-realworld-treatment-patterns-and-outcomes-in-european-patients-with-newly-diagnosed-mu.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/eau-20262026-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/healthcare-burden-associated-with-cystectomy-and-trimodal-therapy-among-patients-with-pls.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma2026-02-05https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/ustekinumab-openlabel-induction-and-randomized-blinded-maintenance-therapy-in-pediatric-participant.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-dosing-splitting-tablets.pdf2024-08-01https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-use-of-inlexzo-in-combination-with-docetaxel2025-09-12https://www.jnjmedicalconnect.com/products/balversa/medical-content/can-balversa-cause-nail-or-skin-problems2025-12-05https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/mgfa-20252025-10-29https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/exploring-the-value-of-achieving-complete-or-near-complete-skin-clearance-in-patients-with-a-history.pdf2026-02-17https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-nail-toxicity2025-10-10https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-comparison-of-zytiga-to-cabazitaxel.pdf2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/efficacy-and-safety-of-guselkumab-induction-and-maintenance-therapy-in-patients-with-moderately-to-s.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-amber-study.pdf2025-08-22https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/kit-components-of-invega-trinza2026-01-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/pcdai-eligibility-criteria-into-clinical-trials-post-hoc-analysis-of-the-uniti-j.pdf2026-02-23https://www.jnjmedicalconnect.com/resources/real-world-evidence/rwe-partnerships2025-10-13https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/nei/longterm-adjunctive-lumateperone-treatment-in-major-depressive-disorder-results-from-a-sixmonth-open.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rhapp/efficacy-and-safety-of-subcutaneous-guselkumab-induction-therapy-in-patients-with-ulcerative-colitis.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aua/sunrise3-tar200-plus-cetrelimab-or-tar200-versus-intravesical-bacillus-calmetteguerin-in-patients-wi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsumit/medical-content/initial-combination-therapy-in-pulmonary-arterial-hypertension2025-10-16https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-atrial-fibrillation-patients-with-congestive-heart-failure2024-11-12https://www.jnjmedicalconnect.com/products/invokana/medical-content/effects-of-invokana-following-discontinuation2025-02-10https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/wclc-20242025-08-28https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension2026-02-19https://www.jnjmedicalconnect.com/products/spravato/medical-content/individual-items-of-the-madrs-in-the-spravato-aspire-trials2026-02-02https://www.jnjmedicalconnect.com/products/tremfya/medical-content/does-tremfya-pen-contain-latex2025-08-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-hawaii/visible-cohort-a-guselkumab-demonstrated-skin-clearance-through-week-48-in-participants-with-moderat.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-west/efficacy-and-safety-of-guselkumab-in-participants-with-active-psoriatic-arthritis-and-inadequate-res.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/general/unbranded-minimal-residual-disease-mrd-educational-proactive-infographic.pdf2025-04-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/overall-survival-os-with-ciltacabtagene-autoleucel-ciltacel-versus-standard-of-care-soc-in-lenalidom.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-east/efficacy-and-safety-of-subcutaneous-guselkumab-induction-therapy-in-patients-with-ulcerative-colitis.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-stardust-trial2025-09-17https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/pharmacodynamics-of-risperdal-consta2026-02-03https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/what-are-the-ingredients-in-inlexzo2025-09-10https://www.jnjmedicalconnect.com/media/attestation/products/lazcluze/amilaz-nccn-nsclc-infographic.pdf2026-02-06https://www.jnjmedicalconnect.com/products/xarelto/medical-content/real-world-evidence-use-of-xarelto-in-the-elderly2026-03-09https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/sunrise-1-infographic-summarizing-published-efficacy-and-safety-results-from-cohort-2.pdf2025-10-03https://www.jnjmedicalconnect.com/products/spravato/medical-content/effect-of-spravato-on-anhedonia2026-02-10https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-hepatic-impairment2025-11-18https://www.jnjmedicalconnect.com/media/attestation/products/lazcluze/sc-amivantamab-dosage-admin-infographic.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/adaa-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/fgfr3-alterations-fgfralt-in-patients-pts-who-develop-locally-advanced-or-metastatic-urothelial-canc.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsumit/medical-content/can-opsumit-cause-swelling-or-fluid-retention2025-09-30https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-storage-and-stability-protection-from-light2026-02-26https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-norse-study2026-04-03https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/clinical-management-of-idrs-in-the-treatment-of-bladder-cancer-infographic.pdf2026-02-19https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-adverse-event-infections-in-patients-with-newly-diagnosed-multiple-myelo2025-11-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/comparison-of-invega-sustenna-or-invega-trinza-to-once-monthly-or-once-every-two-months-subcutaneous2026-03-10https://www.jnjmedicalconnect.com/products/invokana/medical-content/drug-interaction-of-invokana-with-ritonavir2026-02-12https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/comparison-of-invega-sustenna-or-invega-trinza-to-abilify-asimtufii-aripiprazole2026-03-04https://www.jnjmedicalconnect.com/products/stelara/medical-content/do-stelara-prefilled-syringes-contain-latex2025-07-18https://www.jnjmedicalconnect.com/products/erleada/medical-content/how-should-i-store-erleada012026-01-09https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-safety-data-sheet-sds.pdf2025-11-17https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-posttraumatic-stress-disorder2026-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-hawaii/visible-cohort-b-guselkumab-improves-scaling-itch-and-shedding-or-flaking-through-week-48-in-partici.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/during-treatment-initiation2025-06-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-psoriasis-or-psoriatic-arthritis-with-comorbid-hematologic-disor2026-01-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/comparative-effectiveness-of-ciltacabtagene-autoleucel-from-the-cartitude4-trial-vs-realworld-physic.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-management-of-bleeding-and-reversal-agents-in-pediatric-patients2025-11-17https://www.jnjmedicalconnect.com/products/darzalex/medical-content/dosage-and-administration-of-darzalex-missed-dose2025-07-08https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aacr/prmt5-as-a-target-in-crc-interception-synthetic-lethal-dependency-identified-in-apclof-preclinical-m.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/rhapp/a-phase-2b-longterm-extension-doseranging-study-of-oral-jnj77242113-for-the-treatment-of-moderatetos.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/wcp-20252025-09-29https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-dosing-conversion-tofrom-another-antipsychotic2026-03-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/efficacy-of-nipocalimab-a-novel-neonatal-fragment-crystallizable-receptor-blocker-as-measured-using.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/administration-of-invega-sustenna-deltoid-and-gluteal-injection2025-11-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/final-survival-analysis-of-daratumumab-plus-lenalidomide-and-dexamethasone-versus-lenalidomide-and-d.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis-with-comorbid-hiv-infect2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/icotrokinra-the-first-targeted-oral-peptide-that-selectively-blocks-the-interle.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/deep-learningbased-digital-pathology-algorithm-overcomes-tumor-content-limitations-for-fgfr-alterati.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/prior-authorization-restrictiveness-negatively-impacts-time-to-receipt-of-endothelin-receptor-antago.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/preventing-infusionrelated-reactions-with-intravenous-amivantamab-updated-results-from-skippirr-a-ph.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-of-darzalex-darzalex-faspro-in-combination-with-carfilzomib-and-dexamethasone-in-multiple-myelo2025-07-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/healthrelated-quality-of-life-in-patients-with-transplantineligible-or-transplantdeferred-newly-diag.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-tablets-25-mg-safety-data-sheet-sds.pdf2025-05-01https://www.jnjmedicalconnect.com/media/attestation/products/edurant/symtuza-prezcobix-prezista-intelence-edurantmedia-statementlegal-actioncounterfeit-products.pdf2025-05-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/effects-of-subcutaneous-guselkumab-induction-and-maintenance-on-histologic-outcomes-in-patients-with.pdf2026-01-07https://www.jnjmedicalconnect.com/products/nipocalimab-investigational/medical-content/nipocalimab-clinical-use-in-sjogrens-disease-sjd2026-03-09https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-dosage-and-administration-of-zytiga-prednisone-regimen.pdf2025-12-29https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-splittingcrushing.pdf2025-06-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/enhanced-vs-standard-dermatologic-management-with-amivantamablazertinib-in-advanced-nsclc-phase-2-co.pdf2026-01-20https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-second-progressionfree-survival-pfs22025-12-23https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/adverse-event-of-invega-hafyera-hyperglycemia-and-diabetes-mellitus2025-09-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/comparative-efficacy-of-ciltacel-vs-approved-comparator-treatments-for-patients-with-relapsedrefract.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/6year-time-to-next-treatment-ttnt-extrapolation-curve-for-glow-study-firstline-ibrutinib-venetoclax.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/efficacy-and-safety-of-subcutaneous-guselkumab-induction-and-maintenance-therapy-in-patients-with-ul.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/risk-of-relapse-among-medicare-advantage-members-diagnosed-with-schizophrenia-and-receiving-oncemont.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/impact-of-fanca-atm-cdk12-alterations-on-survival-in-metastatic-castrationresistant-prostate-cancer.pdf2026-01-20https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rhuph20-overview-and-mechanism-of-action2025-12-18https://www.jnjmedicalconnect.com/products/xarelto/medical-content/stability-of-xarelto-oral-suspension-shipping-temperature-data2026-01-22https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/predicting-total-immunoglobulin-g-change-from-baseline-when-switching-from-efgartigimod-to-nipocalim.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/maui-derm-hawaii-20262026-01-23https://www.jnjmedicalconnect.com/products/rybrevant/pivotal-clinical-trial-publications2026-01-08https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-use-of-akeega-in-non-metastatic-prostate-cancer2025-07-01https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-faspro-rybrevant-paloma-study2026-03-27https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-sequencing-with-enzalutamide-in-metastatic-castration-resistant-prostate-cancer.pdf2025-12-29https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-previous-experience-with-biologics-in-patients-with-plaque-psoriasis2026-03-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/efficacy-and-safety-of-apalutamide-in-metastatic-castration-sensitive-prostate-cancer-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/switching-patients-with-plaque-psoriasis-from-stelara-ustekinumab-to-tremfya2025-09-08https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-combination-therapy-with-riociguat2025-10-10https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-open-bottle-and-repackaging-stability-of-60-mg-tablets2025-09-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/daratumumab-dara-bortezomiblenalidomide-dexamethasone-dvrd-with-dr-maintenance-in-transplanteligible.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/efficacy-and-safety-of-ibrutinib-plus-venetoclax-in-patients-with-mantle-cell-lymphoma-and-tp53-muta.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant/infographic-on-skippirr-study-design-and-key-final-results.pdf2025-10-02https://www.jnjmedicalconnect.com/media/attestation/products/tracleer/tracleer-interstitial-lung-disease-ild.pdf2025-02-25https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-dosing-dosage-and-administration.pdf2026-03-09https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-use-during-pregnancy-lactation-and-effect-on-fertility2026-03-13https://www.jnjmedicalconnect.com/products/erleada/medical-content/publication-summary-bilen-et-al-2025-realworld-os-comparison-with-enzalutamide-in-patients-with-mcs2025-06-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-nppa-fall/phase-3-results-from-an-innovative.pdf2026-02-17https://www.jnjmedicalconnect.com/products/zavesca2026-01-21https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-in-pregnancy2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/lazcluze/an-infographic-including-prophylaxis-information-for-venous-thromboembolism-vte-risk-assessment-and.pdf2025-09-09https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/chest/characteristics-and-outcomes-of-patients-with-pulmonary-arterial-hypertension-transitioning-to-selex.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/risk-of-complications-associated-with-oral-corticosteroid-use-in-patients-with-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-patients-with-renal-impairment-and-multiple-myeloma2026-04-01https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/longitudinally-collected-physiological-data-from-wearable-devices-identifies-inflammatory-activity-f.pdf2026-01-20https://www.jnjmedicalconnect.com/products/stelara/medical-content/treatment-of-guttate-psoriasis-with-stelara2025-08-12https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/nei/longterm-efficacy-of-esketamine-nasal-spray-dosed-in-accordance-with-us-prescribing-information-in-a.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/long-term-safety-and-efficacy-of-esketamine-nasal-spray-as-monotherapy.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/latent-variable-analysis-of-antipsychotic-adherence-among-south-carolina-medicaid-beneficiaries-with.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/cardiovascular-and-metabolism/congress/ash-20242025-08-28https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/phpn-20252025-09-18https://www.jnjmedicalconnect.com/products/invega-hafyera2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/guselkumab-and-il17-inhibitors-show-comparable-treatment-persistence-and-effectiveness-in-psoriatic.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/use-of-intestinal-ultrasound-and-other-imaging-tests-in-ulcerative-colitis-and-c.pdf2026-02-23https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-pain2025-06-11https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-pharmacokinetics-of-veletri-compared-to-flolan.pdf2026-02-27https://www.jnjmedicalconnect.com/products/rybrevant-faspro2026-02-04https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-injection-site-reactions-in-adult-patients-with-plaque-psoriasis-or-psoriatic2025-10-30https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-impact-of-earlier-line-carvykti-on-immune-fitness2026-02-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/mechanisms-of-acquired-resistance-to-firstline-amivantamab-plus-lazertinib-versus-osimertinib-in-pat.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/cvct/unisus-study-design-an-ongoing-eventdriven-phase-3-superiority-study.pdf2026-01-20https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-lazcluze-projected-overall-survival-benefit-in-the-mariposastudy2025-09-22https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/deep-prostatespecific-antigen-psa-decline-among-early-participants-pts-in-libertas-a-phase-3-study-o.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/pooled-efficacy-and-safety-of-teclistamab-in-217-patients-with-triple-class-exposed-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/risperdal-consta-microsphere-technology2024-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/daratumumab-bortezomiblenalidomidedexamethasone-in-transplanteligible-patients-with-newly-diagnosed.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-storage-and-stability-of-diluted-solution2026-03-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/maui-derm-caribbean/unmet-needs-and-disease-burden-perspectives-from-adults-with-psoriasis-and-clinicians-treating-psori.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-skin-clearance-through-week-48-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/safety-of-intravenous-and-subcutaneous-guselkumab-induction-administration-results-from-the-galaxi-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-event-of-spravato-cardiovascular-effects2026-03-13https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/prezcobix-open-bottle-stability.pdf2025-12-02https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/early-and-durable-improvements-in-patient-reported-outcomes-with-the-targeted-or-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/products/xarelto/medical-content/dose-of-xarelto-for-switching-from-another-anticoagulant-during-initial-dvt-or-pe-treatment2025-06-30https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-invega-trinza-and-invega-hafyera-considerations-for-use-of-lais-during-covid19-pand2025-06-05https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-trinza-quality-of-life-and-functioning2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/integrating-the-carbon-footprint-into-health-technology-assessment-in-france-the-example-of-the-heal.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/acute-management-of-stroke-early-anticoagulation-with-xarelto2024-08-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/a-realworld-study-of-lenalidomide-refractory-multiple-myeloma-patients-in-finland-treatment-and-outc.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/invega-hafyera/invega-hafyera-safety-data-sheet-1560-mg.pdf2025-10-02https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-dosage-and-administration2026-01-29https://www.jnjmedicalconnect.com/products/xarelto/medical-content/what-is-xarelto2025-10-15https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-hyperphosphatemia2025-06-30https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-compatibility-of-solutions-at-high-concentrations-with-iv-administration-equipment.pdf2024-08-18https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-how-do-i-use-tremfya-200mg2ml-pen.pdf2026-03-19https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-pollux-study2026-03-05https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-patients-with-renal-impairment2026-02-09https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/dosing-of-invega-hafyera-alternative-injection-site2025-05-06https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-use-of-closed-system-transfer-devices-in-clinical-trials2025-07-22https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/adolescents-with-psoriasis-in-the-united-states-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-occurrence-of-peripheral-edema-in-patients-with-generalized-myasthenia-gravis2025-06-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/updated-comparative-effectiveness-of-talquetamab-vs-realworld-physicians-choice-of-treatment-in-pati.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-and-darzalex-faspro-use-for-the-treatment-of-autoimmune-hemolytic-anemia2025-06-12https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-elevate/change-in-clinicianrated-and-patientreported-depression-severity-after-esketamine-nasal-spray-as-mon.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/ibromics-a-realworld-study-of-clinical-and-biological-parameters-determining-response-in-patients-wi.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/addressing-an-urgent-unmet-need-in-meth-apah2025-10-16https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/wclc-2025/paloma-2-subcutaneous-amivantamab-video2025-09-09https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-occurrence-and-management-of-tumor-lysis-syndrome2025-11-14https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/suo/penelope-tissue-penetration-of-gemcitabine-phosphate-metabolites-following-tar200-administration-vs.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/invega-hafyera/invega-hafyera-safety-data-sheet-1092-mg.pdf2025-10-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/daratumumab-monotherapy-versus-active-monitoring-in-patients-with-high-risk-smoldering-multiple-myel.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-infusion-duration-less-than-24-hours-in-advanced-soft-tissue-sarcoma.pdf2025-10-27https://www.jnjmedicalconnect.com/products/darzalex/medical-content/maintenance-use-after-autologous-stem-cell-transplant2026-01-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/effect-of-gender-and-follow-up-time-in-damage-accrual-data-from-a-latin-america-lupus-cohort.pdf2026-02-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/treatment-of-adult-patients-with-plaque-psoriasis-using-tremfya-one-press2025-10-16https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-metastatic-nsclc-with-atypical-or-uncommon-egfr-mutations2026-01-13https://www.jnjmedicalconnect.com/media/attestation/products/remicade/safety-data-sheet-for-remicade-infliximab-intravenous-infusion.pdf2026-03-25https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/healthcare-costs-in-a-commercially-insured-population-of-patients-with-generalized-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/crossstudy-comparison-of-ibrutinib-in-combination-with-venetoclax-iv-versus-venetoclax-in-combinatio.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-dosing-missed-dose2026-03-17https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-congress/lumateperone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-and-anxious-distress.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-adverse-event-hematologic-events-in-patients-with-newly-diagnosed-multip2025-11-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/do-stelara-single-dose-vials-contain-latex2025-12-03https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/clinical-research-tools/abi-s2026-02-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/efficacy-and-safety-of-erdafitinib-in-adults-with-nsclc-and-prespecified-fibroblast-growth-factor-re.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-treatment-of-atopic-dermatitis2026-03-18https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/safety-profile-of-invega-trinza-relative-to-invega-sustenna2025-05-13https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-removal-of-non-pvc-equipment-requirement2025-08-25https://www.jnjmedicalconnect.com/media/attestation/products/opsynvi/opsynvi-the-a-due-phase-3-trial-ipdf.pdf2026-04-03https://www.jnjmedicalconnect.com/therapeutic-areas2025-08-04https://www.jnjmedicalconnect.com/media/attestation/products/sporanox-capsules/sporanox-administration-via-a-nasogastric-tube.pdf2026-01-30https://www.jnjmedicalconnect.com/products/spravato/medical-content/rationale-for-nasal-administration-of-spravato2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/response-and-remission-on-esketaminenasal-spray-in-patients-with-treatment-resistant-depression.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/psych-congress-20252025-09-15https://www.jnjmedicalconnect.com/products/xarelto/medical-content/events-after-treatment-discontinuationrebound-of-xarelto2026-03-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-miami/longterm-comparative-effectiveness-of-guselkumab-vs-other-biologic-therapies-among-plaque-psoriasis.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-coronavirus-disease-2019-covid19.pdf2024-08-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/effectiveness-of-remote-patient-monitoring-in-enabling-outpatient-step-up-dosing-for-bispecifics-at.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/dosing-overview2025-06-16https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-pharmacology2026-03-18https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-in-use-stability2026-02-05https://www.jnjmedicalconnect.com/products/xarelto/medical-content/do-xarelto-tablets-contain-lactose2025-07-24https://www.jnjmedicalconnect.com/media/attestation/products/invega-trinza/paliperidone-palmitate-3month-safety-data-sheet-sds.pdf2025-10-02https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-sustenna-invega-trinza-and-invega-hafyera-how-do-they-work-and-what-are-their-unique-charact2025-07-01https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ccr-east-20252026-02-03https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/background-and-conversion-from-erzofri2026-02-02https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/initiation-clinical-rationale2025-06-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/one-press-patient-controlled-injector-instructions-for-use/preparation2025-12-08https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/realitec-subgroup-analysis-a-multicountry-observational-retrospective-study-of-teclistamab-in-patien.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/elevatedermatologysummerconference/icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-the-interleukin23receptor-for-the-treatm.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ash/partnering-with-patients-to-guide-the-development-of-impactful-educational-resources-for-warm-autoim.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/first-line-ibrutinib-venetoclax-shows-benefit-across-genomic-subgroups-in-patients-with-chronic-lym.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/intelence/intelence-once-daily-dosing.pdf2025-08-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aacr/jnj87890387-a-novel-enpp3-bispecific-tcell-redirector-enpp3xcd3-with-tumor-selectivity-through-targe.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/retina2026-02-19https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-coagulation-monitoring2026-02-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/treatment-discontinuation-in-patients-with-ulcerative-colitis-or-crohns-disease-receiving-biologic-t.pdf2026-02-17https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-amplitude-study2026-01-15https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/predictive-value-of-pulmonary-artery-pulsatility-index-in-pulmonary-arterial-hypertension-reveal-ana.pdf2026-01-20https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-pharmacokinetics-blood-brain-barrier-penetration2025-06-04https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/visible-cohort-a-guselkumab-demonstrated-skin-clearance-through-week-48-in-participants-with-moderat.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-darzalex-faspro-in-patients-with-hepatic-impairment-and-multiple-myeloma2025-06-19https://www.jnjmedicalconnect.com/products/opsumit/medical-content/how-should-i-store-opsumit2025-07-22https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/impact-of-baseline-hot-flashes-on-sleep-metrics-during-initial-treatment-in-libe-presentation.pdf2026-02-26https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-drug-interactions2026-03-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/papillon-tp53-comutations-sites-of-insertion-and-ctdna-clearance-among-patients-with-egfr-ex20insmut.pdf2026-01-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-of-spravato-with-covid-19-vaccines2025-11-14https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/analysis-of-repeat-stepup-dosing-and-cytokine-release-syndrome-events-following-prolonged-dosing-int.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/does-tremfya-single-dose-vial-contain-latex2025-08-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/safety-and-efficacy-of-pasritamig-pas-docetaxel-doce-in-presentation.pdf2026-02-26https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-monumental-6-study2025-12-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/longterm-followup-from-the-phase-12-majestec1-trial-of-teclistamab-in-patients-with-relapsedrefracto.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/other/activated-charcoal2025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/neoadjuvant-gemcitabine-intravesical-system-cetrelimab-or-cet-alone-in-patients-with-muscleinvasive.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-peripheral-edema-and-decrease-in-serum-albumin2025-11-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-hawaii/spectrem-guselkumab-demonstrates-significant-clearance-at-multiple-high-impact-sites-in-participants.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/patient-and-clinician-satisfaction-and-quality-of-life-of-patients-with-schizophrenia-using-paliperi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-bedivere-study2025-08-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/optimizing-multiple-myeloma-assessment-for-newly-diagnosed-patients-across-a-large-33-hospital-healt.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/dosing-of-invega-trinza-alternative-injection-site2026-01-13https://www.jnjmedicalconnect.com/products/stelara/medical-content/switching-from-other-biologics-to-stelara-in-crohns-disease2026-03-31https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-use-of-prezista-in-pediatric-and-adolescent-patients.pdf2025-01-13https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/wfsbp-20252025-10-30https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec1-mmy1001-study-cohort-c2025-07-18https://www.jnjmedicalconnect.com/products/invokana/medical-content/tablet-size-of-invokana2024-12-15https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/risk-factors-for-pulmonary-manifestations-in-gladel-20-a-systemic-lupus-erythematosus-latin-americ.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-schizoaffective-disorder2026-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-the-interleukin23receptor-for-the-treatm.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/esmo-2025/patient-reported-outcomes-from-amplitude2025-10-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/talquetamab-tal-teclistamab-tec-in-patients-pts-with-relapsedrefractory-multiple-myeloma-rrmm-update.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/wclc-20252025-09-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aua/tar200-in-patients-with-bacillus-calmetteguerinunresponsive-highrisk-nonmuscleinvasive-bladder-cance.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/safety-tolerability-and-activity-of-jnj67484703-in-participants-with-active-rheumatoid-arthritis-res.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/what-information-is-available-on-stelara-and-cancers2025-07-11https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/smfm-2026/alloimmunization-in-pregnancy-video2026-01-23https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-use-of-erleada-in-high-risk-localized-or-locally-advanced-prostate-cancer2025-05-27https://www.jnjmedicalconnect.com/products/carvykti/medical-content/what-should-i-avoid-after-receiving-carvykti2025-07-03https://www.jnjmedicalconnect.com/products/symtuza/pivotal-clinical-trial-publications2025-12-26https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-interaction-with-serological-testing-for-oncologists2025-07-31https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/health-beliefs-and-practices/better-understanding-social-identities2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/epidemiology-and-realworld-management-of-monoclonal-gammopathies-patients-in-spain-based-on-natural.pdf2026-02-17https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-treatment-of-psoriatic-arthritis-iconic-psa-program2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/diagnostic-challenges-across-the-multiple-myeloma-pathway-perspectives-of-primary-care-physicians-an.pdf2026-01-20https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-storage-and-stability-prepared-syringe2025-12-17https://www.jnjmedicalconnect.com/products/uptravi/medical-content/storage-and-handling-of-the-intravenous-formulation-of-uptravi2025-04-10https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-adverse-event-cerebrovascular-effects.pdf2024-08-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/phase-1-study-results-of-jnj78278343-pasritamig-in-metastatic-castrationresistant-prostate-cancer-mc.pdf2026-01-20https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-lymphodepleting-regimens-in-cartitude-1-and-cartitude-42026-01-12https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-amy3001-andromeda-study2025-11-13https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/ishlt-20242025-08-28https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-use-in-pediatric-patients2025-09-12https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/video-inlexzo-insertion-animation2026-02-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/real-world-assessment-of-new-onset-central-nervous-system-conditions-in-patients-with-non-metastatic.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-pharmacokinetics.pdf2025-04-10https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-cannabis2026-01-29https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/what-are-the-possible-side-effects-of-invega-trinza2025-06-13https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-acute-kidney-injury2025-04-24https://www.jnjmedicalconnect.com/products/akeega/medical-content/use-of-akeega-after-prior-taxane-based-chemotherapy2025-12-25https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-preparation-technique-to-prevent-stopper-coring2025-12-11https://www.jnjmedicalconnect.com/products/xarelto/medical-content/drug-interaction-of-xarelto-with-chloroquine-or-hydroxychloroquine2025-02-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/realworld-onlabel-treatment-persistence-through-24-months-in-biologicnaive-and-biologicexperienc-tu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-transition-from-or-to-dual-antiplatelet-therapy-in-coronary-artery-disease-or-peripheral-ar2025-07-25https://www.jnjmedicalconnect.com/products/spravato/medical-content/mechanism-of-action-of-spravato2025-12-11https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2024/psych/adjunctive-lumateperone-in-patients-with-major-depressive-disorder-results-from-an-additional-random.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/the-efficacy-of-maintenance-treatment-with-guselkumab-in-patients-with-moderately-to-severely-active.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/efficacy-and-safety-of-erdafitinib-in-adults-with-breast-cancer-and-prespecified-fibroblast-growth-f.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/team-phenomenal-hope/transitioning-prostacyclin-pathway-agents-to-oral-selexipag-in-patients-with-pulmonary-arterial-hype.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/disease-burden-in-patients-with-generalized-myasthenia-gravis-mg-2.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/aua-20242025-08-28https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-less-frequent-dosing-real-world-evidence2025-08-31https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/the-efficacy-and-safety-of-guselkumab-as-maintenance-therapy-in-patients-with-moderately-to-severely.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokamet/pivotal-clinical-trial-publications2025-12-22https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-darzalex-faspro-in-combination-with-bortezomib-lenalidomide-and-dexamethasone-in-mu2026-01-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/guselkumab-maintenance-therapy-mediates-further-improvements-in-intestinal-immune-homeostasis-and-mu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-total-fill-volume-and-extractable-volume-in-vials2026-02-06https://www.jnjmedicalconnect.com/products/invokana/medical-content/effect-of-invokana-on-cardiovascular-outcomes-real-world-evidence2025-02-10https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aan-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/products/erleada/erleada-use-of-erleada-in-patients-with-cerebrovascular-or-cardiovascular-disease.pdf2026-02-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suna/sunrise-1-updated-study-results-from-cohorts-2-and-4-poster.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/association-of-somatic-germline-homologous-recombination-repair-alterations-with-prostatespecific-an.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-pyoderma-gangrenosum2025-07-17https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-overview-of-the-phase-23-vibrance-mg-clinical-trial2025-11-20https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-is-it-safe-for-elderly-patient-to-take-caplyta2026-01-23https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/major-depressive-disorder-with-clinically-relevant-insomnia-symptoms-healthcare-professional-assessm.pdf2026-01-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-treatment-response-in-patients-without-early-response2025-10-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/adverse-event-of-invega-trinza-cardiovascular-effects2025-12-18https://www.jnjmedicalconnect.com/products/invokana/medical-content/comparison-of-invokana-to-ertugliflozin2024-10-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-latex-content2025-08-04https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/gpcc-20262026-02-02https://www.jnjmedicalconnect.com/products/xarelto/pivotal-clinical-trial-publications2025-12-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/longterm-efficacy-and-safety-results-from-the-phase-12-monumental1-study-of-talquetamab-a-gprc5dcd3.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-the-elderly2026-04-02https://www.jnjmedicalconnect.com/products/imaavy/medical-content/how-will-i-receive-imaavy2025-05-01https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/can-i-take-rybrevant-if-i-am-pregnant-or-breastfeeding2025-08-13https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/nei/unraveling-the-treatment-preferences-of-patients-and-healthcare-providers-in-treatmentresistant-depr.pdf2026-01-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/clinical-trials-of-spravato-in-patients-with-major-depressive-disorder-and-active-suicidal-ideation2025-10-22https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-comparison-with-other-atypical-antipsychotics2026-03-18https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/psych-20242025-08-29https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-dilution-in-volume-less-than-500-ml.pdf2025-06-06https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-define-study.pdf2025-09-02https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-use-of-bsa-x-iga-to-evaluate-guselkumab-efficacy-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-adherence-and-persistence2024-12-06https://www.jnjmedicalconnect.com/products/icotyde/medical-content/how-should-i-store-icotyde2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/enhanced-vs-standard-dermatologic-management-with-amivantamablazertinib-in-advanced-nsclc-slides.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-and-talvey-rems-dispense-authorization-rda2025-07-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/efficacy-and-safety-of-talquetamab-in-chinese-patients-with-relapsedrefractory-multiple-myeloma-from.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/lazcluze-open-bottle-stability2026-03-06https://www.jnjmedicalconnect.com/products/darzalex/medical-content/what-is-the-recommended-dosing-for-darzalexwith-bortezomib-and-dexamethasone-to-treat-multiple-myelo2025-07-03https://www.jnjmedicalconnect.com/products/erleada/medical-content/can-i-take-erleada-through-a-feeding-tube2025-08-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/talquetamab-vs-realworld-physicians-choice-in-patients-with-relapsedrefractory-multiple-myeloma-and.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ecop/overall-survival-in-patients-with-metastatic-castration-sensitive-prostate-cancer-treated-with-apalu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-bipolar-disorder2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad/spectrem-guselkumab-demonstrates-significant-clearance-across-the-most-commonly-presenting-special-s.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/paloma-2-study2025-12-18https://www.jnjmedicalconnect.com/products/remicade/medical-content/home-care-administration-of-remicade2026-02-24https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2024/psych/lumateperone-treatment-in-patients-with-major-depressive-disorder-with-mixed-features-results-from-a.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/rybrevant-faspro/rybrevant-faspro-what-is-the-dosing-schedule-of-rybrevant-faspro.pdf2026-02-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/mhncs/neoadjuvant-and-adjuvant-amivantamab-plus-pembrolizumab-in-resectable.pdf2026-02-20https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-weight-change2026-03-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/major-depressive-disorder-patient-voice-aiassisted-insights-from-inspires-online-health-community-pl.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/esmo-2025/translational-analyses-of-t-cell-phenotypes-video2025-10-17https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-older-patients-with-multiple-myeloma012026-01-27https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/use-of-invega-trinza-in-renal-impairment2026-03-10https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/first-line-treatment-in-patients-with-transplant-ineligible-video2025-12-06https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-event-of-spravato-urinary-disorders2025-11-18https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/treatment-related-characteristics-among-younger-women-with-gmg.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/association-of-endoscopic-histologic-and-composite-outcomes-with-longterm-gus.pdf2026-02-23https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/does-taking-simponi-aria-increase-my-risk-for-infections2025-07-18https://www.jnjmedicalconnect.com/products/invokana/medical-content/monitoring-of-invokana2025-05-16https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ats/a-teambased-patient-engagement-approach-to-selexipag-initiation-and-maintenance-in-pulmonary-arteria.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2024/ascp/lumateperone-in-the-treatment-of-major-depressive-disorder-and-bipolar-depression-with-mixed-feature.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/real-world-treatment-patterns-among-patients-with-generalized-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/efficacy-and-safety-of-guselkumab-maintenance-therapy-among-guselkumab-induction-week-24-clinical-re.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-aerosolized-administration.pdf2026-03-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/patterns-of-management-and-multidisciplinary-care-in-highvery-high-and-presentation.pdf2026-02-27https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-galahad-study2025-08-12https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-use-in-patients-with-hepatic-impairment.pdf2024-10-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/pvri/macitentan-and-phosphodiesterase5-inhibitor-as-monotherapy-or-in-combination-in-newly-diagnosed-pati.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/firstinhuman-study-of-jnj79635322-jnj5322-a-novel-nextgeneration-trispecific-antibody-tsab-in-patien.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/outcomes-in-patients-with-tripleclassexposed-relapsedrefractory-multiple-myeloma-treated-with-realli.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/invokana/invokana-300mg-safety-data-sheet-sds.pdf2025-08-19https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/efficacy-and-safety-of-nipocalimab-vs-efgartigimod-in-a-randomized-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/longterm-followup-from-the-phase-12-majestec1-trial-of-teclistamab-in-patients-with-relapsedrefracto.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/updated-comparative-efficacy-of-ciltacabtagene-autoleucel-versus-idecabtagene-vicleucel-in-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-infections-in-adult-patients-with-crohns-disease-or-ulcerative-colitis2026-02-25https://www.jnjmedicalconnect.com/products/invega-sustenna2026-01-21https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/dosing-of-risperdal-consta-discontinuation-of-therapy2025-07-31https://www.jnjmedicalconnect.com/resources/interactive-ingredient-checker2025-08-01https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-what-is-icotyde2026-03-18https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/wclc-2025/finegfr-cns-real-world-video2025-09-09https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-overview-of-visible-clinical-trial2025-12-18https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-fatigue2025-06-17https://www.jnjmedicalconnect.com/resources/safety-data-sheet2026-02-18https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-dental-procedures2025-05-26https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/predictors-of-composite-response-in-mgbased-on-patient-and-clinicianreported-assessmentsin-vivacitym.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-dosing-interval-adjustments-in-adult-patients-with-plaque-psoriasis2026-01-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/pharmacodynamic-profiles-of-patients-pts-with-newly-diagnosed-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-comparison-to-nogapendekin-alfa-inbakicept-pmin2025-09-11https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/wclc-2025/enhanced-vs-standard-dermatologic-video2025-09-09https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/management-bleeding/registry-data2025-10-16https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/aonn-20242025-08-28https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-adult-patients-with-psoriatic-arthritis-and-spondylarthritis-and-peripheral-joint2026-03-31https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-candor-study2026-01-29https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/spectrem-guselkumab-significantly-improves-patient-reported-outcomes-at-week-16-in-participants-wit.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-differences-from-risperdal-consta2025-11-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/patientreported-outcomes-pros-and-safety-in-patients-pts-with-ndmm-achieving-mrd-negativity-and-cr-m.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/unmet-needs-and-disease-burden-perspectives-from-adults-with-psoriasis-and-clinicians-in-the-united.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-once-weekly-dosing-in-chronic-kidney-disease.pdf2025-06-06https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/corticosteroid-sparing-effects-of-treatment-with-guselkumab-in-patients-with-moderate-to-severely-ac.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/how-do-i-store-tremfya-prefilled-syringes2026-03-05https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ash/treatment-patterns-and-outcomes-among-patients-with-warm-autoimmune-hemolytic-anemia-receiving-ritux.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-immunogenicity-in-patients-with-generalized-myasthenia-gravis2025-11-07https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-treatment-of-ulcerative-colitis-in-adult-patients-overview-of-clinical-trials-data2025-09-15https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-adverse-event-infusion-related-reactions2025-11-04https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/acnp-20262026-01-15https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-every-four-week-dosing-in-treating-anemia-in-patients-with-cancer.pdf2024-11-06https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/las-vegas-dermatology-2025/efficacy-and-safety-of-icotrokinra-a-novel-targeted-oral-peptide-il23rinhibitor-in-adolescents-with.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-conversion-from-invega-sustenna-vs-invega-trinza2025-09-08https://www.jnjmedicalconnect.com/products/veletri2026-01-21https://www.jnjmedicalconnect.com/products/talvey/talvey-pharmacovigilance-safety-alert2025-08-20https://www.jnjmedicalconnect.com/media/attestation/products/icotyde/icotyde-how-should-i-take-icotyde.pdf2026-04-01https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/trimm2-mmy1002-study-talvey-and-darzalex2025-11-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/population-based-assessment-of-treatment-patterns-for-high-risk-localized-prostate-cancer-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/efficacy-and-safety-of-esketamine-nasal-spray-as-monotherapy-in-adult-patients-with-treatmentresista.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/isbd/lumateperone-treatment-for-major-depressive-episodes-with-mixed-features-in-major-depressive-disorde.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/efficacy-and-safety-of-guselkumab-through-week-96-after-intravenous-or-subcutane.pdf2026-02-23https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-effect-on-qt-interval2026-03-13https://www.jnjmedicalconnect.com/products/imaavy/medical-content/what-should-i-tell-my-healthcare-provider-before-starting-imaavy2025-05-01https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/updated-analysis-of-survival-and-treatment-video2025-12-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/comparative-effectiveness-of-ciltacabtagene-autoleucel-from-the-cartitude4-trial-vs-realworld-physic.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-occurrence-of-hypersensitivity-reactions-in-patients-with-generalized-myasthenia-gravis2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/psych-congress-np-institute/lumateperone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder-and-anxious-distress.pdf2026-03-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/characteristics-and-outcomes-of-non-transplanted-newly-diagnosed-multiple-myeloma-patients-treated-w.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-occurrence-and-management-of-cytokine-release-syndrome-crs2026-02-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/realworld-characteristics-and-treatment-patterns-of-transplanteligible-patients-with-newly-diagnosed.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-effect-of-guselkumab-on-psoriasis-severity-through-week-48-in-participants-with-low-bsa-m.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/impact-of-weight-on-efficacy-in-the-treatment-of-adult-patients-with-crohns-disease2025-10-27https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-and-adalimumab-in-crohns-disease-seavue-study2026-01-08https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-comparison-to-pembrolizumab2025-09-11https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-hematologic-events2026-01-09https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/mariposa-2-study2026-02-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aacr/mechanisms-of-acquired-resistance-and-ctdna-clearance-in-egfrmutated-advanced-nsclc-following-lazert.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-and-invega-trinza-comparison-with-oral-antipsychotics2025-10-15https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-evidence-and-value-summary.pdf2024-04-29https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/adverse-event-of-invega-trinza-weight-change2025-05-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/what-is-the-recommended-dosing-for-darzalex-in-combination-with-carfilzomib-and-dexamethasone-to-tre2025-07-02https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-pediatric-use.pdf2024-04-12https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-the-treatment-of-pustular-psoriasis2026-02-17https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-what-are-the-ingredients-in-caplyta2026-02-13https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/wclc-2025/mechanisms-of-acquired-resistance-video2025-09-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/dose-escalation-in-participants-with-primarysecondary-loss-of-response-to-conven.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-6-mg-tablet-safety-data-sheet-sds.pdf2025-05-02https://www.jnjmedicalconnect.com/products/tremfya2026-01-21https://www.jnjmedicalconnect.com/products/remicade/medical-content/storage-and-stability-of-unreconstituted-remicade2025-06-19https://www.jnjmedicalconnect.com/products/rybrevant2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-hawaii/spectrem-guselkumab-demonstrates-consistent-complete-clearance-at-week-16-across-special-sites-in-pa.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-peripheral-artery-disease2024-08-19https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-transitioning-from-epoprostenol-for-infusion2025-07-11https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/aepc/efficacy-and-safety-of-selexipag-in-pediatric-pulmonary-arterial-hypertension-results-from-the-rando.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/comparison-of-time-to-next-treatment-between-patients-with-chronic-lymphocytic-leukemia-initiating-f.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-hawaii/onlabel-persistence-in-psoriasis-after-switching-to-guselkumab-or-tnf-inhibitors-from-other-advanced.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-adverse-event-genital-mycotic-infections012025-09-10https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-overview-of-the-evolution-clinical-trial2025-10-06https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-residual-medication-in-used-devices2025-11-18https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-patients-with-renal-impairment2026-03-18https://www.jnjmedicalconnect.com/products/stelara/medical-content/treatment-of-pityriasis-rubra-pilaris-with-stelara2026-01-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/postinduction-outcomes-and-updated-minimal-residual-disease-analysis-from-gmmghd10dsmmxx-majestec5-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/botaretigene-sparoparvovec/medical-content/phase-12-clinical-trials2025-05-15https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/nei-20252025-11-06https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-does-caplyta-increase-my-risk-for-suicidal-thoughts-and-actions2026-02-25https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-pharmacokinetics-and-pharmacodynamics2025-11-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aua/tar210-erdafitinib-intravesical-delivery-system-in-nonmuscleinvasive-bladder-cancer-with-select-fgfr.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-extensive-clot-burden2025-07-22https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/impact-of-covid19-on-outcomes-with-teclistamab-in-the-phase-12-majestec1-study-in-patients-with-rela.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/efficacy-of-guselkumab-in-bionaive-psoriatic-arthritis-patients-with-severe-disease-activity-posthoc.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-transition-from-or-to-unfractionated-heparin2025-09-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/outcomes-in-highrisk-subgroups-after-fixedduration-ibrutinib-venetoclax-for-chronic-lymphocytic-leu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-portal-vein-thrombosis2025-05-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/delayed-response-in-adult-patients-with-crohns-disease-or-ulcerative-colitis-receiving-stelara2026-01-12https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-interstitial-lung-diseasepneumonitis2025-06-11https://www.jnjmedicalconnect.com/media/attestation/products/xarelto/xarelto-safety-data-sheet-sds-for-the-suspension.pdf2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/healthcare-resource-utilization-and-medical-costs-in-patients-with-metastatic-castration-sensitive-p.pdf2026-01-07https://www.jnjmedicalconnect.com/products/remicade/medical-content/drug-interactions-of-remicade2025-10-01https://www.jnjmedicalconnect.com/products/risperdal/medical-content/risperdal-oral-solution-instructions-for-use2025-03-17https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-use-in-patients-co-infected-with-hepatitis-b-or-c.pdf2025-06-06https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-how-do-i-use-tremfya-100mgml-prefilled-syringe.pdf2025-12-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aua/real-world-treatment-sequence-and-survival-in-localized-or-locally-advanced-prostate-cancer-and-post.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-use-in-plasma-cell-leukemia2026-02-05https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/safety-data-sheet-for-tremfya-guselkumab-intravenous-usage.pdf2025-09-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/enhanced-vs-standard-dermatologic-management-with-amivantamablazertinib-in-egfrm-advanced-nsclc-the.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/eular-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/design-of-a-digital-solution-to-improve-myasthenia-gravis-patient-symptom-tracking-in-routine-clinic.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/safety-and-effectiveness-of-nipocalimab-in-adolescent-participants-in-the-open-label-phase-23-vibran.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/physician-experiences-with-tar-200-in-high-risk-non-muscle-invasive-bladder-cancer-a-qualitative-stu.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/wcpd/icotrokinra-a-novel-targeted-oral-peptide-il23rinhibitor-in-adolescents-with-moderatetosevere-plaque.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/drug-interactions-of-invega-sustenna-strong-cyp3a4-andor-p-gp-inducers2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aacr/geographic-and-racial-disparities-in-bladder-cancer-care-in-the-us.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/treatment-patterns-and-outcomes-in-the-second-and-third-lines-and-after-tripleclass-exposure-subanal.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/impact-of-somaticgermline-homologous-recombination-repair-hrr-alterations-on-metastatic-hormonesensi.pdf2026-01-20https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/adverse-event-of-risperdal-consta-hematologic-effects2025-06-18https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-pah-associated-with-connective-tissue-disease2025-08-25https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-clinical-outcomes-of-subsequent-therapies-following-talvey012026-03-06https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-corticosteroid-tapering-before-or-after-administration2026-01-08https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/las-vegas-dermatology-20252025-10-30https://www.jnjmedicalconnect.com/products/simponi-aria2026-02-09https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/stability-of-invega-sustenna-at-elevated-temperature-excursion2025-07-02https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-creatinine-clearance-or-estimated-glomerular-filtration-rate-in-adults2025-07-29https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/assessment-of-pharmacokinetic-and-pharmacodynamic-drugdrug-interactions-with-nipocalimab-and-relevan.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/masterclass-in-dermatology-20262026-02-18https://www.jnjmedicalconnect.com/products/invokana/medical-content/mechanism-of-action2025-04-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/teclistamab-in-a-large-cohort-of-100-asian-patients-with-triple-class-exposed-multiple-myeloma-exper.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/effect-of-spravato-on-cognition2025-09-24https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-dosage-and-administration-restarting-after-prolonged-treatment-interruption2026-01-19https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-discontinuation-of-premedications2025-10-09https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-faspro-rybrevant-dosage-and-administration-intravenous-to-subcutaneous-switch2026-02-13https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-should-i-tell-my-provider-before-receiving-darzalex-faspro2025-09-22https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/management-of-an-incomplete-administration-of-invega-trinza2025-12-15https://www.jnjmedicalconnect.com/media/attestation/products/intelence/intelence-25-100mg-tablets-safety-data-sheet-sds.pdf2025-06-11https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/patient-and-caregiver-resources/patient-resources2026-02-27https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-cardiovascular-events.pdf2025-06-02https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-hypercoagulable-states2025-07-14https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-serious-adverse-event-death2026-03-03https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-how-supplied-storage-and-handling2025-09-24https://www.jnjmedicalconnect.com/products/uptravi/medical-content/what-are-the-possible-side-effects-of-uptravi2025-07-31https://www.jnjmedicalconnect.com/products/spravato/medical-content/dosage-and-administration-spravato-dosing-above-84-mg2026-03-23https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/long-term-safety-and-efficacy-of-nipocalimab-in-generalized-myasthenia-gravis-vivacity-mg3-open-labe.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-combination-with-azathioprine-6mercaptopurine-or-methotrexate-in-the-treatment-of2026-02-04https://www.jnjmedicalconnect.com/media/attestation/products/talvey/talvey-evidence-and-value-summary-one-pager.pdf2025-01-24https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/prezcobix-safety-information-effect-on-lipids.pdf2025-04-08https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-sphere-registry2026-01-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/clinical-characteristics-and-treatment-patterns-of-highrisk-prostate-cancer-hr-lpc-patients-treated.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/amivantamab-in-recurrent-metastatic-head-and-neck-squamous-cell-cancer-hnscc-after-disease-progressi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/prezista/isi-english2025-03-05https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-cardiovascular-events.pdf2026-01-30https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/nei/monotherapy-madrs-analysis-encore-change-in-clinician-rated-and-patient-reported-depression-sever.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/design-and-methodological-considerations-for-real-world-dataderived-progressionfree-survival-in-mult.pdf2026-01-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/dosage-and-administration-management-of-missed-dose-or-reinitiation-after-spravato-discontinuation2025-12-30https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/use-of-invega-hafyera-in-bipolar-disorder2025-12-18https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-sustenna-invega-trinza-and-invega-hafyera-how-do-they-work-and-what-are-their-unique-charact2025-07-01https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/apa-20252025-09-08https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fsr/efficacy-and-safety-of-subcutaneous-guselkumab-induction-therapy-in-patients-with-ulcerative-colitis.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/icotrokinra/oncedaily-oral-icotrokinra-versus-placebo-and-oncedaily-oral-deucravacitinib-in-participants-with-mo.pdf2026-02-18https://www.jnjmedicalconnect.com/products/invokana/isi-english2025-03-03https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-repackaging-stability2025-11-14https://www.jnjmedicalconnect.com/products/uptravi/medical-content/transitioning-to-uptravi-from-inhaled-prostacyclin-therapy2025-07-30https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/masterclass-in-dermatology/efficacy-and-safety-of-guselkumab-in-participants-with-active-psoriatic-arthritis-and-inadequate-res.pdf2026-02-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/estimating-the-united-states-cure-adjusted-prevalence-of-diffuse-large-b-cell-lymphoma-dlbcl-an-epid.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-miami/spectrem-guselkumab-demonstrates-consistent-significant-clearance-at-week-16-across-the-full-range-o.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-palmoplantar-pustulosis2025-12-31https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/comparison-of-rybrevant-monotherapy-to-osimertinib2025-09-23https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-treatment-in-the-vadod-clinical-practice-guidelines-for-the-management-of-major-depressive2026-01-26https://www.jnjmedicalconnect.com/products/tremfya/isi-english2025-05-20https://www.jnjmedicalconnect.com/products/remicade/medical-content/use-of-remicade-at-doses-greater-than-10-mgkg2025-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ash/a-us-retrospective-observational-study-of-rituximab-initial-and-retreatment-in-patients-with-warm-au.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/longterm-safety-and-efficacy-of-nipocalimab-in-generalized-myasthenia-gravis-vivacitymg3-openlabel-e.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-dosing-timing-of-dose2026-03-17https://www.jnjmedicalconnect.com/products/inlexzo/pivotal-clinical-trial-publications2025-09-26https://www.jnjmedicalconnect.com/media/attestation/products/xarelto/xarelto-what-are-the-possible-side-effects-of-xarelto.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/realworld-experience-with-talquetamab-clinical-management-in-relapsed-refractory-multiple-myeloma-rr.pdf2026-01-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-adverse-event-hypogammaglobulinemia2026-03-24https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/can-i-receive-darzalex-faspro-if-i-am-pregnant-or-breastfeeding2025-12-17https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-use-in-waldenstrm-macroglobulinemia2026-01-08https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-psoriasis-and-comorbid-latent-tuberculosis-infection-ltbi-withou2026-03-25https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-how-do-i-use-the-one-press-patient-controlled-injector.pdf2026-01-12https://www.jnjmedicalconnect.com/products/tremfya/medical-content/jnj78934804-golimumab-and-guselkumab-vs-simponi-or-tremfya-monotherapy-in-ulcerative-colitis2026-02-24https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aad-20262026-03-27https://www.jnjmedicalconnect.com/products/invokana/medical-content/drug-drug-interaction-profile-of-invokana2024-11-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/exploratory-biomarkers-associated-with-talquetamab-resistance-and-relapse-in-the-monumental1-china-4.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/can-i-receive-imaavy-if-i-am-pregnant-planning-to-become-pregnant-breastfeeding-or-planning-to-breas2025-05-01https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-use-as-bridging-therapy-prior-to-car-t-therapy2025-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/treatment-of-plaque-psoriasis-involving-high-impact-sites-with-icotrokinra-a-ta-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/guselkumab-decreases-key-cellular-inflammatory-processes-across-ileum-and-colon-tissue-in-crohns-dis.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/subcutaneous-amivantamab-and-lazertinib-as-firstline-treatment-in-patients-with-egfrmutated-advanced.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invokana/medical-content/effect-of-invokana-on-body-weight-randomized-controlled-trials2025-03-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/realworld-characteristics-stepup-dosing-patterns-and-early-safety-outcomes-of-patients-with-multiple.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-use-of-zytiga-in-combination-with-docetaxel-for-the-treatment-of-mcrpc.pdf2025-12-24https://www.jnjmedicalconnect.com/products/akeega2026-03-24https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/adverse-event-neuroleptic-malignant-syndrome-and-invega-sustenna-invega-trinza-and-invega-hafyera2026-04-01https://www.jnjmedicalconnect.com/locate-scientific-account-lead2026-02-03https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-long-term-phase-3-safety-and-efficacy-in-adult-patients-with-generalized-myasthenia-gravis2025-10-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad/visible-cohort-a-guselkumab-demonstrated-skin-clearance-and-improved-healthrelated-quality-of-life-t.pdf2026-01-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-use-in-plasma-cell-leukemia2026-03-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/prospective-iterative-data-visualization-study-to-enhance-health-literacy-in-prostate-cancer.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/comparison-to-secukinumab-in-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis2025-07-07https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-adverse-event-hematological-disorders.pdf2024-11-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-nppa-fall/efficacy-and-safety-of-icotrokinra.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-trinza-paliperidone-palmitate-3month032026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/a-delphi-panel-to-identify-optimal-clinical-outcome-measures-coas-in-chronic-inflammatory-demyelinat.pdf2026-02-17https://www.jnjmedicalconnect.com/products/xarelto/medical-content/drug-interactions-of-xarelto-with-proton-pump-inhibitors2024-05-10https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-event-of-spravato-sedation-and-somnolence2025-10-31https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-dose-escalation-during-stelara-90-mg-every-8-weeks-maintenance-therapy-in-crohns-disease2025-06-20https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/concomitant-use-of-invega-sustenna-invega-trinza-or-invega-hafyera-with-covid19-vaccines2025-08-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/winter-clinical-hawaii/durability-of-response-to-the-targeted-oral-peptide-icotrokinra-for-highimpact-site-psoriasis-1year.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/spectrem-guselkumab-demonstrates-consistent-significant-clearance-at-week-16-across-the-full-range-o.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-safety-data-sheet.pdf2025-06-04https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience2026-02-19https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/dosing-of-risperdal-consta-dosage-and-administration2026-02-03https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/prezcobix-repackaging.pdf2024-04-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/durability-of-response-to-the-targeted-oral-peptide-icotrokinra-for-high-impact-site-psoriasis-1-ye.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/life-years-gained-from-the-fda-accelerated-approval-program-in-hematology-a-portfolio-model.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/realworld-characterization-of-response-kinetics-in-patients-with-metastatic-nsclc-receiving-firstlin.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-use-of-zytiga-in-metastatic-castrationresistant-prostate-cancer-mcrpc.pdf2025-12-29https://www.jnjmedicalconnect.com/media/attestation/products/balversa/hyperphosphatemia-associated-with-erdafitinib-treatment-infographic-rprd.pdf2026-04-03https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-onset-of-action-in-major-depressive-disorder2026-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/talquetamab-vs-realworld-physicians-choice-in-patients-with-relapsedrefractory-multiple-myeloma-and.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/effect-of-specific-ssrissnris-in-combination-with-spravato2026-01-30https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-effect-of-guselkumab-on-psoriasis-signs-and-symptoms-through-week-48-in-participants-with.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/adjunctive-treatment-with-seltorexant-improved-patientreported-depressive-symptoms-insomnia-symptoms.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/efficacy-of-guselkumab-through-48-weeks-in-chinese-psoriasis-patients-with-and-without-metabolic-com.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/longterm-followup-from-the-phase-12-majestec1-trial-of-teclistamab-in-patients-with-relapsedrefracto.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imbruvica2024-12-06https://www.jnjmedicalconnect.com/products/xarelto/medical-content/real-world-data-of-xarelto-vs-apixaban-in-non-valvular-atrial-fibrillation2025-07-28https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-sustenna-in-patients-with-comorbid-substance-abuse2025-09-11https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ats/longterm-treatment-of-singletablet-combination-of-macitentan-and-tadalafil-in-pulmonary-arterial-hyp.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/isds/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il-23i-in-participants-wit.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/pivotal-clinical-trial-publications2025-12-22https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/does-the-invega-hafyera-prefilled-syringe-contain-latex012025-10-27https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-use-of-erleada-with-concurrent-radiotherapy2025-06-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/longerterm-followup-of-patients-receiving-prophylactic-tocilizumab-for-cytokine-release-syndrome-in.pdf2026-01-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-use-after-prior-bcell-maturation-antigen-bcma-car-tcell-therapy2025-12-05https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/gdpapearls-20252025-09-03https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-administration-of-zytiga-without-prednisone.pdf2025-12-29https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-conversion-to-invega-sustenna-from-long-acting-injectable-antipsychotics2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/las-vegas-dermatology-2025/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il23i-in-participants-with-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/what-is-carvykti2025-07-02https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-crushing-splitting-or-dispersion-of-tablets2025-05-24https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-shelf-life-of-lyophilized-powder-after-temperature-excursions.pdf2026-03-11https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-pediatric-patients2026-02-13https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/carvykti-adverse-event-management-guide.pdf2025-12-08https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/rybrevant-chrysalis-2-study2026-02-19https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-impact-of-comorbidities2025-06-06https://www.jnjmedicalconnect.com/products/uptravi/medical-content/does-uptravi-for-injection-contain-preservatives2025-08-06https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ash/treatment-response-relapse-and-survival-of-hospitalized-adult-primary-warm-autoimmune-hemolytic-anem.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/simponi-aria/safety-data-sheet-for-simponi-aria-intravenous-golimumab.pdf2025-12-12https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/capp/10year-data-on-oral-selexipag-longterm-survival-safety-and-dosing-insights-in-pulmonary-arterial-hyp.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/frontline-treatment-patterns-in-patients-with-newly-diagnosed-multiple-myeloma-realworld-evidence-f.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/analysis-of-patients-with-prior-bcmatargeted-therapy-and-those-achieving-cr-in-realital-a-multicount.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/nei/impact-of-major-depressive-disorder-with-prominent-anhedonia-on-polypharmacy-resource-utilization-an.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/healthrelated-quality-of-life-in-transplanteligible-patients-with-newly-diagnosed-multiple-myeloma-d.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/identification-of-tissue-associated-remodeling-endotypes-in-rheumatic-disease-cohorts.pdf2026-02-17https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-in-patients-with-plaque-psoriasis-and-comorbid-hepatic-impairment2026-03-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/stigma-and-mental-health/overview2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/outcomes-of-patients-with-extramedullary-disease-and-relapsed-or-refractory-multiple-myeloma-from-hi.pdf2026-01-20https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-combination-with-immunomodulators-5asas-and-corticosteroids-in-crohns-disease-unit2025-08-21https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/does-darzalex-faspro-contain-sorbitol2026-02-03https://www.jnjmedicalconnect.com/products/icotyde/medical-content/dosage-and-administration-per-protocol-in-phase-3-plaque-psoriasis-trials2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/acg/week-48-efficacy-of-guselkumab-and-ustekinumab-in-crohns-disease-based-on-prior-responseexposure-to.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ideom/visible-cohort-b-guselkumab-demonstrated-scalp-clearance-and-improved-healthrelated-quality-of-life.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-elderly-patients-with-treatment-resistant-depression2025-09-22https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/first-results-from-realital-a-multicountry-observational-retrospective-study-of-talquetamab-in-patie.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/durability-of-icotrokinra-targeted-oral-peptide-effects-in-adolescents-with-mo-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/products/uptravi/medical-content/what-is-the-recommended-dosing-for-uptravi-tablets-for-pulmonary-arterial-hypertension2025-08-14https://www.jnjmedicalconnect.com/products/stelara/medical-content/ustekinumab-an-unbranded-biologic-of-stelara-ustekinumab2026-03-18https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-overview-of-the-star-clinical-trial2025-10-17https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/what-should-i-tell-my-healthcare-provider-before-receiving-rybrevant-faspro2025-12-18https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/can-rybrevant-cause-eye-problems2025-09-05https://www.jnjmedicalconnect.com/products/darzalex/medical-content/storage-and-stability-of-darzalex-vials-at-room-temperature2026-03-20https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/pharmacokinetics-of-invega-sustenna2025-11-05https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-dual-antiplatelet-therapy2024-05-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/longerterm-followup-of-patients-receiving-prophylactic-tocilizumab-for-the-reduction-of-cytokine-rel.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/efficacy-and-safety-of-guselkumab-in-patients-with-active-psoriatic-arthritis-and-inadequate-respons.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/comparison-of-uptravi-and-inhaled-treprostinil2026-02-27https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-4-study2026-02-27https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-density-of-intravenous-infusion-formulation-130-mg26-ml5-mgml-solution-in-a-singledose-vial2026-03-31https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/apcc-pcc/escolar-et-al-20152025-10-16https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-occurrence-and-management-of-administration-related-reactions2025-05-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/elevatedermatologysummerconference/inhibition-of-structural-damage-progression-with-guselkumab-a-selective-il23i-in-participants-with-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-sustenna-in-developmental-disorders2025-10-17https://www.jnjmedicalconnect.com/products/erleada/medical-content/can-erleada-cause-rash2025-10-29https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/general-administration-instructions2025-06-16https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-safety-information-renal-effects.pdf2025-08-04https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/patient-and-caregiver-experiences-of-symptom-instability-and-unpredictability-from-a-myasthenia-grav.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/chest/characteristics-treatment-patterns-and-outcomes-of-pulmonary-arterial-hypertension-patients-by-ethni.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/effect-of-amivantamab-dose-interruptions-on-efficacy-and-safety-of-firstline-amivantamab-plus-lazert.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/use-of-invega-trinza-in-highlow-body-weight2026-02-27https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/can-opsynvi-cause-swelling-or-fluid-retention2025-04-29https://www.jnjmedicalconnect.com/products/imaavy/medical-content/can-i-receive-vaccines-before-or-while-receiving-imaavy2025-05-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/eau/longitudinal-assessment-of-urine-tumor-dna-in-highrisk-nonmuscle-invasive-blad.pdf2026-03-12https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2026/mda/efficacy-and-safety-of-nipocalimab-vs-efgartigimod-poster.pdf2026-03-06https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-adult-patients-with-ulcerative-colitis-real-world-evidence2025-10-30https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/psych-congress-np-institute/lumateperone-for-the-prevention-of-relapse-in-patients-with-schizophrenia-results-from-a-doubleblind.pdf2026-03-19https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/safety-results-from-realital-a-multi-country-observational-retrospective-study-of-talquetamab-in-pat.pdf2026-01-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-cartitude1-mmy2001-study2025-12-16https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-realitec-study2025-09-15https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ipcu-2026/comparison-of-early-and-deep-prostate-specific-antigen-video2026-02-06https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-dosage-and-administration-post-administration-observation-time2025-12-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/spartan/associations-between-clinical-characteristics-and-screening-magnetic-resonance-imaging-mri-findings.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-administration-setting.pdf2024-04-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-il23-receptor-activation-in-moderately-t.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal/medical-content/adverse-event-of-risperdal-effect-on-bone-mineral-density2026-03-19https://www.jnjmedicalconnect.com/media/attestation/products/lazcluze/lazcluze-safety-data-sheet-sds-240-mg-tablets.pdf2025-08-26https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/does-the-invega-trinza-prefilled-syringe-contain-latex2025-10-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-guselkumab-efficacy-and-patient-reported-outcomes-through-week-48-across-multiple-high-imp.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/effects-of-spravato-on-driving-performance2025-10-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/real-world-comparison-of-timetonexttreatment-ttnt-timetocastrationresistance-ttcr-and-overall-surviv.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-management-of-infusion-related-reactions2026-01-22https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/biomarker-testing-patterns-among-patients-newly-diagnosed-with-prostate-cancer-in-a-community-oncolo.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/phpn/transitioning-prostacyclin-pathway-agents-to-oral-selexipag-in-patients-with-pulmonary-arterial-hype.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/use-of-tremfya-in-patients-undergoing-surgery-aadnpf-guidelines-for-the-treatment-of-psoriasis-with2026-02-23https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-patients-with-prior-stroke-or-tia2025-10-06https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/aanem/adverse-pregnancy-outcomes-in-myasthenia-gravis-a-retrospective-cohort-study-in-a-us-health-insuranc.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/use-of-invega-invega-sustenna-invega-trinza-and-invega-hafyera-in-pregnancy-or-lactation2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/prezcobix/prezcobix-safety-information-sulfa-allergy.pdf2025-04-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/realworld-characteristics-and-outcomes-in-patients-with-multiple-myeloma-receiving-teclistamab-stepu.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-pediatric-patients-with-plaque-psoriasis2026-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/analysis-of-long-term-efficacy-of-nipocalimab-in-myasthenia-gravis-open-label-extension-of-the-vivac.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/chest/expert-consensus-on-the-definition-of-methamphetamineassociated-pulmonary-arterial-hypertension-meth.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/drug-interactions-with-invega-invega-sustenna-invega-trinza-and-invega-hafyera-general2025-06-04https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-patients-with-crohns-disease-and-prior-surgery-or-postoperative2025-08-18https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/risk-of-mental-health-outcomes-video2025-12-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-in-elderly-patients-with-crohns-disease-or-ulcerative-colitis2025-10-06https://www.jnjmedicalconnect.com/products/tremfya/medical-content/use-of-tremfya-during-pregnancy2026-02-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/real-world-less-frequent-dosing-of-teclistamab-in-patients-with-relapsedrefractory-multiple-myeloma.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-mechanism-of-action.pdf2025-04-23https://www.jnjmedicalconnect.com/products/stelara/medical-content/ustekinumabtremfya-guselkumab2025-11-03https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/clinical-effectiveness-of-esketamine-for-treatmentresistant-depression-a-realworld-study-of-patients.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/rhapp-20242025-08-28https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/eadv-20252025-09-17https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-permitted-and-prohibited-medications-in-the-monumental-1-study2025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/origami3-a-randomized-phase-3-study-of-amivantamab-plus-folfiri-vs-cetuximab-or-bevacizumab-plus-fol.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/aanem/factors-influencing-exacerbations-and-crises-in-gmg-findings-from-a-claims-database-study.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/effects-of-body-weight-on-xarelto2025-07-15https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/discontinuation-of-invega-hafyera-therapy2026-02-27https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-pediatric-patients-with-ulcerative-colitis-or-crohns-disease2025-09-26https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-alternative-injection-site2025-09-22https://www.jnjmedicalconnect.com/media/attestation/products/amivantamab-sc/paloma-3-summary-infographic.pdf2025-09-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/higher-teclistamab-step-up-dosing-in-patients-with-relapsed-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ascpt-20252025-08-28https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-transition-from-or-to-apixaban2024-08-22https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-nausea-and-vomiting2025-06-10https://www.jnjmedicalconnect.com/products/tremfya/medical-content/use-of-tremfya-in-patients-with-comorbid-lupus2026-03-16https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/acnp/first-onset-and-duration-of-treatmentemergent-adverse-events-in-patients-with-major-depressive-disor.pdf2026-01-14https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/health-beliefs-and-practices/respect-model-of-engaging-with-patients2026-02-27https://www.jnjmedicalconnect.com/media/attestation/products/edurant/edurant-safety-data-sheet-pediatric-25-mg-tab.pdf2025-06-06https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-stroke-risk-reduction-in-atrial-fibrillation2025-11-20https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-stability-of-prepared-infusions2025-05-29https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-adverse-event-weight-change.pdf2025-04-28https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ecco-2026/use-of-intestinal-ultrasound-and-other-imaging-tests-in-uc-and-cd2026-02-27https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-comparison-of-the-compass-and-voyager-pad-trials2025-04-16https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/safety-results-from-realital-video2025-12-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-how-should-i-take-caplyta2026-01-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/daratumumab-dara-bortezomibthalidomidedexamethasone-dvtd-followed-by-dara-maintenance-in-transplant.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/realworld-safety-profile-of-esketamine-nasal-spray-during-the-first-12-treatment-sessions-an-analysi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/amivantamab-plus-lazertinib-vs-osimertinib-patient-relevant-outcomes-from-mariposa.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/visible-guselkumab-impact-on-psoriatic-arthritis-at-week-16-in-participants-with-moderate-to-severe.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/tolerability2025-06-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/amivantamab-an-egfrmet-bispecific-antibody-with-cetrelimab-an-antipd1-antibody-in-advanced-nsclc-pha.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/lazcluze-drug-interactions2025-08-21https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-what-should-i-avoid-while-taking-caplyta2026-01-14https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-treatment-of-fistulizing-crohns-disease-overview-of-pivotal-clinical-trials2025-01-11https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-use-of-erleada-in-patients-taking-oral-anticoagulants2026-03-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/suo/baseline-urinary-tumor-dna-minimal-residual-disease-and-genomic-disease-burden-in-relation-to-clinic.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-use-in-pregnancy-and-lactation.pdf2024-08-09https://www.jnjmedicalconnect.com/products/xarelto/medical-content/can-i-use-xarelto-if-i-have-kidney-disease2025-07-31https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/subcutaneous-daratumumab-dara-bortezomiblenalidomidedexamethasone-vrd-with-dara-lenalidomide-dr-ma.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-use-of-erleada-for-the-treatment-of-breast-cancer2026-02-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/quality-adjusted-survival-analysis-of-neurologic-events-with-ciltacabtagene-autoleucel-vs-standard-o.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-tablet-image.pdf2025-05-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/efficacy-of-niraparib-and-abiraterone-acetate-plus-prednisone-in-metastatic-castrationresistant-pros.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-difference-between-formulations2025-09-10https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/suna-20252025-09-30https://www.jnjmedicalconnect.com/products/symtuza/isi-english2025-05-21https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-human-positron-emission-tomography-studies2026-03-13https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-patients-with-renal-impairment2026-02-13https://www.jnjmedicalconnect.com/products/imaavy/medical-content/nipocalimab-mechanism-of-action2026-03-09https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-dosing-over-54-mg-per-day-in-children.pdf2026-03-06https://www.jnjmedicalconnect.com/resources/congress-materials/policy-research-congresses/amcp-nexus-20252025-10-06https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/masterclass-in-dermatology-20252025-08-28https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-mmy2004-griffin-study2025-07-24https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-ulcerative-colitis-with-subcutaneous-induction-astro-study2026-02-26https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-real-world-data-of-rivaroxaban-vs-apixaban-in-treatment-of-vte2024-11-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad/the-visible-study-burden-of-comorbidities-in-participants-with-moderatetosevere-psoriasis-across-all.pdf2026-02-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-overview-of-the-apex-clinical-trial2025-12-17https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/can-i-receive-invega-hafyera-treatment-if-i-am-breastfeeding-pregnant-or-planning-to-become-pregnant2025-07-07https://www.jnjmedicalconnect.com/products/talvey/medical-content/specialty-distributors-and-specialty-pharmacy2025-11-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-east/safety-of-guselkumab-in-inflammatory-bowel-disease-up-to-1-year-integrated-safety-analysis-of-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/nutrition-and-diet/provider-checklist2026-02-27https://www.jnjmedicalconnect.com/products/concerta2026-01-21https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-washout-period-in-cartitude-1-and-cartitude-42026-01-21https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/what-is-the-recommended-dosing-for-darzalex-faspro-in-combination-with-pomalidomide-and-dexamethason2025-05-14https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/guselkumab-shows-strong-longterm-effectiveness-and-high-drug-survival-in-patients-with-moderatetosev.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-use-in-schizophrenia.pdf2025-10-22https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-patients-with-multiple-myeloma-and-requires-dialysis012026-01-29https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-neutropenia.pdf2024-10-15https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/adverse-event-neuroleptic-malignant-syndrome-and-invega-sustenna-invega-trinza-and-invega-hafyera2026-04-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aua/apalutamide-for-highrisk-localized-prostate-cancer-following-radical-prostatectomy-aparp-a-multicent.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/rhapp/early-fatigue-improvement-with-guselkumab-associates-with-longer-term-disease-control-in-patients-wi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-adverse-event-incidence-of-infections-in-patients-with-relapsedrefractor2025-11-10https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-alternative-dosing-intervals2025-10-01https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-hawaii/visible-cohort-b-guselkumab-demonstrates-comparable-1year-efficacy-in-moderatetosevere-scalp-psorias.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokana/medical-content/use-of-invokana-in-patients-with-renal-impairment2025-08-19https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-monoclonal-gammopathy-of-renal-significance2025-04-17https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/opsynvi-treatment-nave-and-prior-treated-patients2026-02-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/teclistamy-emn40-a-phase-2-trial-of-teclistamab-in-patients-with-previously-treated-light-chain-al-a.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/what-should-i-mention-to-my-healthcare-provider-before-starting-uptravi2025-07-31https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/urinebased-molecular-testing-identifies-fgfr-alterationpositive-patients-for-treatment-with-tar210.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-congress/efficacy-of-lumateperone-42-mg-in-the-treatment-of-major-depressive-disorder-a-pooled-analysis-of-ph.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-event-of-spravato-sexual-dysfunction2025-08-22https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-treatment-of-chronic-thromboembolic-pulmonary-hypertension-cteph2025-10-02https://www.jnjmedicalconnect.com/locate-my-medical-science-liaison2026-02-03https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-hepatotoxicity.pdf2025-12-30https://www.jnjmedicalconnect.com/products/rybrevant-faspro/guidelines2025-12-18https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/how-long-does-it-take-invega-trinza-to-leave-my-body2025-06-23https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-mechanism-of-action2025-07-31https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/pharmacodynamic-effects-of-nipocalimab-on-disease-biomarkers-in-patients-with-moderatetosevere-activ.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-trinza-nano-particle-technology2025-12-18https://www.jnjmedicalconnect.com/products/darzalex/medical-content/what-is-the-recommended-dosing-for-darzalex-alone-to-treat-multiple-myeloma2026-03-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/emmpower-a-longitudinal-multi-center-chart-review-consortium-for-multiple-myeloma.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-congress/cardiometabolic-effects-of-pharmacologic-treatments-for-major-depressive-disorder-a-systematic-revie.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/adverse-event-of-xarelto-hepatotoxicity2025-06-02https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-effect-on-lipids-in-patients-with-generalized-myasthenia-gravis2026-04-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/impact-of-baseline-hot-flashes-on-sleep-metrics-during-initial-treatment-in-libe-sm.pdf2026-02-26https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-congestive-heart-failure-in-adult-patients-with-plaque-psoriasis-or-psoriatic2025-08-05https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/pha/expert-consensus-to-explore-the-use-of-telehealth-and-associated-strategies-to-improve-access-to-car.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/singleagent-ibrutinib-versus-allogeneic-hematopoietic-cell-transplantation-for-patients-with-relapse.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/posthoc-analysis-of-clinically-relevant-antivaccine-antibodies-in-participants-treated-with-nipocal.pdf2026-01-07https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-fibroblast-growth-factor-receptor-fgfr-alterations-and-companion-diagnostic-cdx-overview2025-12-18https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/opsynvi-treatment-discontinuation-due-to-adverse-events-in-phase-3-a-due-study2026-01-30https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/achieving-clear-or-almostclear-skin-clearance-in-moderatetosevere-psoriasis-is-associated-with-clini.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/phase-2-redirectt1-study-of-talquetamab-teclistamab-in-relapsed-or-refractory-multiple-myeloma-with.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/association-of-psma-pet-results-at-biochemical-recurrence-with-metastasis-free-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/suo-20252025-12-03https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/spda-fall-20252025-11-05https://www.jnjmedicalconnect.com/media/attestation/general/imwg-recommendations-for-bispecific-antibodies-summary-infographic.pdf2026-01-05https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/apa/longterm-adjunctive-lumateperone-treatment-in-major-depressive-disorder-results-from-a-sixmonth-open.pdf2026-01-07https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-as-firstline-therapy-in-cisplatinineligible-patients-with-locally-advanced-or-metast2025-06-02https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-rybrevant-paloma-study2026-03-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/efficacy-of-subcutaneous-guselkumab-induction-therapy-by-baseline-demographics-and-concomitant-medic.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-adult-patients-with-psoriatic-arthritis-real-world-evidence2026-01-29https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/perseus-study-progression-free-survival-in-the2025-08-14https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-patients-with-hepatic-impairment2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-once-everyfourweeks-q4w-dosing-in-chronic-kidney-disease.pdf2024-07-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/survival-benefit-of-ciltacabtagene-autoleucel-in-secondline-compared-with-laterline-treatment-of-len.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/spectrem-guselkumab-demonstrates-significant-clearance-at-week-16-across-special-sites-in-participan.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/ipcu/comparison-of-early-and-deep-prostate-specific-antigen-response-in-real-world-presentation.pdf2026-02-06https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-immunoglobulin-light-chain-al-amyloidosis2026-03-12https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/what-are-the-possible-side-effects-of-lazcluze2025-11-14https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-major-adverse-cardiovascular-events-in-adult-patients-with-crohns-disease-or2026-03-16https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/dosing-of-invega-trinza-alternate-dosing-interval2026-01-13https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-needle-specifications-in-clinical-trials2025-07-11https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-genital-psoriasis2025-05-14https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/jadpro/effect-of-amivantamab-dose-interruptions-on-efficacy-and-safety-of-firstline-amivantamab-plus-lazert.pdf2026-01-20https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/more-frequent-dosing-of-simponi-aria-in-adult-patients-with-ankylosing-spondylitis2025-09-12https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-use-of-simponi-in-women-during-pregnancy.pdf2024-11-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aonn/postprogression-and-safety-outcomes-with-firstline-amivantamab-plus-lazertinib-versus-osimertinib-in.pdf2026-01-20https://www.jnjmedicalconnect.com/products/prezcobix2026-01-21https://www.jnjmedicalconnect.com/products/uptravi/pivotal-clinical-trial-publications2025-12-29https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-rash-012025-10-08https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/mda-20262026-03-06https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/comparison-of-invega-sustenna-to-aripiprazole-long-acting-injection2026-04-02https://www.jnjmedicalconnect.com/media/attestation/products/edurant/edurant-use-of-edurant-in-coronavirus.pdf2025-01-13https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/psych-congress/safety-and-tolerability-of-lumateperone-42-mg-for-the-adjunctive-treatment-of-major-depressive-disor.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-effect-on-fatigue-in-patients-with-generalized-myasthenia-gravis2025-07-23https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-management-of-infusion-related-reactions-in-patients-with-generalized-myasthenia-gravis2025-12-04https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-infusion-rate-for-induction-therapy-in-ulcerative-colitis-and-crohns-disease2026-03-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-missed-maintenance-dose-in-adult-patients-with-plaque-psoriasis2026-03-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/title-onlabel-persistence-through-24-months-among-patients-with-psoriatic-arthritis-initiating-gusel.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-general-overview2026-03-16https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-hematologic-toxicities-with-combination-treatment2025-06-10https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/composite-response-to-nipocalimab-a-novel-neonatal-fragment-crystallizable-receptor-blocker-based-on.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/can-i-receive-vaccines-before-or-while-taking-stelara2025-07-15https://www.jnjmedicalconnect.com/products/akeega/medical-content/video-akeega-magnitude-study-overview2026-03-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/long-term-benefits-in-patient-reported-outcomes-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-use-in-pediatric-patients-post-fontan-procedure2025-09-05https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-use-of-erleada-in-patients-taking-direct-oral-anticoagulants2026-03-27https://www.jnjmedicalconnect.com/products/xarelto/medical-content/drug-interaction-of-xarelto-with-ritonavir2026-01-30https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/winter-clinical-hawaii/sustained-improvements-in-psoriasis-area-and-severity-index-and-in-percent-body-surface-area-of-psor.pdf2026-02-17https://www.jnjmedicalconnect.com/products/balversa/pivotal-clinical-trial-publications2025-12-22https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/trimm2-mmy1002-study-tecvayli-and-darzalex-faspro-pomalidomide-cohort2025-11-27https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/longterm-efficacy-of-esketamine-nasal-spray-among-early-and-delayed-responders-a-subgroup-analysis-o.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/realworld-safety-profile-of-esketamine-nasal-spray-an-analysis-of-the-risk-evaluation-and-mitigation.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/fatigue-assessed-by-neuro-qol-in-phase-3-vivacity-mg3-trial-of-nipocalimab-vs-placebo-in-generalized.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/perspectives-of-singlecenter-community-hematologistsoncologists-on-minimal-residual-disease-testing.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/hospital-resource-utilization-associated-with-nipocalimab-versus-placebo-post-hoc-analysis-of-the-vi.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-patients-with-comorbid-hiv-infection2025-10-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/safety-results-from-realital-a-multi-country-observational-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aan/real-world-interaction-between-pregnancy-and-generalized-myasthenia-gravis.pdf2026-01-20https://www.jnjmedicalconnect.com/products/stelara/medical-content/does-stelara-contain-preservatives2025-09-11https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-hypothyroidism2025-07-24https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-specialty-pharmacy-and-specialty-distributors2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/effectiveness-and-tolerability-of-guselkumab-or-tnf-inhibitors-as-second-line-treatment-after-receiv.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/capp-20252025-11-14https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/risperdal-consta-kit-components2025-07-31https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-dosing-dosage-and-administration2026-01-13https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-effect-on-white-blood-cell-count2026-03-17https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/can-i-take-simponi-aria-if-i-am-breastfeeding-planning-to-breastfeed-pregnant-or-planning-to-become2025-09-19https://www.jnjmedicalconnect.com/products/tremfya/medical-content/effect-of-tremfya-on-fertility2025-06-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/wclc/overall-survival-after-treatment-with-firstline-osimertinib-for-egfrmutant-advanced-nsclc-in-the-us.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/edurant/edurant-repackaging.pdf2024-05-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/health-related-quality-of-life-in-transplant-eligible-patients-with-newly-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/observed-and-simulated-pharmacokinetics-and-pharmacodynamics-of-nipocalimab-a-fully-human-fcrn-block.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-in-pediatric-patients-with-plaque-psoriasis2026-03-18https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-studies-in-black-patients2025-06-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/longterm-safety-and-efficacy-of-esketamine-nasal-spray-by-dosing-frequency-in-adults-with-treatmentr.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/dosing-conversion-to-risperdal-consta-from-another-antipsychotic2025-08-05https://www.jnjmedicalconnect.com/live-video2025-01-03https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/inlexzo-use-in-bcg-unresponsive-high-risk-nmibc-with-cis-papillary-tumors.pdf2026-03-16https://www.jnjmedicalconnect.com/products/imaavy/medical-content/does-imaavy-contain-preservatives2025-05-01https://www.jnjmedicalconnect.com/products/invokana/medical-content/pharmacokinetics-of-invokana2024-12-03https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-hepatotoxicity.pdf2024-10-24https://www.jnjmedicalconnect.com/products/darzalex/medical-content/what-should-i-tell-my-provider-before-receiving-darzalex2025-09-22https://www.jnjmedicalconnect.com/products/tremfya/medical-content/preparation-and-administration-of-tremfya-for-adult-patients2025-09-13https://www.jnjmedicalconnect.com/products/erleada/medical-content/use-of-erleada-in-patients-with-renal-impairment2025-09-08https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/subcutaneous-amivantamab-plus-chemotherapy-in-egfr-mutant-advanced-nonsmall-cell-lung-cancer-after-d.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-concomitant-use-of-erleada-with-chemotherapy2025-12-11https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/ats/efficacy-and-safety-of-tadalafil-and-sildenafil-in-pulmonary-arterial-hypertension-results-of-a-syst.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/the-impact-of-disease-status-after-biologic-induction-therapy-on-longterm-outcomes-in-persons-with-c.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-hawaii/real-world-on-label-treatment-persistence-through-24-months-in-subcutaneous-tumor-necrosis-factor.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/masterclass-in-dermatology/visible-guselkumab-impact-on-psoriatic-arthritis-through-week-48-in-participants-with-moderatetoseve.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ecco/efficacy-and-safety-of-subcutaneous-guselkumab-induction-therapy-in-patients-with-moderately-to-seve.pdf2026-01-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-cartitude5-mmy3004-study2025-10-28https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/maui-derm-hawaii-20252025-08-28https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-infusion-bag-and-set-materials-and-manufacturers2025-07-28https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-androgen-deprivation-therapy-adt-utilization2025-09-08https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/what-should-i-tell-my-healthcare-provider-before-receiving-invega-trinza2025-05-14https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-safety-data-sheet-sds-500-mg-tablets.pdf2025-05-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/daratumumab-monotherapy-versus-active-monitoring-in-patients-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/spartan-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/trial-in-progress-a-retrospective-multicountry-study-of-clinical-outcomes-in-patients-with-rr-multip.pdf2026-01-20https://www.jnjmedicalconnect.com/products/janssen-covid-19-vaccine2026-01-16https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-guardant360-companion-diagnostic-cdx-overview2025-05-13https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/aibd-20252025-12-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/enhanced-vs-standard-dermatologic-management-with-amivantamablazertinib-in-egfrm-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/real-world-data2024-11-13https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/treatment-patterns-and-persistence-among-patients-with-treatmentresistant-depression-initiated-on-es.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-use-in-patients-with-renal-impairment-with-generalized-myasthenia-gravis2025-11-10https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-storage-and-stability-of-prefilled-syringe-and-onepress-patientcontrolled-injectorprefilled2025-08-27https://www.jnjmedicalconnect.com/products/remicade2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/regional-variability-in-sle-damage-accumulation-by-disease-activity-across-the-lupus-federated-data.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-cou-aa-301-study.pdf2025-06-30https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-amivantamab-and-hyaluronidaselpujrybrevant-amivantamabvmjwrybrevant-faspro-rybrevan2026-02-05https://www.jnjmedicalconnect.com/products/erleada/medical-content/can-i-crush-split-or-mix-erleada-60-mg-tablets-with-orange-juice-applesauce-or-noncarbonated-water2025-07-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/paloma-3-study2025-12-18https://www.jnjmedicalconnect.com/products/sirturo2026-01-21https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-effect-on-fertility-in-patients-with-generalized-myasthenia-gravis2026-01-29https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/dermatologyeducationfoundationnppa/icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-the-interleukin23receptor-for-the-treatm.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/adverse-event-of-invega-hafyera-prolactin-effects2025-08-26https://www.jnjmedicalconnect.com/therapeutic-areas/immunology2026-03-19https://www.jnjmedicalconnect.com/products/balversa/medical-content/can-balversa-cause-eye-problems2025-07-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/am/efficacy-and-safety-of-firstline-ibrutinib-plus-venetoclax-in-patients-with-mantle-cell-lymphoma-mcl.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/how-should-i-store-akeega2026-03-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/frequency-and-patientreported-impact-of-psoriatic-arthritis-and-other-comorbidities-in-patients-with.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-dosing-chewing-splitting-or-crushing-tablets.pdf2025-10-07https://www.jnjmedicalconnect.com/contact-us2025-08-20https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/pharmacokinetics-of-invega-hafyera2025-11-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-rheumatoid-arthritis-in-adult-patients2026-02-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/eau/subsequent-treatment-patterns-and-outcomes-among-patients-with-muscle-invasive-b.pdf2026-03-16https://www.jnjmedicalconnect.com/products/darzalex-faspro/isi-english2025-02-26https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec2-mmy1004-study-cohort-e2025-11-05https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-food-effect-and-meal-timing2024-09-24https://www.jnjmedicalconnect.com/media/attestation/products/opsynvi/opsynvi-macitentan-10-mgtadalafil-40-mg-safety-data-sheet-sds.pdf2026-03-16https://www.jnjmedicalconnect.com/media/attestation/products/sirturo/sirturo-100mg-safety-data-sheet-sds.pdf2025-05-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/eau/final-analysis-of-the-phase-1-firstinhuman-study-of-erda-idrs-an-erdafitinib-i.pdf2026-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/insights-into-methamphetamineassociated-pulmonary-arterial-hypertension-an-analysis-of-medical-and-p.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/phpn/oral-selexipag-in-methamphetamineassociated-pulmonary-arterial-hypertension-realworld-analysis-from.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/spda-fall/the-power-of-imagery-in-clinical-medicine-leveraging-clinical-photos-from-the-visible-study-to-foste.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/ccr-west/associations-between-clinical-characteristics-and-screening-mri-findings-exploratory-analysis-of-the.pdf2026-02-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-uveitis2026-02-03https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-pharmacokinetics-food-effect.pdf2025-08-18https://www.jnjmedicalconnect.com/products/stelara/medical-content/occurrence-of-abnormal-liver-function-tests-in-adult-patients-treated-with-stelara2025-09-22https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/earlier-use-of-ciltacabtagene-autoleucel-cilta-cel-is-associated-with-better-immune-fitness-and-stro.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-occurrence-of-malignancies-in-patients-with-plaque-psoriasis2026-03-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/rwcs/durable-inhibition-of-structural-damage-progression-and-improvements-in-joint-disease-activity-with.pdf2026-02-11https://www.jnjmedicalconnect.com/products/talvey/medical-content/tecvayli-and-talvey-rems-dispense-authorization-rda2025-07-28https://www.jnjmedicalconnect.com/products/invokana/medical-content/use-of-invokana-in-patients-with-active-or-prior-history-of-pancreatitis-acute-or-chronic2025-01-13https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-renal-insufficiency-dvt-prophylaxis-following-hip-or-knee-replacement-surgery2024-12-06https://www.jnjmedicalconnect.com/media/attestation/products/tecvayli/tecvayli-safety-data-sheet-sds.pdf2026-02-02https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-occurrence-and-management-of-oral-toxicities-and-weight-loss2026-03-03https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-treatment-of-pyoderma-gangrenosum2026-02-24https://www.jnjmedicalconnect.com/products/erleada/pivotal-clinical-trial-publications2025-12-22https://www.jnjmedicalconnect.com/products/tremfya/medical-content/air-bubble-in-prefilled-syringe-and-prefilled-syringe-based-injectors2025-10-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/ciltacabtagene-autoleucel-ciltacel-vs-standard-of-care-soc-in-patients-with-lenalidomide-lenrefracto.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/sporanox-capsules/sporanox-bioavailability-effect-of-food.pdf2026-02-12https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-cystectomy-rates-after-inlexzo-treatment2026-02-27https://www.jnjmedicalconnect.com/products/stelara2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/insights-into-nipocalimabfcrn-structure-binding-affinity-and-igg-lowering-and-comparison-with-efga.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-overview-of-the-phase-2-vivacity-mg-clinical-trial2025-07-30https://www.jnjmedicalconnect.com/media/attestation/products/erleada/erleada-safety-data-sheet-sds-60-mg-tablets.pdf2026-02-26https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-prior-and-subsequent-antimyeloma-therapy-in-the-majestec-3-study2026-03-03https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-chief-hf2024-09-11https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-drug-interaction-with-ethinyl-estradiol.pdf2025-08-18https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/inlexzo-gemcitabine-intravesical-system-instructions-for-use-ifu-slide-deck.pdf2025-09-22https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ishlt/early-initiation-of-selexipag-for-pulmonary-arterial-hypertension-pah-realworld-evidence-from-the-ex.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/how-should-i-take-lazcluze2025-12-18https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-safety-information-gastrointestinal-adverse-effects.pdf2025-03-11https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-trinza-injection-site-reactionpain2026-02-25https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-oral-suspension-stability-shipping-and-storage-temperature-excursions.pdf2025-07-02https://www.jnjmedicalconnect.com/products/akeega/medical-content/dosage-administration2025-10-06https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-use-in-comorbid-substance-abuse-disorder2026-03-13https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-androgen-receptor-anomalies2025-08-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/access-to-healthcare2026-02-27https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-density-and-specific-gravity2026-03-04https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-guselkumab-impact-on-nail-psoriasis-and-psoriatic-arthritis-through-week-48-in-participant.pdf2026-01-07https://www.jnjmedicalconnect.com/products/yondelis2026-01-21https://www.jnjmedicalconnect.com/products/erleada2026-01-21https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-overview-of-the-affinity-clinical-trial2026-01-08https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-reproductive-potential-and-lactation2026-02-16https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-safety-information-hyperglycemia-and-diabetes-mellitus.pdf2025-05-19https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-tablets-100-mg-safety-data-sheet-sds.pdf2025-05-01https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-quest-study2025-08-12https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-disposal-of-inlexzo2026-02-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/occurrence-of-weight-gain-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis2025-07-08https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-use-in-patients-with-extramedullary-disease2025-09-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/isds/treatment-of-plaque-psoriasis-involving-high-impact-sites-with-icotrokinra-subgroup-analyses-of-the.pdf2026-02-17https://www.jnjmedicalconnect.com/products/spravato/medical-content/video-rems-5-year-safety-manuscript2025-10-15https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-adverse-events-general2026-01-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/efficacy-and-safety-of-subcutaneous-guselkumab-induction-therapy-in-patients-with-ulcerative-colitis.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/pdes/visible-post-inflammatory-pigmentation-journeys-exploring-the-impact-of-pigmentation.pdf2026-02-17https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-use-in-patients-with-cardiovascular-and-vascular-disease2026-03-01https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-pediatrics2026-04-02https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-use-of-stelara-in-the-treatment-of-adult-patients-with-microscopic-colitis2025-07-23https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/adverse-event-movement-disorders2025-09-11https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-in-adult-patients-with-comorbid-heart-failure2025-12-04https://www.jnjmedicalconnect.com/products/spravato/pivotal-clinical-trial-publications2025-12-26https://www.jnjmedicalconnect.com/products/opsynvi/isi-english2025-03-05https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-of-spravato-with-somatic-treatments2025-10-08https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/use-of-rybrevant-faspro-in-geriatric-patients2026-02-13https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-and-darzalex-faspro-in-extramedullary-disease2025-06-26https://www.jnjmedicalconnect.com/products/stelara/medical-content/switching-patients-with-plaque-psoriasis-from-stelara-ustekinumab-to-tremfya2025-09-08https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-qt-prolongation-and-torsades-de-pointes.pdf2024-05-24https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-impact-of-primary-immunoglobulin-prophylaxis-on-infections2025-10-15https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/eha-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/the-renal-activity-index-for-lupus-identifies-and-predicts-complete-renal-remission-or-absence-of-ki.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex2026-01-21https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/sunrise1-publication-deck-daneshmand-et-al-jco-2025.pdf2026-01-06https://www.jnjmedicalconnect.com/media/attestation/products/edurant/edurant-media-statement-march-2024-us-fda-approves-edurant-ped.pdf2026-02-19https://www.jnjmedicalconnect.com/products/tremfya/medical-content/real-world-evidence-with-tremfya-in-adult-patients-with-plaque-psoriasis-prospective-studies2026-03-31https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/rybrevant-lazcluze-projected-overall-survival-benefit-in-the-mariposastudy2025-09-22https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/administration-of-darzalex-faspro-use-of-a-filter2025-07-21https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-dosage-and-administration-missed-dose2025-07-31https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/aacr-20242025-08-28https://www.jnjmedicalconnect.com/products/caplyta2026-04-01https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/predictors-of-endoscopic-remission-at-1-year-in-patients-with-ulcerative-colitis.pdf2026-02-23https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/smfm-2026/hemolytic-disease-of-the-fetus-and-newborn-video2026-01-23https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/apapp-20252025-08-28https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-adverse-event-burning-sensation2026-03-17https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/alternative-initiation-regimen-of-invega-sustenna2025-11-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/hopa/subcutaneous-after-intravenous-amivantamab-in-advanced-nsclc-initial-results-from-paloma-2.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/population-based-assessment-of-treatment-patterns-for-high-risk-localized-prostate-cancer.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-administration-of-240-mg-tablet-via-a-feeding-tube2025-07-09https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-dosing-dosage-and-administration.pdf2024-05-15https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/clinical-effectiveness-and-persistence-on-esketamine-nasal-spray-in-patients-with-treatmentresistant.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/persistence-of-guselkumab-in-psoriatic-disease-over-3-years-in-real-life-conditions-a-nationwide-cla.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-overview-of-the-vivacity-mg3-open-label-subcutaneous-substudy2025-11-25https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-hematologic-events2025-05-24https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/oral-antipsychotics2025-06-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-overview-of-spectrem-clinical-trial2026-01-29https://www.jnjmedicalconnect.com/products/tremfya/medical-content/voyage-1-clinical-trial2025-11-18https://www.jnjmedicalconnect.com/products/xarelto/medical-content/site-of-absorption-of-xarelto-within-gastrointestinal-tract2025-04-11https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/opsynvi-dosage-and-administration2026-02-19https://www.jnjmedicalconnect.com/products/xarelto/medical-content/can-i-breastfeed-while-taking-xarelto2025-07-15https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/cinp/long-term-adjunctive-lumateperone-treatment-in-major-depressive-disorder-results-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-panther-study2025-06-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eular/biological-sexrelated-differences-in-radiographic-progression-and-relationship-with-early-clinical-r.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-combination-with-radiation2026-01-19https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-apa-rp-study-rash-management-guide2025-08-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/subcutaneous-daratumumab-bortezomib-cyclophosphamide-and-dexamethasone-in-asian-patients-with-newly.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/apapp/methamphetamineassociated-pulmonary-arterial-hypertension-uncovering-an-urgent-unmet-medical-need-in.pdf2026-01-20https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-mechanism-of-action2025-10-29https://www.jnjmedicalconnect.com/products/erleada/medical-content/sequencing-of-erleada-with-zytiga2026-01-23https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/how-long-does-it-take-invega-hafyera-to-leave-my-body2025-06-13https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-safety-data-sheet-sds-for-600-mg-tablets.pdf2026-01-05https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-patients-with-prior-hit2024-10-23https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-hepatitis-b-virus-reactivation2026-03-17https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/akeega-comparison-of-akeega-with-zytiga.pdf2026-01-09https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-emerald-study.pdf2025-09-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/outcomes-of-guselkumab-in-biologic-naive-psoriasis-patients-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-locommotion-mmy4001-study2025-07-23https://www.jnjmedicalconnect.com/products/xarelto/medical-content/drug-interaction-of-xarelto-with-ritonavir-boosted-nirmatrelvir2025-05-16https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-during-pregnancy-and-lactation2024-10-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/efficacy-and-safety-of-erdafitinib-in-pediatric-patients-with-advanced-solid-tumors-and-fgfr-alterat.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/rhapp/visible-clearance-and-symptom-improvement-with-guselkumab-at-week-16-in-skin-of-color-participants-w.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/ean/efficacy-of-nipocalimab-in-adult-patients-with-moderatetosevere-ocular-manifestations-of-gmg-in-phas.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/ipcu/a-real-world-comparison-of-deep-prostate-specific-antigen-response-in-patients-presentation.pdf2026-02-03https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-alternative-dosing-intervals2025-09-30https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/language-and-communication/working-effectively-with-an-interpreter2026-02-27https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/teclistamab-in-a-large-cohort-of-video2025-12-08https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-of-spravato-with-cognitive-behavioral-therapy-or-psychotherapy2025-09-15https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/inlexzo-safety-data-sheet-sds.pdf2025-09-09https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-use-for-pre-exposure-prophylaxis.pdf2025-09-10https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/eau-2026/final-analysis-of-the-phase-1-first-in-human-study2026-03-12https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/winter-clinical-hawaii-20262026-01-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/subcutaneous-daratumumab-dara-bortezomib-cyclophosphamide-and-dexamethasone-vcd-in-patients-with-ne.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/rhapp/the-efficacy-and-safety-of-guselkumab-as-maintenance-therapy-in-patients-with-moderately-to-severely.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-in-adult-patients-with-comorbid-liver-cirrhosis2025-08-19https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/comparison-of-risperdal-consta-to-oral-risperidone2025-05-23https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-sustenna-invega-trinza-and-invega-hafyera-considerations-for-use-of-lais-during-covid19-pand2025-06-05https://www.jnjmedicalconnect.com/products/icotyde/medical-content/what-are-the-possible-side-effects-of-icotyde2026-03-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/ciltacabtagene-autoleucel-vs-standard-of-care-in-patients-with-functional-highrisk-multiple-myeloma.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/assessment-of-ibdspecific-quality-of-life-impactiii-symptoms-after-treatment-with-ustekinumab-in-pae.pdf2026-02-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/efficacy-of-guselkumab-in-moderately-to-severely-active-ulcerative-colitis-by-extent-of-disease-and.pdf2026-01-07https://www.jnjmedicalconnect.com/products/opsynvi/medical-content/opsynvi-single-tablet-combination-therapy-vs-loose-dose-combination2026-01-30https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-all-adult-indications-evidence-and-value-summary.pdf2025-10-08https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-magnitude-study2025-07-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/frontline-treatment-patterns-in-patients-with-newly-diagnosed-multiple-slides.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/maintenance-of-endoscopic-and-histologic-improvements-with-guselkumab-for-ulcerative-colitis-at-week.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/adverse-event-of-xarelto-epistaxis2024-09-30https://www.jnjmedicalconnect.com/media/attestation/products/sporanox-oral-solution/sporanox-oral-solution-safety-data-sheet.pdf2026-01-05https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-patients-with-covid-192024-11-06https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/fostering-inclusive-language-for-genitourinary-cancer-research-a-multi-stakehold.pdf2026-02-27https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-what-are-the-possible-side-effects-of-procrit.pdf2025-10-14https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/carvykti-patient-wallet-card-spanish.pdf2024-09-13https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-sustenna-in-recently-diagnosed-patients-with-schizoaffective-disorder2025-05-13https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/discontinuation-of-invega-trinza2025-12-18https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/use-of-rybrevant-faspro-in-pediatric-patients2025-12-17https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/use-of-rybrevant-in-combination-with-immune-checkpoint-inhibitors-in-nsclc2026-03-27https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-effect-on-immunoglobulin-g-levels-in-patients-with-generalized-myasthenia-gravis2026-04-03https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-scalp-psoriasis2026-02-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/survival-outcomes-of-multiple-myeloma-patients-previously-exposed-presentation.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/safety-information-for-rybrevant-ocular-toxicity2025-06-04https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-prior-electroconvulsive-therapy-ect2026-01-22https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-seraphin-and-open-label-extension2026-01-24https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-how-is-xarelto-supplied2025-08-22https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-use-in-combination-with-antiemetics.pdf2025-08-07https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/paloma-2-study2025-12-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/effectiveness-of-bridging-therapy-corresponds-to-improved-outcomes-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/talquetamab-cetrelimab-in-patients-with-relapsedrefractory-multiple-myeloma-initial-safety-and-effi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/aanem/efficacy-and-safety-of-nipocalimab-in-patients-with-generalized-myasthenia-gravis-topline-results-fr.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosing-of-invega-sustenna-discontinuation-of-therapy2025-12-15https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/ascp/adjunctive-lumateperone-in-patients-with-major-depressive-disorder-results-from-an-additional-random.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/pharmacokinetics-and-safety-of-seltorexant-a-selective-orexin2-receptor-antagonist-in-healthy-elderl.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-use-of-zytiga-in-patients-with-renal-impairment.pdf2025-12-30https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-adult-patients-with-plaque-psoriasis-or-psoriatic-arthritis-with-comorbid-hepatic-im2025-08-11https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/maintenance-of-response-after-guselkumab-withdrawal.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/spectrem-guselkumab-demonstrates-consistent-significant-clearance-across-the-full-range-of-low-body.pdf2026-01-07https://www.jnjmedicalconnect.com/products/edurant2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/patient-characteristics-treatment-patterns-and-early-outcomes-of-patients-with-relapsed-or-refractor.pdf2026-01-07https://www.jnjmedicalconnect.com/products/nipocalimab-investigational/medical-content/nipocalimab-clinical-studies-in-rheumatoid-arthritis2026-03-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/recent-trends-in-realworld-frontline-treatment-patterns-and-outcomes-for-patients-with-multiple-myel.pdf2026-01-07https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-administration-using-a-non-leukocyte-depleting-filter2025-07-18https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-scrollable-mechanism-of-action2025-01-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/guselkumab-maintenance-dose-regimens-in-patients-with-high-disease-activity-and-severity-subgroup-an.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-of-darzalex-darzalex-faspro-in-patients-with-hepatic-impairment-and-multiple-myeloma2025-06-19https://www.jnjmedicalconnect.com/products/uptravi/medical-content/can-i-breastfeed-while-taking-uptravi2025-07-29https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-ulcerative-colitis-and-crohns-disease-evidence-summary.pdf2025-10-08https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-dosage-and-administration2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-abuse-liability.pdf2025-11-03https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/efficacy-and-safety-of-subcutaneous-guselkumab-rescue-therapy-in-patients-with-moderately-to-severel.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/efficacy-of-guselkumab-intravenous-and-subcutaneous-induction-symptoms-healthrelated-quality-of-life.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/uptravi/uptravi-iv-safety-data-sheet-sds.pdf2025-06-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/ulcerative-colitisrelated-medical-encounters-in-patients-treated-with-guselkumab-an-analysis-of-the.pdf2026-01-07https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-storage-and-handling2026-03-18https://www.jnjmedicalconnect.com/products/darzalex/medical-content/interference-with-determination-of-complete-response2025-07-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/elcc/evaluating-the-effectiveness-of-amivantamab-plus-lazertinib-in-chrysalis-2-vs-egfr-tki-mono-pls.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/realworld-observations-on-the-evolving-treatment-landscape-and-improved-survival-outcomes-for-multip.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/isds-20252025-11-13https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/trimm2-mmy1002-study-tecvayli-and-darzalex-faspro-pomalidomide-cohort2025-11-27https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/cartitude4-a-randomized-phase-3-trial-of-ciltacabtagene-autoleucel-ciltacel-in-patients-with-rela.pdf2025-11-20https://www.jnjmedicalconnect.com/products/darzalex/medical-content/what-is-the-recommended-dosing-for-darzalex-in-combination-with-bortezomib-thalidomide-and-dexametha2025-07-22https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/team-phenomenal-hope-20252025-12-05https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/latex-content-of-invega-sustenna-invega-trinza-and-invega-hafyera2025-05-20https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/how-does-rybrevant-work2025-09-05https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/density-of-simponi-aria-final-vialed-product2025-12-16https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-preparation-and-administration-for-patients-with-generalized-myasthenia-gravis2026-04-01https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-and-talvey-majestec-7-study2026-03-02https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/more-frequent-dosing-of-simponi-aria-in-adult-patients-with-psoriatic-arthritis2025-08-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/neoadjuvant-gemcitabine-intravesical-system-gemidrs-plus-presentation.pdf2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/management-strategies-and-patient-outcomes-among-lpc-patients-with-persistently-positive-psa-after-r.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/health-literacy2026-02-27https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/comparative-efficacy-of-invega-sustenna-pride-study2026-01-21https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-hrr-mutations-and-companion-diagnostic-cdx-overview2025-12-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/radiographic-progression-without-psa-progression-in-advanced-prostate-cancer-patients.pdf2026-01-07https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-nail-disorders2025-10-31https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-adverse-event-mortality2026-03-10https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/efficacy-and-safety-of-icotrokinra-a-novel-targeted-oral-peptide-il-23r-inhibitor-in-adolescents.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/phase-2-study-of-talquetamab-tal-teclistamab-tec-in-patients-pts-with-relapsedrefractory-multiple-m.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/pivotal-clinical-trial-publications2025-02-21https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/ats-20242025-08-28https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/storage-and-stability-of-simponi-aria-final-vialed-product2025-09-25https://www.jnjmedicalconnect.com/media/attestation/products/akeega/akeega-evidence-value-summary.pdf2025-12-16https://www.jnjmedicalconnect.com/products/darzalex/medical-content/does-darzalex-contain-preservatives2026-02-03https://www.jnjmedicalconnect.com/products/opsynvi/pivotal-clinical-trial-publications2025-12-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/realworld-healthcare-resource-utilization-and-costs-among-tripleclassexposed-tce-relapsedrefractory.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-comparison-to-bacillus-calmettegurin-bcg-retreatment2025-09-11https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/nei-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/assessing-the-suitability-of-the-neuroqol-fatigue-to-evaluate-fatigue-in-patients-living-with-myasth.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/prophylactic-tocilizumab-to-mitigate-cytokine-release-syndrome-in-patients-receiving-talquetamab-for.pdf2026-01-07https://www.jnjmedicalconnect.com/products/botaretigene-sparoparvovec/medical-content/ongoing-clinical-trials2025-10-15https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-prophylaxis-of-venous-thromboembolism-in-acutely-ill-medical-patients2024-07-16https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-combination-with-ixazomib-in-multiple-myeloma2026-01-11https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-calcium-channel-blockers2025-07-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ccr-east/onlabel-persistence-through-24-months-in-patients-with-psoriatic-arthritis-using-guselkumab-or-subcu.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/efficacy-and-safety-of-nipocalimab-vs-efgartigimod-in-a-randomized-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/ciltacabtagene-autoleucel-out-of-specification-manufacturing-outcomes-improve-with-earlier-lines-of.pdf2026-01-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/estimation-of-overall-survival-in-immunotherapy-treated-bladder-cancer-using-computer-vision.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/uptravi/uptravi-selexipag-titration-schedule-one-pager.pdf2025-05-05https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/maui-derm-hawaii/sustained-improvements-in-psoriasis-area-and-severity-index-and-in-percent-body-surface-area-of-psor.pdf2026-02-17https://www.jnjmedicalconnect.com/products/spravato2026-01-21https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-crushing-splitting-or-dispersion-of-60-mg-tablets2025-05-30https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-imaagen-study.pdf2025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/systemic-lupus-erythematosus-and-statins-in-gladel-20-are-cardiovascular-risk-prevention-guideline.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/am-20242025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/safety-profile-of-nipocalimab-a-new-neonatal-fragment-crystallizable-receptor-blocker-in-the-phase-3.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/real-world-incidence-and-management-of-non-icans-neurologic-events-following-ciltacabtagene-autoleuc.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/smfm-2026/fnait-patient-journey-video2026-01-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/prostatespecific-antigen-response-in-black-patients-with-metastatic-castrationsensitive-prostate-can.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-effect-of-guselkumab-on-patient-reported-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/guselkumab-versus-risankizumab-as-maintenance-treatment-for-moderately-to-severely-active-ulcerative.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/association-of-molecular-markers-with-clinical-response-to-tar200-in-the-phase-2b-sunrise1-trial-in.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/patient-preferences-regarding-the-use-of-combination-erapde5i-for-the-treatment-of-pulmonary-arteria.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-patients-with-multiple-myeloma-and-requires-dialysis012026-01-29https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-patients-undergoing-spinal-or-epidural-anesthesia2025-08-18https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/maintenance-use-after-autologous-stem-cell-transplant2026-01-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/spectrem-guselkumab-significantly-improves-patient-reported-outcomes-at-week-16-in-participants-with.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-in-mild-plaque-psoriasis2026-03-19https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-onset-of-action2026-02-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/efficacy-of-carvykti-in-cartitude4-versus-other-conventional-treatment-regimens-for-lenalidomiderefr.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/investigating-unmet-needs-among-advanced-therapynaive-patients-with-crohns-disease-treated-with-uste.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/inlexzo-infographic-an-intravesical-drug-releasing-system.pdf2026-02-23https://www.jnjmedicalconnect.com/products/janssen-covid-19-vaccine/medical-content/discontinuation-and-eua-withdrawal012025-05-30https://www.jnjmedicalconnect.com/products/stelara/medical-content/can-stelara-make-you-tired2025-07-11https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-combination-with-carfilzomib-lenalidomide-and-dexamethasone-in-mul2026-02-09https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/use-of-invega-hafyera-in-elderly-patients2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/risperdal/risperdal-2-mg-tablet-safety-data-sheet-sds.pdf2025-05-19https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-darzalex-faspro-in-combination-with-cyclophosphamide-and-bortezomib-and-dexamethaso2025-08-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/prevalence-incidence-and-outcomes-of-multiple-myeloma-patients-using-electronic-health-records-and-n.pdf2026-01-07https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-use-in-patients-with-prior-intravesical-bacillus-calmette-gurin-use2025-09-11https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-use-for-post-exposure-prophylaxis.pdf2024-10-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/ascp/impact-of-duration-of-esketamine-nasal-spray-treatment-on-change-in-depression-symptoms-in-realworld.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/icotrokinra/durability-of-response-to-the-targeted-oral-peptide-icotrokinra-for-high-impact-site-psoriasis.pdf2026-02-18https://www.jnjmedicalconnect.com/products/stelara/medical-content/dose-escalation-during-stelara-maintenance-therapy-in-ulcerative-colitis2026-02-25https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/concomitant-use-of-invega-trinza-with-antipsychotics2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/realworld-clinical-effectiveness-of-esketamine-nasal-spray-based-on-the-montgomeryasberg-depression.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/zavesca/zavesca-reformulation.pdf2026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/real-world-evidence-on-patient-reported-outcomes-among-newly-diagnosed-multiple-myeloma-patients-tre.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-nursing-mothers2025-12-03https://www.jnjmedicalconnect.com/products/stelara/medical-content/infusion-rate-of-stelara-for-induction-therapy-in-crohns-disease-or-ulcerative-colitis2025-11-24https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-repackaging.pdf2026-03-30https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-monumental-1-subgroup-analysis2026-02-04https://www.jnjmedicalconnect.com/products/spravato/medical-content/rationale-for-use-of-spravato-in-conjunction-with-oral-antidepressant-during-phase-3-studies2025-12-16https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/adverse-event-of-invega-hafyera-cardiovascular-effects2025-08-26https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-comparison-of-akeega-with-erleada2025-05-24https://www.jnjmedicalconnect.com/medical-search2025-01-06https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/safety-and-efficacy-results-of-nipocalimab-in-adolescents-with-generalized-myasthenia-gravis-during.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/phpn/preplanned-study-design-adaptations-in-unisus-a-phase-3-randomized-superiority-study-comparing-the-e.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-comorbid-personality-disorders2025-09-05https://www.jnjmedicalconnect.com/products/talvey/isi-english2025-03-10https://www.jnjmedicalconnect.com/products/uptravi/medical-content/griphon-and-open-label-extension2026-01-30https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-urinary-tract-infection-uti2026-03-12https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-study-design-of-the-einstein-program2025-05-15https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/time-burden-and-healthcare-costs-associated-with-docetaxel-in-patients-with-metastatic-castrationsen.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/las-vegas-dermatology-2025/treatment-of-plaque-psoriasis-involving-high-impact-sites-with-icotrokinra.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/glycoprotein-inducers2025-06-16https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/use-of-risperdal-consta-in-adolescentpediatric-populations2024-12-13https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-pharmacoeconomic-outcomes2026-03-18https://www.jnjmedicalconnect.com/products/inlexzo/procedural-videos-and-information2025-09-25https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-preparation-for-intravenous-infusion-using-dextrose-5-in-water-d5w2025-10-09https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/finegfr-cns-real-world-survival-and-patient-characteristics-of-egfr-mutated-nsclc-patients-with-cns.pdf2026-01-07https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-dosing-more-frequently-than-every-12-weeks-during-the-maintenance-period-in-adult-patients2025-06-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/efficacy-and-safety-of-teclistamab-in-patients-with-relapsedrefractory-multiple-myeloma-with-highris.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/inlexzo/inlexzo-what-is-inlexzo.pdf2025-09-12https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/socu/visible-cohort-a-longterm-patientreported-outcomes-through-week-100-in-participants-with-moderatetos.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/access-to-healthcare/barriers-to-care2026-02-27https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-pharmacokinetics-and-pharmacodynamics2025-07-22https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/factors-influencing-exacerbations-and-crisis-in-generalized-myasthenia-gravis-findings-from-a-claims.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2025/quality-adjusted-survival-analysis-of-neurologic-video2025-12-08https://www.jnjmedicalconnect.com/products/tremfya/medical-content/do-tremfya-one-press-patient-controlled-injectors-contain-latex2025-07-08https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-of-spravato-with-treatments-for-substance-use-disorder2025-11-14https://www.jnjmedicalconnect.com/products/spravato/video-spravato-rems-patient-monitoring-form-overview2026-02-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/tcell-phenotyping-supports-the-use-of-tcell-engaging-antibodies-for-treatment-of-calreticulin-mutate.pdf2026-02-17https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/video-effects-pcc-xarelto2025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/ciltacabtagene-autoleucel-vs-standard-of-care-in-lenalidomiderefractory-multiple-myeloma-phase-3-car.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-patients-with-acute-pulmonary-infections2025-12-11https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-overview-of-the-iconic-lead-clinical-trial2026-03-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/satisfaction-and-experiences-with-talquetamab-results-from-qualitative-patient-and-physician-researc.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-seizure2025-04-10https://www.jnjmedicalconnect.com/media/attestation/products/carvykti/carvykti-patient-wallet-card.pdf2025-08-05https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ddw/safety-of-guselkumab-in-inflammatory-bowel-disease-up-to-1-year-integrated-safety-analysis-of-phase.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/adverse-event-of-risperdal-consta-injection-site-pain-or-reactions2025-07-31https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/pcc/eerenberg-et-al-20112025-10-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/efficacy-and-safety-of-subcutaneous-guselkumab-induction-and-maintenance-therapy-in-patients-with-ul.pdf2026-01-07https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-latex-content2025-10-08https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-use-in-plasma-cell-leukemia2025-10-12https://www.jnjmedicalconnect.com/products/nipocalimab-investigational/medical-content/nipocalimab-clinical-studies-in-fetal-and-neonatal-alloimmune-thrombocytopenia2026-03-09https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-bioequivalence-of-3x-100-mg-tablets-vs-1x-300-mg-tablet2024-09-24https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-patients-with-acrodermatitis-continua-of-hallopeau2025-06-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/reallife-outcomes-in-tripleclass-exposed-tce-relapsedrefractory-multiple-myeloma-rrmm-treated-with-c.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/balversa/balversa-safety-data-sheet-sds-4-mg-tablets.pdf2025-11-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/clinical-outcomes-in-black-patients-with-relapsedrefractory-multiple-myeloma-following-talquetamab-t.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/ash-20252025-12-06https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/mapping-out-the-patient-journey-of-generalized-myasthenia-gravis-insights-and-challenges.pdf2026-01-20https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/use-of-invega-sustenna-in-acute-schizophrenia2025-10-14https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-in-patients-with-comorbid-metabolic-syndrome2026-03-20https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-previous-experience-with-deucravacitinib-or-apremilast-in-patients-with-plaque-psoriasis2026-03-18https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/nutrition-and-diet/overview2026-02-27https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-active-psoriatic-arthritis-discover22025-12-09https://www.jnjmedicalconnect.com/products/erleada/medical-content/video-crushing-splitting-or-mixing-of-240mg-tablet2025-08-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/symptom-and-quality-of-life-benefits-of-achieving-deep-remission-a-realworld-study-of-crohns.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/economic-value-of-tocilizumab-prophylaxis-to-prevent-cytokine-release-syndrome-crs-during-outpatient.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-adverse-events-in-pediatric-patients2025-06-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/ciltacabtagene-autoleucel-vs-standard-of-care-in-patients-with-functionally-highrisk-multiple-myelom.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-event-of-spravato-potential-for-withdrawal-symptoms2025-12-16https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/chest-20242025-08-28https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/eha-20252025-08-28https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/invega-hafyera-conversion-to-invega-trinza2025-09-10https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/risk-of-mental-health-outcomes-and-peak-risk-periods-post-hematologic-cancer-diagnosis-in-the-united.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/association-of-relapse-with-allcause-mortality-in-32071-adults-with-stable-schizophrenia-a-longitudi.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/veletri/veletri-stability-of-infusion-solutions-at-a-concentration-of-less-than-3000-ngml.pdf2024-09-04https://www.jnjmedicalconnect.com/products/risperdal/medical-content/risperdal-dosing-splitting-or-crushing-tablets2026-03-11https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/ecnp/evaluation-of-sexual-function-with-adjunctive-lumateperone-in-patients-with-major-depressive-disorde.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/utility-and-sensitivity-of-wett-sa53-to-measure-dysgeusia-associated-with-talquetamab-a-gprc5dcd3-bi.pdf2026-01-07https://www.jnjmedicalconnect.com/resources/congress-materials/policy-research-congresses2025-10-06https://www.jnjmedicalconnect.com/resources/real-world-evidence2025-10-13https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-in-adult-patients-with-proctitis2025-08-11https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/cinp/long-term-adjunctive-lumateperone-treatment-in-major-depressive-disorder-results-poster.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/lazcluze-specialty-pharmacy-and-specialty-distributors2026-01-05https://www.jnjmedicalconnect.com/media/attestation/products/tremfya/tremfya-what-is-the-dosing-schedule-of-tremfya-for-active-psoriatic-arthritis.pdf2025-10-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych-elevate/comparative-effectiveness-of-oral-and-longacting-injectable-antipsychotics-in-schizophrenia-a-realwo.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-2024/long-term-benefits-in-patient-reported-outcomes-and-time-to-next-anti-myeloma-therapy-of2026-02-24https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/spda-fall/maintenance-of-response-with-icotrokinra-a-targeted-oral-peptide-for-the-treatment-of-moderatetoseve.pdf2026-02-17https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-effect-of-food2026-03-13https://www.jnjmedicalconnect.com/products/opsumit/medical-content/considerations-for-splitting-crushing-chewing-and-manipulating-opsumit-tablets2026-02-17https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/use-of-rybrevant-faspro-in-patients-with-hepatic-impairment2025-12-17https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/pha/a-qualitative-interview-study-to-evaluate-singletablet-combination-therapy-stct-within-a-phase-3-pul.pdf2026-01-20https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-minimal-residual-disease-in-clinical-trials2025-10-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/translational-analyses-of-tcell-phenotypes-and-their-association-with-clinical-efficacy-in-the-first.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-cassini-study2024-05-22https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/aad-innovation-academy/treatment-of-plaque-psoriasis-involving-highimpact-sites-with-icotrokinra-subgroup-analyses-of-the-p.pdf2026-02-17https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-adverse-event-second-primary-malignancies2026-03-02https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/dosing-of-invega-trinza-missed-dose2026-03-10https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2026/psych-congress-np-institute/remission-with-lumateperone-42-mg-adjunctive-to-antidepressant-therapy-in-patients-with-major-depres.pdf2026-03-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/efficacy-and-safety-of-icotrokinra-a-novel-targeted-oral-peptide-in-adolescents-with-moderate-to.pdf2026-02-17https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-in-combination-with-oral-medications-in-patients-with-plaque-psoriasis2026-03-20https://www.jnjmedicalconnect.com/products/erleada/medical-content/use-of-erleada-in-metastatic-castrationresistant-prostate-cancer-mcrpc2025-05-28https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/smfm-20262026-01-23https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-adverse-event-infections-in-patients-with-newly-diagnosed-multiple-myelo2025-11-07https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-safety-data-sheet-sds-for-oral-suspension.pdf2026-01-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/talquetamab-tal-daratumumab-dara-pomalidomide-pom-in-patients-pts-with-relapsedrefractory-multiple-m.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/the-phase-2-cartitude2-trial-updated-efficacy-and-safety-of-ciltacabtagene-autoleucel-in-patients-wi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/clinical-pharmacology-strategies-to-support-dose-optimization-of-the-supplemental-materials.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invokana/medical-content/use-of-invokana-in-pediatrics2025-09-09https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-use-with-vaccines2025-07-01https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-comorbid-psychosis-schizophrenia-or-schizoaffective-disorder2026-02-10https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/icotrokinra-ico-a-novel-targeted-oral-peptide-in-patients-pts-with-psoriatic-disease-explorat.pdf2026-02-17https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-trinza-paliperidone-palmitate-3month032026-03-18https://www.jnjmedicalconnect.com/products/tracleer2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/clinical-unmet-need-of-lenalidomiderefractory-vs-nonlenalidomiderefractory-patients-with-multiple-my.pdf2026-01-20https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-occurrence-and-management-of-skin-toxicities2026-03-03https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-retreatment-of-crohns-disease-after-a-drug-free-interval2025-06-17https://www.jnjmedicalconnect.com/media/attestation/products/erleada/erleada-safety-data-sheet-sds-240-mg-tablet.pdf2026-02-26https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aua/sunrise5-a-phase-3-randomized-openlabel-study-of-tar200-compared-with-intravesical-chemotherapy-afte.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/efficacy-and-safety-of-talquetamab-teclistamab-in-patients-with-relapsedrefractory-multiple-myeloma.pdf2026-01-11https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-dosing-crushing-chewing-or-splitting.pdf2026-03-09https://www.jnjmedicalconnect.com/resources/temperature-stability-checker2026-01-05https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-severe-cutaneous-adverse-reactions-scars2025-12-17https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ash/mortality-associated-with-warm-autoimmune-hemolytic-anemia-among-medicare-beneficiaries.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/visible-cohort-a-guselkumab-skin-clearance-and-patient-reported-outcomes-across-poster.pdf2026-03-27https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/what-should-i-tell-my-healthcare-provider-before-receiving-invega-hafyera2025-08-04https://www.jnjmedicalconnect.com/products/opsumit/medical-content/what-are-the-possible-side-effects-of-opsumit2025-10-01https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-stability-of-reconstituted-and-diluted-solution.pdf2025-07-15https://www.jnjmedicalconnect.com/products/lazcluze2026-01-21https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-mmy2002-sirius-study2025-07-16https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-use-in-patients-with-plaque-psoriasis-and-comorbid-renal-impairment2026-03-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/the-power-of-photos-leveraging-clinical-photos-from-the-visible-study-to-create-an-image-library-for.pdf2026-02-17https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-dosage-and-administration-flow-regulator2025-08-06https://www.jnjmedicalconnect.com/products/opsumit/medical-content/what-is-the-recommended-dosing-for-opsumit-in-the-treatment-of-pulmonary-arterial-hypertension2025-08-01https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-acute-coronary-syndromes2025-06-24https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/real-world-use-safety-and-efficacy-of-teclistamab-with-or-without-prophylactic-tocilizumab-in-relaps.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/isi-english2025-02-26https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/sentiment-analysis-of-digital-conversations-related-to-myasthenia-gravis-by-raceethnicity.pdf2026-01-20https://www.jnjmedicalconnect.com/products/icotyde/medical-content/overview-of-the-iconic-total-clinical-trial2026-03-24https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-adverse-event-hematologic-events-in-patients-with-relapsed-and-refractor2025-11-10https://www.jnjmedicalconnect.com/products/spravato/medical-content/comparison-of-spravato-to-atypical-antipsychotics2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aacr/establishing-optimal-care-coordination-in-localized-bladder-cancer-in-the-united-states-a-modified-d.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/imaavy/imaavy-gmg-one-pager.pdf2026-01-05https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-management-of-oral-mucositis2025-06-13https://www.jnjmedicalconnect.com/disease-state/schizophrenia2026-03-26https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/use-of-rybrevant-faspro-in-patients-with-renal-impairment2025-12-17https://www.jnjmedicalconnect.com/products/invokana/medical-content/effect-of-invokana-on-blood-pressure-and-heart-rate-outcomes2025-04-03https://www.jnjmedicalconnect.com/media/attestation/products/intelence/intelence-200mg-tablets-safety-data-sheet-sds.pdf2025-10-08https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/quality-of-care-measures-among-patients-with-recurrent-papillaryonly-bacillus.pdf2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/validation-analysis-of-met-ihc-as-a-biomarker-for-amivantamablazertinib-response-in-postosimertinib.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/ibromics-a-realworld-study-of-clinical-and-biological-parameters-determining-response-in-patients-wi.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/efficacy-and-safety-in-patients-with-lenalidomiderefractory-multiple-myeloma-and-13-prior-lines-who.pdf2026-01-07https://www.jnjmedicalconnect.com/products/risperdal/medical-content/adverse-event-of-risperdal-galactorrhea-gynecomastia2026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/aanem/treatment-outcomes-among-patients-with-generalized-myasthenia-gravis-in-the-czech-republic-results-f.pdf2026-01-20https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-how-does-erleada-work2025-06-24https://www.jnjmedicalconnect.com/media/attestation/products/darzalex-faspro/darzalex-faspro-safety-data-sheet-sds.pdf2026-04-01https://www.jnjmedicalconnect.com/products/spravato/medical-content/adverse-event-of-spravato-psychosis2026-03-27https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-major-adverse-cardiovascular-events-in-adult-patients-with-plaque-psoriasis-o2025-08-05https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-interaction-with-serological-testing-for-blood-banks2025-07-31https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/overview-of-therapeutic-management-and-disease-progression-in-patients-with-localized-prostate-cance.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/esmo/amivantamab-plus-paclitaxel-in-recurrent-metastatic-r-m-head-and-neck-squamous-cell-cancer-hnscc-aft.pdf2026-01-07https://www.jnjmedicalconnect.com/products/simponi-aria/medical-content/simponi-aria-overview-of-pharmacology2026-03-19https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2024/fall-clinical/sustained-improvements-in-psoriasis-area-and-severity-index-and-in-percent-body-surface-area-of-psor.pdf2026-02-17https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-occurrence-of-malignancies2026-03-17https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/invega-sustenna-invega-trinza-and-invega-hafyera-how-do-they-work-and-what-are-their-unique-charact2025-07-01https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/aacr/amivantamab-in-wildtype-advanced-nonsmall-cell-lung-cancer-nsclc-after-disease-progression-on-checkp.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-dosage-and-administration-injection-set-materials-and-closed-system-transfer-devi2026-02-06https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/ash/heterogeneity-of-treatment-regimens-and-related-health-resource-use-in-managing-patients-with-waiha.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/amivantamab-plus-lazertinib-vs-osimertinib-in-firstline-egfrmutant-advanced-nonsmall-cell-lung-cance.pdf2026-01-20https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/mechanism-of-action2025-08-21https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-drug-interaction-qt-prolongation.pdf2025-07-21https://www.jnjmedicalconnect.com/products/opsumit/medical-content/opsumit-idiopathic-pulmonary-fibrosis2026-01-14https://www.jnjmedicalconnect.com/products/tecvayli/pivotal-clinical-trial-publications2025-12-29https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-minimal-residual-disease-in-clinical-trials2025-12-12https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-can-i-take-spravato-if-i-am-pregnant-plan-to-become-pregnant-breastfeeding-or-plan-to-brea2026-01-23https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/andexanet-alfa-prt064445/annexa-r2025-10-16https://www.jnjmedicalconnect.com/products/xarelto/medical-content/comparison-of-xarelto-to-edoxaban2024-10-29https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/gdpa-pearls/icotrokinra-a-novel-targeted-oral-peptide-il23rinhibitor-in-adolescents-with-moderatetosevere-plaque.pdf2026-02-17https://www.jnjmedicalconnect.com/products/tremfya/medical-content/one-press-patient-controlled-injector-instructions-for-use2025-12-08https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/pdes-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/aanem/composite-response-to-nipocalimab-a-novel-neonatal-fragment-crystallizable-receptor-blocker-based.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/ash-20242026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/team-phenomenal-hope/perceptions-of-the-prostacyclin-pathway-insights-from-a-pulmonary-arterial-hypertension-patient-enga.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-castor-study2026-03-10https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/dosage-and-administration-of-darzalex-darzalex-faspro-pre-and-postinfusion-medications2025-07-10https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/dosage-and-administration-of-invega-hafyera-general-information2026-01-13https://www.jnjmedicalconnect.com/products/spravato/medical-content/use-of-spravato-in-patients-with-comorbid-substance-or-alcohol-use-disorder2026-02-03https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-effect-on-fertility2026-03-19https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-healthcare-resource-utilization-outpatientinpatient-administration2025-10-01https://www.jnjmedicalconnect.com/products/invega-hafyera/medical-content/dosing-of-invega-hafyera-maximum-dose2025-09-11https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-dosage-and-administration2025-07-22https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-comparison-with-apixaban-in-venous-thromboembolism-treatment2026-03-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-hepaticrelated-safety-events-in-adult-patients-with-crohns-disease-or-ulcerat2025-11-13https://www.jnjmedicalconnect.com/products/xarelto/medical-content/drug-interaction-of-xarelto-with-azithromycin2025-06-02https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-mechanism-of-action-binding-affinity.pdf2024-10-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/firstline-subcutaneous-amivantamab-plus-chemotherapy-in-egfr-exon-20-insertionmutated-advanced-nsclc.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-majestec-9-study2026-03-18https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/dosing-of-invega-trinza-maximum-dose2026-01-13https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-antiarrhythmics2024-10-18https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/can-i-take-lazcluze-if-i-am-pregnant-or-breastfeeding2026-03-04https://www.jnjmedicalconnect.com/products/risperdal-consta/medical-content/comparison-of-risperdal-consta-to-once-monthly-or-once-every-two-months-subcutaneous-risperidone-lon2025-04-28https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-injectable-iv-im-sc-administration2024-11-14https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/what-is-the-dosing-schedule-for-rybrevant2026-01-21https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-overview-of-the-solstice-clinical-trial2025-10-06https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/efficacy-of-nipocalimab-in-open-label-extension-in-patients-transitioned-from-placebo-results-from-v.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/ciltacabtagene-autoleucel-in-patients-with-lenalidomiderefractory-multiple-myeloma-cartitude2-cohort.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/isi-english2025-02-27https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-spartan-study2025-12-04https://www.jnjmedicalconnect.com/products/carvykti/medical-content/carvykti-prior-lines-of-therapy-in-cartitude-1-and-cartitude-42026-03-05https://www.jnjmedicalconnect.com/products/tremfya/medical-content/use-of-tremfya-in-adult-patients-with-enthesitis2026-03-13https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/phase-1b-study-of-meninkmt2a-inhibitor-bleximenib-in-combination-with-intensive-chemotherapy-in-newl.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/language-and-communication/overview2026-02-27https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-comparison-to-deucravacitinib-in-the-treatment-of-plaque-psoriasis2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-safety-information-effect-on-lipids-in-treatment-naive-patients.pdf2025-11-25https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/team-phenomenal-hope/patient-perspectives-on-engagement-and-shared-decision-making-in-pulmonary-arterial-hypertension-a-m.pdf2026-01-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/effect-of-spravato-on-brain-volume-and-structure2026-04-02https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-mmy3008-maia-study2025-11-13https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/sid/relationship-of-icotrokinra-effects-in-participants-with-moderatetosevere-plaque-psoriasis-phase-2b.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/erleada-use-of-erleada-in-combination-with-zytiga.pdf2025-06-18https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/response-and-remission-on-esketamine-nasal-spray-in-patients-with-treatmentresistant-depression-over.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/video-rybrevant-mechanism-of-action2026-02-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-proton-pump-inhibitors2025-05-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/isds/spectrem-guselkumab-demonstrates-consistent-significant-clearance-across-the-full-range-of-low-body.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-origin-of-antibody-genes-in-the-development-of-guselkumab2026-02-05https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-latex-content2025-09-25https://www.jnjmedicalconnect.com/media/attestation/products/invega/invega-adverse-event-movement-disorders.pdf2025-12-05https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/ciltacabtagene-autoleucel-ciltacel-vs-standard-of-care-soc-in-patients-pts-with-relapsedrefractory-m.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/dosage-administration/geriatric-use2025-06-16https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/tar-200-monotherapy-in-patients-with-bacillus-calmette-guerinunresponsive-papillary-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-adult-patients-with-baseline-thrombocytopenia2025-05-28https://www.jnjmedicalconnect.com/products/tremfya/medical-content/treatment-effect-of-tremfya-on-radiographic-progression-in-adult-patients-with-active-psoriatic-arth2026-02-17https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-hafyera-paliperidone-palmitate-6month012025-12-24https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/psych-elevate/longitudinal-realworld-study-of-the-patient-journey-of-a-national-sample-of-beneficiaries-with-schiz.pdf2026-02-17https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-comparison-of-akeega-with-olaparib2025-05-30https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/use-of-invega-trinza-in-elderly-patients2025-12-24https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/maui-derm-caribbean-20262026-01-14https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-postinjection-observation-time2025-12-22https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-dosage-and-administration-priming-infusion-sets2025-06-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/minimal-residual-disease-dynamics-in-post-transplant-patients-with-newly-diagnosed-multiple-myeloma.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/reallife-outcomes-in-patients-with-bcmaexposed-relapsedrefractory-multiple-myeloma-treated-with-stan.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/simponi/simponi-storage-and-stability.pdf2024-11-21https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-use-in-patients-with-prior-intravesical-gemcitabine-use2025-09-12https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-blood-brain-barrier-and-central-nervous-system-involvement2025-07-02https://www.jnjmedicalconnect.com/products/invokana/medical-content/invokana-the-canvas-program-canvas-canvasr2025-01-20https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-occurrence-of-cardiovascular-toxicity2026-02-17https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-dosing-crushing-tablets-and-special-administration-suspensionng-tube-and-rectal.pdf2025-04-17https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/isbd-20252025-10-30https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/qcs-20242025-08-28https://www.jnjmedicalconnect.com/products/carvykti2026-01-21https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rheumatology-convergence-congress/biological-sex-related-differences-in-radiographic-progression-and-relationship-with-early-clinical.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/use-of-darzalex-faspro-in-pregnancy-and-lactation2025-06-19https://www.jnjmedicalconnect.com/products/remicade/medical-content/retreatment-of-crohns-disease-or-ulcerative-colitis-with-remicade-after-a-drug-free-interval2025-09-08https://www.jnjmedicalconnect.com/media/attestation/products/sirturo/sirturo-what-is-the-availability-of-sirturo.pdf2025-10-28https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-retreatment-of-ulcerative-colitis-after-a-drug-free-interval2025-10-27https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/exposure-optimisation-substudy-eos-of-ustekinumab-in-paediatric-ulcerative-col.pdf2026-02-23https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-stability-of-diluted-solution-for-intravenous-infusion2025-10-06https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-use-in-pediatric-patients.pdf2025-04-23https://www.jnjmedicalconnect.com/media/attestation/congresses/policy-research/2025/amcp-nexus/suitability-of-cost-effectiveness-thresholds-for-drug-reimbursement-decision-making-in-the-us-market.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/jens/clinical-and-patient-reported-outcomes-in-hdfn-a-european-perspective.pdf2026-01-20https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-magnitude-gene-by-gene-analysis2025-10-01https://www.jnjmedicalconnect.com/media/attestation/products/edurant/edurant-safety-data-sheet-sds.pdf2026-01-05https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/invega-sustenna-and-invega-trinza-pharmacodynamics2025-12-17https://www.jnjmedicalconnect.com/products/xarelto/medical-content/what-should-i-do-if-i-miss-a-dose-of-xarelto2025-06-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/eha/firstline-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-demonstrates-overall-survival-comp.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/composite-response-to-nipocalimab-based-on-both-myasthenia-gravis-activity-of-daily-living-and-quant.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/maui-derm-caribbean/durability-of-response-to-the-targeted-oral-peptide-icotrokinra-for-highimpact-site-psoriasis-1year.pdf2026-02-17https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ats/qualitative-interviews-of-patients-with-methamphetamineassociated-pulmonary-arterial-hypertension-un.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/mgfa-20242025-08-28https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/tecvayli-preparation-and-administration2026-03-10https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-subcutaneous-formulation-of-stelara-during-induction-in-crohns-disease2025-08-18https://www.jnjmedicalconnect.com/media/attestation/products/prezista/prezista-safety-data-sheet-sds-for-800-mg-tablets.pdf2026-01-05https://www.jnjmedicalconnect.com/products/stelara/medical-content/re-induction-with-iv-infusion-of-stelara-during-maintenance-therapy-in-ulcerative-colitis2025-09-24https://www.jnjmedicalconnect.com/media/attestation/products/caplyta/caplyta-safety-data-sheet-sds.pdf2026-03-30https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/a-discrete-choice-experiment-analysis-to-understand-treatment-preferences-of-patients-with-relapsed.pdf2026-01-20https://www.jnjmedicalconnect.com/products/tremfya/medical-content/how-do-i-store-tremfya-one-press-patient-controlled-injector2026-03-03https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-occurrence-of-tuberculosis-in-adult-patients-with-crohns-disease-or-ulcerative-colitis2026-02-25https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/daratumumab-plus-lenalidomide-dr-versus-lenalidomide-r-alone-as-maintenance-therapy-in-newly-diagnos.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/rwcs/title-onlabel-persistence-through-24-months-among-patients-with-psoriatic-arthritis-initiating-gusel.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/general/visible-guselkumab-improves-key-healthrelated-quality-of-life-measures-through-week-48-in-participan.pdf2026-01-07https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-treatment-of-erythrodermic-psoriasis2026-03-25https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-use-in-high-risk-multiple-myeloma-in-clinical-trials2026-02-09https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/how-does-darzalex-faspro-work2026-01-05https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/rhuph20-overview-and-mechanism-of-action2025-12-18https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/fcdc/spectrem-primary-skin-clearance-through-week-48-with-guselkumab-in-participants-with-low-body-surfa.pdf2026-01-07https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-transitioning-from-intravenous-or-subcutaneous-prostacyclin-therapy2025-09-17https://www.jnjmedicalconnect.com/products/icotyde2026-03-20https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/uncontrolled-myasthenia-gravis-can-contribute-to-additional-stress-burden-and-adverse-mental-health.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/video-targeted-oral-peptides2026-03-19https://www.jnjmedicalconnect.com/products/opsumit/medical-content/combination-therapy-of-opsumit-in-pulmonary-arterial-hypertension2025-10-08https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-use-in-pediatric-patients.pdf2025-09-23https://www.jnjmedicalconnect.com/products/tecvayli/medical-content/restarting-tecvayli-after-dosage-delay2026-03-18https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-after-bariatric-surgery2024-12-05https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-dosing-interval-reduction-in-crohns-disease2025-08-22https://www.jnjmedicalconnect.com/products/darzalex/medical-content/dosage-and-administration-of-darzalex-split-first-dose-infusion2025-07-15https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/reversal-agents-human-studies/andexanet-alfa-prt064445/annexa-42025-10-16https://www.jnjmedicalconnect.com/media/attestation/products/simponi/safety-data-sheet-for-simponi-subcutaneous-golimumab.pdf2025-12-12https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/wclc/longterm-survival-outcome-after-firstline-osimertinib-monotherapy-in-advanced-metastatic-nsclc-resul.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa-international/partnering-with-patients-and-caregivers-to-guide-the-development-of-impactful-study-engagement-tools.pdf2026-01-20https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-stability-of-final-vialed-product-for-intravenous-infusion2025-12-09https://www.jnjmedicalconnect.com/products/xarelto/medical-content/xarelto-definition-of-bleeding2025-11-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/dgho/final-survival-analysis-of-daratumumab-plus-lenalidomide-and-dexamethasone-versus-lenalidomide-and-d.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/real-world-evidence-use-of-xarelto-in-cancer-associated-thrombosis2024-04-23https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/ean-20252025-08-28https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/uegw/efficacy-of-guselkumab-for-small-bowel-lesions-using-balloon-assisted-enteroscopy.pdf2026-01-07https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-treatment-of-facial-psoriasis2026-03-18https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-of-spravato-with-opioids2025-09-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/gdpa-pearls/spectrem-guselkumab-efficacy-and-patientreported-outcomes-across-multiple-highimpact-sites-in-partic.pdf2026-01-07https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-preparation-and-administration2024-11-21https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/ispor/medical-costs-in-patients-with-pulmonary-arterial-hypertension-pah-on-oral-triple-therapy-including.pdf2026-01-07https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/rybrevant-chrysalis-study2026-03-23https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/adverse-event-of-invega-sustenna-injection-site-reactionpain2025-08-22https://www.jnjmedicalconnect.com/products/inlexzo/dosing-infographics2025-09-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/spectrem-guselkumab-skin-clearance-and-patient-reported-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/products/xarelto/medical-content/management-bleeding/summary-studies-assessing-reversal-agents-xarelto/pcc2025-10-16https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-the-treatment-of-pouchitis2026-02-04https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/healthcare-burden-associated-with-cystectomy-and-trimodal-therapy-among-patients-with-poster.pdf2026-01-20https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-acute-pulmonary-embolism-treatment2025-06-23https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/aua/real-world-comparison-of-prostate-specific-antigen-response-in-black-patients-with-metasta-pls.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/patient-preferences-for-use-of-car-t-therapy-as-an-early-line-treatment-in-multiple-myeloma.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/consistency-of-skin-clearance-with-the-targeted-oral-peptide-icotrokinra-result-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-shipping-stability.pdf2025-07-21https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2025/mgfa/design-of-a-digital-solution-to-improve-myasthenia-gravis-patient-symptom-monitoring-in-routine-clin.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-18-mg-tablet-safety-data-sheet-sds.pdf2025-05-02https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-storage-and-stability-for-prefilled-syringes-prefilled-pens-and-onepress-patientcontrolled2026-01-26https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/jadpro-2024/amivantamab-plus-lazertinib-vs-osimertinib-video2025-08-29https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/aanem/assessing-the-suitability-of-the-neuroqol-fatigue-to-evaluate-fatigue-in-patients-living-with-gmg.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ipcu/head-to-head-comparison-of-overall-survival-in-subgroups.pdf2026-01-07https://www.jnjmedicalconnect.com/products/xarelto/medical-content/can-i-take-xarelto-if-i-am-pregnant-or-planning-to-become-pregnant2025-06-27https://www.jnjmedicalconnect.com/products/invega-trinza2026-01-21https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/stability-of-invega-sustenna-invega-trinza-and-invega-hafyera-once-needle-attached2025-07-07https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-pavo-study2026-02-11https://www.jnjmedicalconnect.com/products/uptravi/medical-content/uptravi-treatment-of-pulmonary-arterial-hypertension-in-patients-with-comorbid-interstitial-lung-di2025-07-24https://www.jnjmedicalconnect.com/products/erleada/medical-content/erleada-dysphagia2026-02-05https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/eadv/guide-phase-3b-trial-results-early-intervention-with-guselkumab-results-in-higher-rates-of-fingernai.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/efficacy-of-carvykti-in-cartitude-4-versus-other-conventional-slides.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/mgfa/adverse-pregnancy-outcomes-in-myasthenia-gravis-a-retrospective-cohort-study-in-a-us-health-insuranc.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/concerta/concerta-36-mg-tablet-safety-data-sheet-sds.pdf2025-05-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/eau/periprocedural-prophylactic-antibiotic-use-with-gemcitabine-intravesical-system.pdf2026-03-13https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-poster-summary-cost-per-responder-of-inlexzo-vs-other-fdaapproved-novel-and-generic-treatme2025-11-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ecop/realworld-headtohead-analysis-of-overall-survival-in-patients-with-metastatic-castrationsensitive-pr.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ims/efficacysafety-of-ciltacel-lenalidomide-maintenance-in-patients-with-multiple-myeloma-who-had-subop.pdf2026-01-07https://www.jnjmedicalconnect.com/products/erleada/medical-content/publication-summary-lowentritt-et-al-2025-realworld-os-comparison-with-abiraterone-acetate-in-patie2025-06-24https://www.jnjmedicalconnect.com/products/imaavy/medical-content/imaavy-use-in-combination-with-corticosteroids-in-patients-with-generalized-myasthenia-gravis2026-02-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/efficacy-and-safety-of-ibrutinib-plus-venetoclax-in-patients-with-mantle-cell-lymphoma-and-tp53-muta.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/pharmacokinetics-of-invega-trinza2025-12-16https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/psych/how-do-patients-with-depression-and-their-providers-talk-about-anhedonia-an-ethnographic-analysis-of.pdf2026-01-20https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/qcs-2024/elevating-the-patient-voice-video2025-08-29https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/eha/clinical-outcomes-of-patients-with-relapsed-or-refractory-multiple-myeloma-with-and-without-extramed.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/yondelis/yondelis-administration-sets.pdf2025-07-01https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-ssri-or-snri2025-01-08https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/front-line-treatment-and-recurrence-patterns-among-patients-with-high-risk-nonm.pdf2026-02-27https://www.jnjmedicalconnect.com/products/caplyta/medical-content/caplyta-effect-on-fertility2026-03-13https://www.jnjmedicalconnect.com/products/xarelto/medical-content/rationale-for-once-daily-dosing-of-xarelto-for-nonvalvular-atrial-fibrillation2024-09-23https://www.jnjmedicalconnect.com/products/spravato/medical-content/spravato-suicidal-ideation-and-behavior-assessment-tool-sibat2026-02-11https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-storage-and-stability-after-dilution-in-diluents-other-than-normal-saline2026-01-26https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-patients-with-renal-impairment-and-multiple-myeloma2026-04-01https://www.jnjmedicalconnect.com/therapeutic-areas/pulmonary-hypertension/congress/ers-20252025-09-30https://www.jnjmedicalconnect.com/products/xarelto/medical-content/use-of-xarelto-in-vte-prevention-in-hip-replacement-surgery2024-05-30https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-safety-information-sulfa-allergy.pdf2025-03-11https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ims/daratumumab-dara-bortezomibthalidomidedexamethasone-dvtd-and-dara-maintenance-in-transplanteligible.pdf2026-01-07https://www.jnjmedicalconnect.com/products/spravato/medical-content/can-spravato-cause-sedation-dissociation-and-respiratory-depression2025-05-21https://www.jnjmedicalconnect.com/products/stelara/medical-content/stelara-occurrence-of-major-adverse-cardiovascular-events-mace2026-02-02https://www.jnjmedicalconnect.com/products/darzalex/medical-content/use-in-combination-with-bortezomib-and-dexamethasone-in-multiple-myeloma2026-01-19https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/ascp/seltorexant-adjunctive-to-antidepressants-in-adults-with-mdd-with-insomnia-symptoms-results-of-a-dou.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/hopa/amivantamab-plus-lazertinib-vs-osimertinib-in-firstline-egfrmutant-advanced-nsclc-final-overall-surv.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/aad/durability-of-response-with-icotrokinra-a-targeted-oral-peptide-in-adults-with-presentation.pdf2026-03-27https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/congress/smfm-2026/patient-focused-alloimmunization-in-pregnancy-video2026-01-23https://www.jnjmedicalconnect.com/media/attestation/products/zytiga/zytiga-crushing-and-splitting-tablets.pdf2025-12-23https://www.jnjmedicalconnect.com/media/attestation/products/lazcluze/cocoon-final-analysis-infographic.pdf2025-12-11https://www.jnjmedicalconnect.com/products/akeega/medical-content/use-of-akeega-in-metastatic-castrationsensitive-prostate-cancer-mcspc2025-12-25https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/the-uniti-jr-study-safety-and-efficacy-results-of-ustekinumab-in-paediatric-pati.pdf2026-02-23https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/evaluation-of-complete-bowel-symptomatic-remission-cbsr-in-patients-with-moderately-to-severely-acti.pdf2026-02-19https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/paloma-3-study2025-12-18https://www.jnjmedicalconnect.com/products/spravato/medical-content/long-term-trials-in-treatment-resistant-depression2026-03-17https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/am/daratumumab-dara-bortezomiblenalidomidedexamethasone-vrd-with-darar-dr-maintenance-in-transplanteli.pdf2026-01-07https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/can-i-receive-invega-sustenna-treatment-if-i-am-breastfeeding-pregnant-or-planning-to-become-pregnan2025-08-04https://www.jnjmedicalconnect.com/products/balversa/medical-content/use-of-balversa-in-cholangiocarcinoma2025-07-23https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-reinduce-with-intravenous-infusion-during-maintenance-therapy-in-crohns-disease2025-06-17https://www.jnjmedicalconnect.com/products/invega-sustenna/medical-content/antipsychotic-use-and-risk-of-breast-cancer-in-women-with-schizophrenia2025-12-24https://www.jnjmedicalconnect.com/products/talvey/medical-content/talvey-passage-across-blood-brain-barrier2025-09-17https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-extravasation2025-06-05https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-pediatric-patients-weighing-less-than-40-kg-with-plaque-psoriasis2025-10-21https://www.jnjmedicalconnect.com/media/attestation/congresses/policy-research/2025/amcp-nexus/understanding-state-medicaid-spending-on-prescription-drugs-a-10state-comprehensive-analysis-of-net.pdf2026-01-20https://www.jnjmedicalconnect.com/media/attestation/products/topamax/topamax-sprinkle-capsules-safety-data-sheet-sds-15-mg.pdf2025-05-01https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/aanem-20252026-02-19https://www.jnjmedicalconnect.com/products/erleada/medical-content/use-of-erleada-in-combination-with-bone-sparing-agents2025-09-08https://www.jnjmedicalconnect.com/products/darzalex/medical-content/can-darzalex-cause-infusion-related-reactions2025-04-25https://www.jnjmedicalconnect.com/products/stelara/medical-content/treatment-of-adult-patients-with-crohns-disease-uniti-clinical-trial-program2025-10-16https://www.jnjmedicalconnect.com/products/invega-trinza/medical-content/dosage-and-administration-of-invega-trinza-general-information2025-11-20https://www.jnjmedicalconnect.com/products/spravato/medical-content/concomitant-use-of-spravato-with-augmentation-therapy-including-antipsychotics-and-antidepressants-i2026-02-11https://www.jnjmedicalconnect.com/media/attestation/products/xarelto/xarelto-safety-data-sheet-sds-for-25-mg-tablets.pdf2025-09-16https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/winter-clinical-hawaii/efficacy-and-safety-of-icotrokinra-through-week-24-in-participants-with-moderatetosevere-plaque-psor.pdf2026-02-17https://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-2-study2026-03-03https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/dose-and-btk-occupancy-relationship-in-the-prospective-phase-2-tailor-study-exploratory-end-point-an.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/winter-clinical-hawaii/maintenance-of-response-with-icotrokinra-a-targeted-oral-peptide-for-the-treatment-of-moderatetoseve.pdf2026-02-17https://www.jnjmedicalconnect.com/therapeutic-areas/neuroscience/congress/acnp-20242025-08-29https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-faspro-aquarius-study2025-12-26https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-comparison-to-il17a-inhibitors-in-the-treatment-of-adult-patients-with-active-psoriatic-art2025-11-10https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2026/nanos/efficacy-of-nipocalimab-in-adult-patients-with-moderate-to-severe-ocular-manifes.pdf2026-03-23https://www.jnjmedicalconnect.com/products/balversa/medical-content/balversa-mechanism-of-action2025-10-06https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/safety-information-for-rybrevant-ocular-toxicity2025-06-04https://www.jnjmedicalconnect.com/products/remicade/medical-content/remicade-treatment-of-ulcerative-colitis-dose-increase-to-10-mgkg-or-dosing-interval-reduction012025-08-22https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/jadpro-2024/amivantamab-plus-chemotherapy-vs-chemotherapy-video2025-08-29https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-dosage-and-administration-restarting-after-prolonged-interruptions2025-05-08https://www.jnjmedicalconnect.com/products/stelara/medical-content/use-of-stelara-as-a-treatment-of-lupus2026-01-21https://www.jnjmedicalconnect.com/products/xarelto/medical-content/concomitant-use-of-xarelto-with-tissue-plasminogen-activator-tpa2025-06-02https://www.jnjmedicalconnect.com/media/attestation/products/lazcluze/infographic-on-skippirr-study-design-and-key-final-results.pdf2025-10-02https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/realworld-characteristics-stepup-dosing-patterns-and-early-safety-outcomes-in-black-patients-with-mu.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/gu/treatment-patterns-and-clinical-outcomes-in-patients-with-metastatic-urothelial-carcinoma-muc-in-eng.pdf2026-01-07https://www.jnjmedicalconnect.com/products/akeega/medical-content/akeega-open-bottle-repackaging-and-light-exposure-stability2025-07-09https://www.jnjmedicalconnect.com/media/attestation/congresses/itci/2025/wcp/adjunctive-lumateperone-in-patients-with-major-depressive-disorder-and-anxious-distress.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2024/ats/expert-consensus-on-best-practices-for-oral-selexipag-titration-and-management-of-expected-side-effe.pdf2026-01-07https://www.jnjmedicalconnect.com/products/rybrevant/medical-content/rybrevant-specialty-distributors2026-01-05https://www.jnjmedicalconnect.com/products/spravato/medical-content/comparison-of-spravato-to-auvelity-dextromethorphan-hbr-and-bupropion-hcl2025-06-05https://www.jnjmedicalconnect.com/products/rybrevant-faspro/medical-content/rybrevant-faspro-lazcluze-copernicus-study2025-12-20https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2026/asco-gu/real-world-clinical-outcomes-among-patients-with-localized-prostate-cancer-under.pdf2026-02-26https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2025/acg/comparison-of-serum-il22-and-tissue-molecular-changes-between-guselkumab-subcutaneous-and-intravenou.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/products/symtuza/symtuza-use-in-combination-with-dolutegravir.pdf2025-03-14https://www.jnjmedicalconnect.com/products/lazcluze/medical-content/what-should-i-avoid-while-taking-lazcluze2025-11-13https://www.jnjmedicalconnect.com/therapeutic-areas/immunology/ibd-impact-toolkit/stigma-and-mental-health/mental-health-support-checklist2026-02-27https://www.jnjmedicalconnect.com/media/attestation/congresses/neuroscience/2024/nei/longterm-safety-and-efficacy-of-esketamine-nasal-spray-by-dosing-frequency-in-adults-with-treatmentr.pdf2026-01-07https://www.jnjmedicalconnect.com/therapeutic-areas/oncology/congress/elcc-2025/amivantamab-plus-lazertinib-vs-osimertinib-video2025-08-29https://www.jnjmedicalconnect.com/media/attestation/congresses/immunology/2026/ecco/efficacy-and-safety-of-guselkumab-in-participants-with-moderately-to-severely-ac.pdf2026-02-23https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-intravenous-vs-subcutaneous-daratumumab-administration-in-multiple-myelom2026-02-03https://www.jnjmedicalconnect.com/products/darzalex-faspro/medical-content/darzalex-darzalex-faspro-hydrashift-24-daratumumab-immunofixation-assay012026-01-23https://www.jnjmedicalconnect.com/products/icotyde/medical-content/icotyde-occurrence-of-tuberculosis-in-patients-with-plaque-psoriasis2026-03-18https://www.jnjmedicalconnect.com/media/attestation/products/procrit/procrit-multidose-vials-freezemarker-indicator.pdf2025-07-18https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/ash/realworld-stepup-dosing-practice-for-patients-who-initiated-talquetamab-in-us-hospitals-an-analysis.pdf2026-01-07https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2024/esmo/preventing-infusionrelated-reactions-with-intravenous-amivantamab-updated-results-from-skippirrslide.pdf2026-01-07https://www.jnjmedicalconnect.com/products/darzalex/medical-content/darzalex-darzalex-faspro-use-in-immune-thrombocytopenia2025-06-27https://www.jnjmedicalconnect.com/media/attestation/congresses/oncology/2025/ash-onc/updated-analysis-of-survival-and-treatment-evolution-in-european-multiple-myeloma-patients-20122023.pdf2026-01-07